kool20170930

0001437749-17-019375.txt : 20171114 0001437749-17-019375.hdr.sgml : 20171114 20171114164147 ACCESSION NUMBER: 0001437749-17-019375 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171114 DATE AS OF CHANGE: 20171114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CESCA THERAPEUTICS INC. CENTRAL INDEX KEY: 0000811212 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY APPARATUS & FURNITURE [3821] IRS NUMBER: 943018487 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-82900 FILM NUMBER: 171202267 BUSINESS ADDRESS: STREET 1: 2711 CITRUS ROAD CITY: RANCHO CORDOVA STATE: CA ZIP: 95742 BUSINESS PHONE: 9168585100 MAIL ADDRESS: STREET 1: 2711 CITRUS ROAD CITY: RANCHO CORDOVA STATE: CA ZIP: 95742 FORMER COMPANY: FORMER CONFORMED NAME: THERMOGENESIS CORP DATE OF NAME CHANGE: 19951117 FORMER COMPANY: FORMER CONFORMED NAME: INSTA COOL INC OF NORTH AMERICA DATE OF NAME CHANGE: 19920703 10-Q 1 kool20170930_10q.htm FORM 10-Q kool20170930_10q.htm

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2017.

___

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition from _____________ to _______________.

Commission File Number: 000-16375 Cesca Therapeutics Inc. (Exact name of registrant as specified in its charter)

Delaware (State of incorporation)		94-3018487 (I.R.S. Employer Identification No.)

2711 Citrus Road Rancho Cordova, California 95742 (Address of principal executive offices) (Zip Code)

(916) 858-5100 (Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ] Accelerated filer [ ]	Smaller reporting company [X]
Non-accelerated filer [ ] (Do not check if a smaller reporting company)	Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding at November 10, 2017
Common stock, $.001 par value		9,965,276

Table of Contents

Cesca Therapeutics Inc.

INDEX

Page Number

Part I Financial Information

Item 1.	Financial Statements	1

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	23

Item 4.	Controls and Procedures	23

Part II Other Information

Item 1.	Legal Proceedings	24
Item 1A.	Risk Factors	24
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3.	Defaults upon Senior Securities	24
Item 4.	Mine Safety Disclosure	24
Item 5.	Other Information	24
Item 6.	Exhibits	24

Signatures		26

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Cesca Therapeutics Inc.

Condensed Consolidated Balance Sheets

	September 30, 2017			June 30, 2017
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	2,464,000		$	3,623,000
Accounts receivable, net of allowance for doubtful accounts of $139,000 ($102,000 at June 30, 2017)		3,404,000			3,701,000
Inventories, net of reserves of $1,257,000 ($1,230,000 at June 30, 2017)		4,157,000			3,617,000
Prepaid expenses and other current assets		282,000			237,000
Total current assets		10,307,000			11,178,000

Equipment, less accumulated depreciation		2,971,000			2,330,000
Goodwill		13,794,000			13,195,000
Intangible assets, net		21,809,000			20,165,000
Other assets		61,000			64,000
Total assets	$	48,942,000		$	46,932,000

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	2,038,000		$	1,601,000
Accrued payroll and related expenses		429,000			385,000
Deferred revenue		603,000			597,000
Related party payable		606,000			606,000
Other current liabilities		1,319,000			1,331,000
Total current liabilities		4,995,000			4,520,000

Long-term debt-related party		5,000,000			3,500,000
Noncurrent deferred tax liability		6,968,000			6,968,000
Derivative obligations		743,000			730,000
Other non-current liabilities		403,000			377,000
Total liabilities		18,109,000			16,095,000

Commitments and contingencies

Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding		--			--
Common stock, $0.001 par value; 350,000,000 shares authorized; 9,959,943 issued and outstanding (9,915,868 at June 30, 2017)		10,000			10,000
Paid in capital in excess of par		218,801,000			216,222,000
Accumulated deficit		(187,707,000	)		(185,357,000	)
Accumulated other comprehensive loss		(34,000	)		(38,000	)

Total Cesca Therapeutics Inc. stockholders’ equity		31,070,000			30,837,000

Noncontrolling interests		(237,000	)		--
Total equity		30,833,000			30,837,000
Total liabilities and stockholders’ equity	$	48,942,000		$	46,932,000

See accompanying notes.

Table of Contents

Cesca Therapeutics Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

	Three Months Ended September 30,
	2017			2016

Net revenues	$	3,069,000		$	3,767,000

Cost of revenues		2,138,000			2,385,000

Gross profit		931,000			1,382,000

Expenses:

Sales and marketing		517,000			481,000

Research and development		1,063,000			670,000

General and administrative		1,701,000			2,179,000


Total operating expenses		3,281,000			3,330,000

Loss from operations		(2,350,000	)		(1,948,000	)

Fair value change of derivative instruments		(13,000	)		(326,000	)
Amortization of debt discount		--			(9,851,000	)
Interest Expense		(198,000	)		(10,535,000	)
Other income and (expenses)		(26,000	)		215,000
Net loss		(2,587,000	)		(22,445,000	)

Loss attributable to noncontrolling interests		(237,000	)		--
Net loss attributable to common stockholders	$	(2,350,000	)	$	(22,445,000	)

Net loss	$	(2,587,000	)	$	(22,445,000	)
Other comprehensive income:
Foreign currency translation adjustments		4,000			2,000
Comprehensive loss		(2,583,000	)		(22,443,000	)
Comprehensive loss attributable to noncontrolling interests		(237,000	)		--
Comprehensive loss attributable to common stockholders	$	(2,346,000	)	$	(22,443,000	)

Per share data:

Basic and diluted net loss per common share	$	(0.24	)	$	(3.71	)

Weighted average common shares outstanding – basic and diluted		9,950,776			6,048,982

See accompanying notes.

Table of Contents

Cesca Therapeutics Inc.

Condensed Consolidated Statements of Cash Flows (Unaudited)

	Three Months Ended September 30,
	2017			2016
Cash flows from operating activities:
Net loss	$	(2,587,000	)	$	(22,445,000	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		160,000			261,000
Stock based compensation expense		132,000			298,000
(Recovery of) reserve for excess and slow-moving inventories		27,000			(71,000	)
Bad debt expense		37,000			7,000
Amortization of debt discount and issue costs		--			10,011,000
Change in fair value of derivative		13,000			326,000
Non-cash accrued interest		--			10,373,000
Net change in operating assets and liabilities:
Accounts receivable		258,000			155,000
Inventories		85,000			258,000
Prepaid expenses and other current assets		(48,000	)		43,000
Accounts payable		446,000			(832,000	)
Accrued payroll and related expenses		44,000			(77,000	)
Deferred revenue		6,000			(224,000	)
Other current liabilities		(53,000	)		(122,000	)
Other noncurrent liabilities		30,000			30,000

Net cash used in operating activities		(1,450,000	)		(2,009,000	)

Net cash flows used in investing activities:
Cash paid for business acquisition		(1,000,000	)		--
Capital expenditures		(140,000	)		(154,000	)
Net cash used in investing activities:		(1,140,000	)		(154,000	)

Cash flows from financing activities:
Payments on capital lease obligations		(17,000	)		(23,000	)
Cash paid for taxes on vested restricted stock		(52,000	)		(134,000	)
Proceeds from long-term debt-related party		1,500,000			--
Proceeds from issuance of common stock, net		--			2,091,000

Net cash provided by financing activities		1,431,000			1,934,000
Effects of foreign currency rate changes on cash and cash equivalents		--			2,000
Net decrease in cash and cash equivalents		(1,159,000	)		(227,000	)

Cash and cash equivalents at beginning of period		3,623,000			5,835,000
Cash and cash equivalents at end of period	$	2,464,000		$	5,608,000

Supplemental non-cash financing and investing information:
Common stock issued for payment of convertible debentures and interest		--		$	23,905,000
Subsidiary common stock issued for acquisition of net assets	$	2,499,000			--

See accompanying notes.

Table of Contents

Cesca Therapeutics Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Description of Business and Basis of Presentation

Organization and Basis of Presentation

Cesca Therapeutics Inc. (“Cesca Therapeutics,” “Cesca,” the “Company,” “we,” “our,” “us”), a Delaware corporation, is a regenerative medicine company that was founded in 1986 and is headquartered in Rancho Cordova, CA. We develop, commercialize and market a range of automated technologies and products for cell-based therapeutics. ThermoGenesis Corp. (“ThermoGenesis”), our device subsidiary, provides the AutoXpress^®and BioArchive platforms for automated clinical biobanking, PXP™ platform for point-of-care cell-based therapies and CAR-TXpress™ platform under development for bio-manufacturing for immuno-oncology applications. Cesca is also leveraging its proprietary PXP™ technology platform to develop autologous cell-based therapies that address significant unmet needs in the vascular and orthopedic markets.

Cesca is an affiliate of the Boyalife Group, a China-based industry research alliance encompassing top research institutions for stem cell and regenerative medicine.

Liquidity

The Company has a Revolving Credit Agreement (“Credit Agreement”) with Boyalife Investment Fund II, Inc. (the “Lender”) (Refer to Note 4). As of September 30, 2017, the Company had drawn down $5,000,000 of the $10,000,000 available under the Credit Agreement. Boyalife Investment Fund II, Inc. is a wholly owned subsidiary of Boyalife Group Inc., which is owned and controlled by the Company’s Chief Executive Officer and Chairman of the Board.

On July 7, 2017, the Company, through its wholly-owned subsidiary, ThermoGenesis, acquired the business and substantially all the assets of SynGen Inc. (“SynGen”). In exchange, ThermoGenesis issued to SynGen shares of ThermoGenesis common stock that, after giving effect to the issuance, constitute 20% of ThermoGenesis’ outstanding common shares, and ThermoGenesis also made a one-time cash payment of $1,000,000 to SynGen. (Refer to Note 3).

At September 30, 2017, the Company had cash and cash equivalents of $2,464,000 and working capital of $5,312,000. The Company has incurred recurring operating losses and as of September 30, 2017 had an accumulated deficit of $187,707,000. The Company anticipates requiring additional capital to grow the device business (see Note 8), initiate the Phase III Critical Limb Ischemia trial, to fund other operating expenses and to make interest payments on the line of credit with Boyalife. These conditions raised substantial doubt about the Company’s ability to meet its obligations. To alleviate the substantial doubt, management plans to use existing cash and cash equivalents balances, revenue generating activities and draw down on the available balance from the line of credit. Other sources of liquidity could include potential issuances of debt or equity securities in public or private financings and strategic partnerships.

Based upon the additional funds available to draw down under the amended Credit Agreement, the Company’s cash balance, historical trends, expected outflows and projections for revenues, management believes it will have sufficient cash to provide for its projected needs to maintain operations and working capital requirements for at least the next 12 months from the date of this filing.

Table of Contents

Cesca Therapeutics Inc.

Notes to Condensed Consolidated Financial Statements (Continued)

(Unaudited)

Principles of Consolidation

The consolidated financial statements include the accounts of Cesca, its majority-owned subsidiary, ThermoGenesis, and its wholly-owned subsidiaries, TotipotentRX Cell Therapy, Pvt. Ltd. and TotipotentSC Scientific Product Pvt. Ltd. All significant intercompany accounts and transactions have been eliminated upon consolidation.

Noncontrolling Interests

The 20% ownership interest of ThermoGenesis that is not owned by Cesca, is accounted for as a non-controlling interest as the Company has an 80% ownership interest in the subsidiary. Earnings or losses attributable to other stockholders of a consolidated affiliated company are classified separately as "noncontrolling interest" in the Company's consolidated statements of operations. Net loss attributable to noncontrolling interest reflects only its share of the after-tax earnings or losses of an affiliated company. The Company's consolidated balance sheets reflect noncontrolling interests within the equity section of the consolidated balance sheets.

Interim Reporting

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (“SEC”) rules and regulations and accounting principles applicable for interim periods. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed consolidated financial statements through the date of issuance. Operating results for the three month period ended September 30, 2017 are not necessarily indicative of the results that may be expected for the six months ending December 31, 2017. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended June 30, 2017.

2. Summary of Significant Accounting Policies

Revenue Recognition

Revenues from the sale of the Company’s products and services are recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured. The Company generally ships products F.O.B. shipping point. There is no conditional evaluation on any product sold and recognized as revenue. Amounts billed in excess of revenue recognized are recorded as deferred revenue on the balance sheet.

Table of Contents

Cesca Therapeutics Inc.

Notes to Condensed Consolidated Financial Statements (Continued)

(Unaudited)

There is no right of return provided for distributors or customers. For sales of products made to distributors, the Company considers a number of factors in determining whether revenue is recognized upon transfer of title to the distributor, or when payment is received. These factors include, but are not limited to, whether the payment terms offered to the distributor are considered to be non-standard, the distributor history of adhering to the terms of its contractual arrangements with the Company, the level of inventories maintained by the distributor, whether the Company has a pattern of granting concessions for the benefit of the distributor, and whether there are other conditions that may indicate that the sale to the distributor is not substantive. The Company currently recognizes revenue primarily on the sell-in method with its distributors.

Revenue arrangements with multiple deliverables are divided into units of accounting if certain criteria are met, including whether the deliverable item(s) has (have) value to the customer on a stand-alone basis. Revenue for each unit of accounting is recognized as the unit of accounting is delivered. Arrangement consideration is allocated to each unit of accounting based upon the relative estimated selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables. Estimated selling prices are determined using vendor specific objective evidence of value (“VSOE”), when available, or an estimate of selling price when VSOE is not available for a given unit of accounting. Significant inputs for the estimates of the selling price of separate units of accounting include market and pricing trends and a customer’s geographic location. The Company accounts for training and installation, and service agreements and the collection, processing and testing of the umbilical cord blood and the storage as separate units of accounting.

Service revenue generated from contracts for providing maintenance of equipment is amortized over the life of the agreement. Revenue generated from storage contracts is deferred and recorded ratably over the life of the agreement, up to 21 years. All other service revenue is recognized at the time the service is completed.

Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.

Fair Value Measurements

In accordance with ASC 820, “Fair Value Measurements and Disclosures,” fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date.

The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value:

Level 1:

Quoted market prices in active markets for identical assets or liabilities.

Level 2:

Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3:

Unobservable inputs reflecting the reporting entity’s own assumptions.

Table of Contents

Cesca Therapeutics Inc.

Notes to Condensed Consolidated Financial Statements (Continued)

(Unaudited)

The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 within the fair value hierarchy since the valuation model of the derivative obligation is based on unobservable inputs.

Segment Reporting

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (“CODM”), or decision making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its chief executive officer and chief operating officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets.

The Company has two reportable business segments:

●

The Clinical Development Division, is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets.

●

The Device Division, engages in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device division is operated through the Company’s ThermoGenesis subsidiary.

Net Loss per Share

Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at September 30:

	2017		2016
Vested Series A warrants		404,412		404,412
Unvested Series A warrants⁽¹⁾		698,529		698,529
Warrants – other		3,725,782		3,725,782
Stock options		420,185		270,016
Restricted stock units		9,163		161,170
Total		5,258,071		5,259,909

⁽¹⁾

Table of Contents

Cesca Therapeutics Inc.

Notes to Condensed Consolidated Financial Statements (Continued)

(Unaudited)

Recently Adopted Accounting Standards

In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. ASU 2016-09 simplifies several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The Company adopted ASU 2016-09 effective July 1, 2017. The Company has elected to continue its current policy of estimating forfeitures rather than recognizing forfeitures when they occur. Adoption of the new standard did not have a material impact on the financial statements of the Company.

In July 2015, the FASB issued ASU No. 2015-11, “Inventory: Simplifying the Measurement of Inventory”, that requires inventory not measured using either the last in, first out (“LIFO”) or the retail inventory method to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal and transportation. The Company adopted ASU 2015-11 effective July 1, 2017. Adoption of the new standard did not have a material impact on the financial statements of the Company.

Recently Issued Accounting Standards

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC Topic 605, “Revenue Recognition” and some cost guidance included in ASC Subtopic 605-35, "Revenue Recognition - Construction-Type and Production-Type Contracts.” The core principle of ASU 2014-09 is that revenue is recognized when the transfer of goods or services to customers occurs in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASU 2014-09 requires the disclosure of sufficient information to enable readers of the Company’s financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. ASU 2014-09 also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 provides two methods of retrospective application. The first method would require the Company to apply ASU 2014-09 to each prior reporting period presented. The second method would require the Company to retrospectively apply ASU 2014-09 with the cumulative effect recognized at the date of initial application. ASU 2014-09 will be effective for the Company beginning in fiscal 2018 as a result of ASU 2015-14, "Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date," which was issued by the FASB in August 2015 and extended the original effective date by one year. The Company is currently evaluating the impact of adopting the available methodologies of ASU 2014-09 and 2015-14 upon its financial statements in future reporting periods. The Company is also in the process of evaluating the new standard against its existing accounting policies, including the timing of revenue recognition, and its contracts with customers to determine the effect the guidance will have on its financial statements and what changes to systems and controls may be warranted.

3. Acquisition of SynGen

On July 7, 2017, Cesca, through its then wholly-owned subsidiary ThermoGenesis, entered into an Asset Acquisition Agreement (the “Asset Acquisition Agreement”) with SynGen, and pursuant to the terms of the Asset Acquisition Agreement, ThermoGenesis acquired on July 7, 2017 substantially all of SynGen’s operating assets, including its proprietary cell processing platform technology (the “Transaction”).

Table of Contents

Cesca Therapeutics Inc.

Notes to Condensed Consolidated Financial Statements (Continued)

(Unaudited)

The business acquired in the Transaction excludes certain assets and liabilities of SynGen that ThermoGenesis did not acquire under the Asset Acquisition Agreement including cash and cash equivalents, accounts receivable, certain prepaid expenses and other current assets, other assets, accounts payable and other accrued liabilities. The acquisition was consummated for the purpose of enhancing the Company’s cord blood product portfolio and settling litigation between the Company and SynGen.

The acquisition was accounted for under the acquisition method of accounting for business combinations which requires, among other things that the assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. Acquisition-related costs are not included as a component of the acquisition accounting, but are recognized as expenses in the periods in which the costs are incurred. Acquisition related costs of $187,000 for the three months ended September 30, 2017 were included in general and administrative expenses. Subsequent to July 7, 2017, Cesca has recorded revenues of approximately $47,000 associated with the operations of SynGen. The amount of net loss specifically related to SynGen operations for the period beginning July 7, 2017, included in the condensed consolidated statements of operations and comprehensive loss is impracticable due to the fact that SynGen and its operations are no longer accounted for on a stand-alone basis.

The consideration for the Transaction consisted of $1,000,000 in cash and ThermoGenesis’ issuance at closing to SynGen of an aggregate of 2,000,000 shares of its common stock, constituting a 20% interest, which had a fair market value of $2,499,000. All outstanding SynGen stock options to purchase shares of SynGen common stock were cancelled.

Table of Contents

Cesca Therapeutics Inc.

Notes to Condensed Consolidated Financial Statements (Continued)

(Unaudited)

Preliminary Allocation of Consideration Transferred to Net Assets Acquired

The following is the summary of the preliminary fair value of the assets acquired and the liabilities assumed by Cesca in the Transaction, reconciled to the consideration transferred.

ThermoGenesis issued 2,000,000 shares of its common stock that had a total fair value of $2,499,000 based on an independent valuation. The final determination of the fair value of certain assets and liabilities will be completed within the 12-month measurement period from the date of acquisition as required. It is anticipated that the goodwill will be deductible for tax purposes. Any potential adjustments made could be material in relation to the preliminary values presented below:

Purchase Price:
Cash			$	1,000,000
2,000,000 common shares of ThermoGenesis				2,499,000
Fair value of assets acquired:
Inventories		649,000
Developed technology	318,000
Trade name	26,000
In process technology	1,296,000
Customer relationships	41,000
Total intangible assets		1,681,000
Property and equipment		585,000
Total assets		2,915,000
Fair value of liabilities assumed:
Other liabilities		15,000
Net assets acquired				(2,900,000	)
Preliminary goodwill			$	599,000

Supplemental Pro Forma Data

The Company used the acquisition method of accounting to account for the SynGen acquisition and, accordingly, the results of SynGen are included in the Company’s consolidated financial statements for the period subsequent to the date of acquisition. The following unaudited supplemental pro forma data for the quarters ended September 30, 2017 and 2016 present consolidated information as if the acquisition had been completed on July 1, 2016. The pro forma results were calculated by combining the results of Cesca Inc with the stand-alone results of SynGen Inc. for the pre-acquisition periods:

	Three Months Ended September 30,
	2017			2016
Net revenues	$	3,069,000		$	4,078,000
Net loss	$	(2,439,000	)	$	(23,141,000	)
Basic and diluted net loss per common share	$	(0.22	)	$	(3.80	)

Table of Contents

Cesca Therapeutics Inc.

Notes to Condensed Consolidated Financial Statements (Continued)

(Unaudited)

The unaudited pro forma financial information reflects certain adjustments related to the acquisition, such as the incremental amortization expense in connection with recording acquired identifiable intangible assets at fair value, the revised payroll expense associated with the new salaries of SynGen employees resulting from the merger, the elimination of SynGen expenses related to debt issuance costs, interest and other warrant related expenses, the elimination of the legal fees paid by both parties related to the litigation between Cesca and SynGen as ceasing the litigation was part of the Asset Acquisition Agreement and costs directly related to the acquisition.

4. Related Party Transactions

Revolving Credit Agreement

On March 6, 2017, Cesca entered into the Credit Agreement with Boyalife Investment Fund II, Inc. (the “Lender”). The Lender is a wholly owned subsidiary of Boyalife Group Inc., which is owned and controlled by the Company’s Chief Executive Officer and Chairman of the Board of Directors. The Credit Agreement grants to the Company the right to borrow up to $5,000,000 in amounts of $500,000 per advance on an unsecured basis (the “Loan”) at any time prior to March 6, 2022 (the “Maturity Date”). The Company has drawn down a total of $5,000,000 as of September 30, 2017.

The Credit Agreement and the Convertible Promissory Note issued thereunder (the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% per annum, simple interest, except that certain borrowed amounts used to pay legal expenses under the bill payment arrangement will not bear interest. The Note can be prepaid in whole or in part by the Company at any time without penalty. If the Note is not repaid in full on or before the Maturity Date, the Lender has the right after the Maturity Date to convert any unpaid principal and accrued interest into shares of the Company’s common stock at a conversion price equal to 90% of the average daily volume-weighted average trading price of the Company’s common stock during the 10 trading days immediately prior to the Maturity Date, provided that the number of shares issuable upon such conversion may not exceed 19.99% of the number of outstanding shares of common stock of the Company on the date of the Credit Agreement (unless the Company obtains stockholder approval for such issuance in the manner required by the Marketplace Rules of the Nasdaq Stock Market, Inc.).

On September 13, 2017, the Company entered into Amendment No. 1 to the Credit Agreement (the “Amended Credit Agreement”). The Amended Credit Agreement amends the Credit Agreement originally entered into by the Company and Lender on March 6, 2017, by increasing the Company’s maximum borrowing availability thereunder from $5,000,000 to $10,000,000. In connection with such amendment, the Company and Lender entered into an amended and restated convertible promissory note to reflect the new aggregate maximum principal amount of $10,000,000.

The Maturity Date of the Note is subject to acceleration at the option of the Lender upon customary events of default, which include a breach of the Loan documents, termination of operations, or bankruptcy. The Lender’s obligation to make advances under the Loan is subject to the Company’s representations and warranties in the Credit Agreement continuing to be true at all times and there being no continuing event of default under the Note. The Credit Agreement provides that if the Lender at any time in the future purchases the Company’s blood and bone marrow processing device business, the Lender would refund to the Company legal fees expended by the Company in connection with certain litigation expenses funded by the Company with proceeds of the Loan. No default has occurred through the date of filing.

Table of Contents

Cesca Therapeutics Inc.

Notes to Condensed Consolidated Financial Statements (Continued)

(Unaudited)

The Company recorded interest expense of $197,000 for the three months ended September 30, 2017 and had an interest payable balance of $319,000 and $122,000 at September 30, 2017 and June 30, 2017, respectively.

Distributor Agreement

On August 21, 2017, ThermoGenesis entered into an International Distributor Agreement with Boyalife W.S.N. Under the terms of the agreement, Boyalife W.S.N. was granted the exclusive right, subject to existing distributors and customers (if any), to develop, sell to, and service a customer base for ThermoGenesis’ AXP^® (“AutoXpress^®^”) System and BioArchive^® System in the People’s Republic of China (excluding Hong Kong and Taiwan), Singapore, Indonesia, and the Philippines (the “Territories”). Boyalife W.S.N. is an affiliate of our Chief Executive Officer and Chairman of our Board of Directors, and Boyalife (Hong Kong) Limited, our largest stockholder. Boyalife W.S.N,’s rights under the agreement include the exclusive right to distribute AXP^® Disposable Blood Processing Sets and use rights to the AXP^®(“AutoXpress^®^”) System, BioArchive System and other accessories used for the processing of stem cells from cord blood in the Territories. Boyalife W.S.N. is also appointed as the exclusive service provider to provide repairs and preventative maintenance to ThermoGenesis products in the Territories.

The term of the agreement is for three years with ThermoGenesis having the right to renew the agreement for successive two-year periods at its option. However, ThermoGenesis has the right to terminate the agreement early if Boyalife W.S.N. fails to meet specified minimum purchase requirements.

Revenues

During the three months ended September 30, 2017, the Company recorded $751,000 of revenues from Boyalife and had an accounts receivable balance of $751,000 and $308,000 at September 30, 2017 and June 30, 2017, respectively.

Bill Payment Arrangement

The Company entered into a bill payment arrangement whereby Boyalife Group Ltd. (“Payor”), the Company’s largest shareholder, agreed to pay the Company’s legal expenses payable to the Company’s attorney related to certain litigation involving SynGen Inc. (the “Bill Payment Arrangement”), although the Company remains jointly and severally liable for the payment of such legal fees. The terms of the Bill Payment Arrangement provided that the Company will reimburse Payor for any and all amounts paid by Payor in connection with the Bill Payment Arrangement under certain specified events. There is no interest payable on outstanding balance of related party payable. This litigation was terminated as part of the SynGen acquisition agreement. As of September 30, 2017, invoices totaling $606,000 had been paid by Payor and are included in related party payable as the Company anticipates repaying this within a year.

5. Commitments and Contingencies

Financial Covenants

Effective May 15, 2017, the Company entered into a Sixth Amended and Restated Technology License and Escrow Agreement with CBR Systems, Inc. which modified the financial covenant that the Company must meet in order to avoid an event of default. The Company must maintain a cash balance and short-term investments net of debt or borrowed funds that are payable within one year of not less than $2,000,000. The Company was in compliance with this financial covenant as of September 30, 2017.

Table of Contents

Cesca Therapeutics Inc.

Notes to Condensed Consolidated Financial Statements (Continued)

(Unaudited)

Warranty

The Company offers a warranty on all of its non-disposable products of one to two years. The Company warrants disposable products through their expiration date. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary.

The warranty liability is included in other current liabilities in the unaudited balance sheets. The change in the warranty liability for the three months ended September 30, 2017 is summarized in the following table:

Balance at July 1, 2017	$	588,000
Warranties issued during the period		40,000
Settlements made during the period		(297,000	)
Changes in liability for pre-existing warranties during the period		(4,000	)
Balance at September 30, 2017	$	327,000

Contingency

In fiscal 2016, the Company signed an engagement letter with a strategic consulting firm. Included in the engagement letter was a success fee due upon the successful conclusion of certain strategic transactions. On May 4, 2017, a lawsuit was filed against the Company and its CEO by the consulting firm as the consulting firm argues that it is owed a transaction fee of $1,000,000 under the terms of the engagement letter due to the conversion of the Boyalife debentures in August 2016. In October 2017, to streamline the case and without acknowledging any liability, the Company deposited $1,000,000 with the Court and the consulting firm is in the process of dismissing the Company’s CEO from the case, without liability. The Company intends to defend the lawsuit vigorously and no accrual has been recorded for this contingent liability as of September 30, 2017.

6. Derivative Obligations

Series A Warrants

Series A warrants to purchase 404,412 common shares were issued and vested during the year ended June 30, 2016. At the time of issuance, the Company determined that as such warrants can be settled for cash at the holders’ option in a future fundamental transaction they constituted a derivative liability. The Company has estimated the fair value of the derivative liability, using a Binomial Lattice Valuation Model and the following assumptions:

	Series A
	September 30, 2017			June 30, 2017
Market price of common stock	$	3.56		$	3.17
Expected volatility		102	%		110	%
Contractual term (years)		3.4			3.7
Discount rate		1.7	%		1.66	%
Dividend rate		0	%		0	%
Exercise price	$	8.00		$	8.00

Table of Contents

Cesca Therapeutics Inc.

Notes to Condensed Consolidated Financial Statements (Continued)

(Unaudited)

Expected volatilities are based on the historical volatility of the Company’s common stock. Contractual term is based on remaining term of the respective warrants. The discount rate represents the yield on U.S. Treasury bonds with a maturity equal to the contractual term.

The Company recorded a loss of $13,000 and $326,000 during the three months ended September 30, 2017 and 2016, respectively, representing the net change in the fair value of the derivative liability, which is presented as fair value change of derivative instruments, in the accompanying consolidated statements of operations and comprehensive loss.

The following table represents the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of September 30, 2017 and June 30, 2017:

Balance at September

30, 2017

Level 1

Level 2

Level 3

Derivative obligation

743,000

Balance at June

30, 2017

Level 1

Level 2

Level 3

Derivative obligation

730,000

The following table reflects the change in fair value of the Company’s derivative liabilities for the three months ended September 30, 2017:

	Amount
Balance – July 1, 2017	$	730,000
Change in fair value of derivative obligation		13,000
Balance – September 30, 2017	$	743,000

Table of Contents

Cesca Therapeutics Inc.

Notes to Condensed Consolidated Financial Statements (Continued)

(Unaudited)

7. Stockholders’ Equity

Stock Based Compensation

The Company recorded stock-based compensation of $132,000 and $298,000 for the three months ended September 30, 2017 and 2016, respectively.

The following is a summary of option activity for the Company’s stock option plans:

	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life		Aggregate Intrinsic Value

Outstanding at June 30, 2017		397,389		$	5.80

Granted		40,000		$	3.47
Forfeited		(14,765	)	$	3.52
Expired		(2,439	)	$	27.04

Outstanding at September 30, 2017		420,185		$	5.54		6	$	182,000

Vested and expected to vest at September 30, 2017		397,590		$	5.66		6	$	175,000

Exercisable at September 30, 2017		278,487		$	6.64		5.5	$	128,000

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were no options exercised during the three months ended September 30, 2017.

The fair value of the Company’s stock options granted for the three months ended September 30, 2017 was estimated using the following weighted-average assumptions:

Expected life (years)	4
Risk-free interest rate	1.7	%
Expected volatility	108	%
Dividend yield	0	%

Table of Contents

Cesca Therapeutics Inc.

Notes to Condensed Consolidated Financial Statements (Continued)

(Unaudited)

Common Stock Restricted Units

The following is a summary of restricted stock activity during the three months ended September 30, 2017:

				Weighted Average
	Number of Shares			Grant Date Fair Value
Balance at June 30, 2017		59,694		$	4.62
Granted		10,000		$	3.26
Vested		(60,531	)	$	4.54
Forfeited		--			--
Outstanding at September 30, 2017		9,163		$	3.65

Warrants

There was no warrant activity for the three months ended September 30, 2017. At September 30, 2017, there were 4,828,723 warrants outstanding with a weighted-average exercise price per share of $9.37 and 4,130,192 warrants exercisable with a weighted-average exercise price per share of $9.60. At September 30, 2017, the total intrinsic value of warrants outstanding and exercisable was $0.

8. Segment Reporting

The Company has two reportable segments, which are the same as its operating segments:

The Clinical Development segment is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets.

The device segment is a pioneer and market leader in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing.

Table of Contents

Cesca Therapeutics Inc.

Notes to Condensed Consolidated Financial Statements (Continued)

(Unaudited)

The following table summarizes the operating results of the Company’s reportable segments:

	Three Months Ended September 30, 2017
	Clinical Development			Device			Total
Net revenues	$	126,000		$	2,943,000		$	3,069,000
Cost of revenues		120,000			2,018,000			2,138,000
Gross profit		6,000			925,000			931,000

Operating expenses		1,169,000			2,112,000			3,281,000
Operating loss	$	(1,163,000	)	$	(1,187,000	)	$	(2,350,000	)

Depreciation and amortization	$	75,000		$	85,000		$	160,000
Stock-based compensation expense	$	85,000		$	47,000		$	132,000

	Three Months Ended September 30, 2016
	Clinical Development			Device		Total
Net revenues	$	156,000		$	3,611,000	$	3,767,000
Cost of revenues		142,000			2,243,000		2,385,000
Gross profit		14,000			1,368,000		1,382,000

Operating expenses		1,964,000			1,366,000		3,330,000
Operating profit (loss)	$	(1,950,000	)	$	2,000	$	(1,948,000	)

Depreciation and amortization	$	139,000		$	122,000	$	261,000
Stock-based compensation expense	$	190,000		$	108,000	$	298,000

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This report contains forward-looking statements. The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained herein. When used in this report, the words "anticipate," "believe," "estimate," "expect" and similar expressions as they relate to the Company or its management are intended to identify such forward-looking statements. Actual results, performance or achievements could differ materially from the results expressed in, or implied by these forward-looking statements. Readers should be aware of important factors that, in some cases, have affected, and, in the future, could affect actual results, and may cause actual results for the six months ended December 31, 2017 and beyond to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company. These factors include without limitation, the ability to obtain capital and other financing in the amounts and at the times needed to complete clinical trials and launch new products, market acceptance of new products, the nature and timing of regulatory approvals for both new products and existing products for which the Company proposes new claims, realization of forecasted revenues, expenses and income, initiatives by competitors, price pressures, failure to meet FDA regulated requirements governing the Company’s products and operations (including the potential for product recalls associated with such regulations), risks associated with initiating manufacturing for new products, failure to meet Foreign Corrupt Practice Act regulations, legal proceedings, and other risk factors listed from time to time in our SEC reports, including, in particular, those set forth in the Cesca Therapeutics Inc. Form 10-K for fiscal year ended June 30, 2017.

Cesca is a regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Cesca’s device subsidiary, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress^® technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the vascular, cardiology and orthopedic markets.

On July 7, 2017, our then wholly-owned subsidiary, ThermoGenesis, acquired the business and substantially all of the assets of SynGen, a privately held Sacramento, California-based technology company that develops, markets, and sells advanced cell separation tools and accessories. In the transaction (the “SynGen Transaction”), ThermoGenesis acquired substantially all of SynGen’s operating assets, including its proprietary cell processing platform. In exchange, ThermoGenesis issued to SynGen shares of ThermoGenesis common stock that, after giving effect to the issuance, constitute 20% of ThermoGenesis’ outstanding common shares, and ThermoGenesis also made a one-time cash payment of $1,000,000 to SynGen. Immediately prior to the SynGen Transaction, the Company contributed the assets, business, and current liabilities of its blood and bone-marrow processing device business to ThermoGenesis and will operate such business (together with the acquired business) through the ThermoGenesis subsidiary.

Prior to the SynGen Transaction, Cesca’s device business was owned and operated directly by Cesca, and from and after the SynGen Transaction, Cesca’s device business (together with the business acquired from SynGen) is and will be owned and operated by ThermoGenesis.

In August 2017, our Board of Directors approved changing our fiscal year from June 30 to a calendar year ending December 31. As a result, we will file a transition report on Form 10-K for the six month period ending December 31, 2017.

Table of Contents

Cesca’s Device Segment

The operations and assets of Cesca’s device segment are conducted through our ThermoGenesis subsidiary, which is a pioneer and market leader in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device segment’s automated solution offerings include:

Clinical BioBanking

AXP^® + BioArchive^® provide automated isolation, collection and storage of cord blood stem cell concentrates.

Point-of-Care Solutions for Cell-Based Therapeutics

PXP^™ allows for the rapid, automated processing of autologous peripheral or bone marrow derived stem cells at the point-of-care, such as surgical centers or clinics. By the end of 2017, we expect to file for Class II clearance from the U.S. FDA for our point-of-care system.

Cellular Processing for Immuno-Oncology Applications

CAR-TXpress (“CXP™”) + BioArchive^® allow for the automated manufacturing, expansion and storage of cellular therapies for immuno-oncology, including various T-cell and natural killer (NK) cell based therapies.

The device segment’s product pipeline includes:

●

AutoXpress^® System (“AXP^®”) - a proprietary, automated system for the isolation and collection of hematopoietic stem cells from cord blood and peripheral blood. By the end of 2017, we expect to launch the AXP II System. The automated system is an upgrade to the AXP and is designed for the separation and processing of biological components and is intended for use in cord blood banking.

●

PXP™ for Point-of-Care Applications – a proprietary, automated system for the rapid, automated processing of autologous peripheral or bone marrow derived stem cells for cell-based therapies at point-of-care situations, such as surgical centers or clinics.

●

CXP™ - a proprietary, automated system for the isolation and collection of cells derived from biological sources, for various laboratory based downstream applications.

●

BioArchive^®System - an automated, cryogenic system used by cord blood banks for the cryopreservation and storage of cord blood stem cell concentrate for future use.

Cesca’s Clinical Development Segment

Using its proprietary AutoXpress^® technology platform, Cesca’s clinical development segment is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that Cesca believes will address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets.

Vascular Diseases - Critical Limb Ischemia (“CLI”) – Cesca is currently in late stage development of its proprietary, point-of-care, autologous stem cell-based therapeutic for the treatment of patients with CLI. The Company’s 362 patient, multi-center pivotal Phase III Critical Limb Ischemia Rapid Stem Cell Treatment (“CLIRST”) trial is designed to evaluate the safety and efficacy of autologous stem cell-based therapy to stimulate the regeneration of blood vessels, promote wound healing and prevent amputation. Previous clinical studies using Cesca’s proprietary, point-of-care-technologies have successfully demonstrated the regeneration of blood vessels and improved blood circulation in the limbs, using a patient’s own bone marrow derived stem cells. The Company is actively seeking strategic partners to co-develop CLIRST.

Table of Contents

Cardiology - Acute Myocardial Infarction – Cesca is developing a proprietary, point-of-care autologous stem cell-based therapy intended as an adjunct treatment for patients who have suffered an acute ST-elevated myocardial infarction (“STEMI”), the most serious type of heart attack. Such treatments are aimed at minimizing the adverse remodeling of the heart post-STEMI.

Orthopedics – OsteoArthritis (“OA”) - Cesca is in early stage development of an autologous stem cell based therapy intended to treat patients with cartilage tissue degeneration that may lead to progressive cartilage loss and painful joint diseases. Localized articular cartilage defects can potentially be repaired by transplantation of autologous cell therapy. Therapies in development using Cesca’s proprietary PXP™system are expected to delay further deterioration and repair the damaged joint cartilage. Treatment is typically via a single procedure in the hospital or clinic.

Critical Accounting Policies

Management’s discussion and analysis of its financial condition and results of operations is based upon the condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. Estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. For a full discussion of our accounting estimates and assumptions that have been identified as critical in the preparation of the Company’s condensed consolidated financial statements, please refer to Cesca’s 2017 Annual Report on Form 10-K.

Results of Operations for the Three Months Ended September 30, 2017 as Compared to the Three Months Ended September 30, 2016

Net Revenues

Consolidated net revenues for the three months ended September 30, 2017 were $3,069,000 compared to $3,767,000 for three months ended September 30, 2016, a decrease of $698,000. Device segment revenues decreased primarily due to a one-time shipment of our remaining inventory associated with a discontinued product line (Res-Q) and AXP disposables, which had lower sales due to a single end user customer purchasing larger than normal orders to stock up inventory levels in the quarter ended September 30, 2016. If it weren’t for these one-time events, revenues would have been higher than the quarter ended September 30, 2016. Clinical development revenues consist of sales generated by our Totipotent subsidiaries. These sales declined due to lower manual bagset sales. Offsetting these decreases for the device segment was an increase in sales of our BioArchive devices as we sold three during the quarter ended September 30, 2017 as compared to none in the quarter ended September 30, 2016. Recently, there has been a significant increase in BioArchive device sales. For the last two quarters ended September 30, 2017, we sold five BioArchive devices, as compared to only two devices in the seven previous quarters combined. We expect this trend to continue, with approximately two to three devices sold per quarter for at least the next three to four quarters.

Table of Contents

Revenues were comprised of the following for the three months ended:

	September 30, 2017		September 30, 2016
Device Segment:
AXP	$	1,443,000	$	1,857,000
BioArchive		1,117,000		905,000
Manual Disposables		334,000		273,000
Bone Marrow		--		551,000
Other		49,000		25,000
		2,943,000		3,611,000
Clinical Development Segment:
Manual Disposables		7,000		71,000
Bone Marrow		92,000		19,000
Other		27,000		66,000
		126,000		156,000
	$	3,069,000	$	3,767,000

Gross Profit

The Company’s consolidated gross profit is driven substantially by our device segment. Our device segment gross profit margin decreased from $1,368,000 or 38% for the quarter ended September 30, 2016 to $925,000 or 31% for the quarter ended September 30, 2017 primarily due to increases in our inventory reserves for the MXP product line, an increase in overhead expenses as a result of the merger with SynGen and our mix of products sold.

Sales and Marketing Expenses

Sales and marketing expenses were $517,000 for the three months ended September 30, 2017, compared to $481,000 for the three months ended September 30, 2016, an increase of $36,000 or 7%. Predominantly all of the Company’s sales and marketing expenses are generated by the device segment. The slight increase is primarily due to higher personnel costs from the SynGen acquisition.

Research and Development Expenses

Research and development expenses were $1,063,000 for the three months ended September 30, 2017, compared to $670,000 for the comparable fiscal 2017 period, an increase of $393,000 or 59%. Research and development expenses in our device segment increased $705,000, while our clinical development segment decreased $312,000. The changes are due to additional headcount in the device segment from the SynGen acquisition, and a shift in existing personnel from the clinical development segment to the device segment as we are not funding clinical development projects until a strategic partner is located.

General and Administrative Expenses

General and administrative expenses include costs associated with accounting, finance, human resources, information system and executive functions.

Consolidated general and administrative expenses were $1,701,000 for the three months ended September 30, 2017, compared to $2,179,000 for the three months ended September 30, 2016, a decrease of $478,000 or 22%. The decrease is primarily due to a decrease in legal expenses of approximately $200,000 due to settlement of the SynGen litigation during the quarter ended September 30, 2017 and severance expenses of $173,000 recorded in the quarter ended September 30, 2016 due to the elimination of positions in both segments.

Table of Contents

Non-U.S. GAAP Measures

In addition to the results reported in accordance with US GAAP, we also use a non-GAAP measure, adjusted EBITDA, to evaluate operating performance and to facilitate the comparison of our historical results and trends. This financial measure is not a measure of financial performance under US GAAP and should not be considered in isolation or as a substitute for loss as a measure of performance. The Company defines adjusted EBITDA as loss from operations adjusted for depreciation and amortization, stock-based compensation expenses and impairment of intangible assets as applicable. The calculation of this non-GAAP measure may not be comparable to similarly titled measures used by other companies. Reconciliations to the most directly comparable US GAAP measure are provided below.

	For the Three Months Ended September 30, 2017
	Clinical Development			Device			Total
Loss from operations	$	(1,163,000	)	$	(1,187,000	)	$	(2,350,000	)
Add:
Depreciation and amortization		75,000			85,000			160,000
Stock-based compensation expense		85,000			47,000			132,000
Adjusted EBITDA	$	(1,003,000	)	$	(1,055,000	)	$	(2,058,000	)

	For the Three Months Ended September 30, 2016
	Clinical Development			Device		Total
Profit (loss) from operations	$	(1,950,000	)	$	2,000	$	(1,948,000	)
Add:
Depreciation and amortization		139,000			122,000		261,000
Stock-based compensation expense		190,000			108,000		298,000
Adjusted EBITDA	$	(1,621,000	)	$	232,000	$	(1,389,000	)

Adjusted EBITDA

The increase in our consolidated adjusted EBITDA loss from $1,389,000 to $2,058,000 and the difference in our device segment adjusted EBITDA from $232,000 profit to $1,055,000 loss is primarily due to the headcount and project expenses added during the quarter ended September 30, 2017 as a result of our SynGen acquisition. The decrease in the clinical development adjusted EBITDA loss from $1,621,000 to $1,003,000 is primarily due to the elimination or transfer of personnel to the device segment to work on those projects versus clinical studies.

Liquidity and Capital Resources

At September 30, 2017, the Company had cash and cash equivalents of $2,464,000 and working capital of $5,312,000. This compares to cash and cash equivalents of $3,623,000 and working capital of $6,658,000 at June 30, 2017. We have primarily financed operations through private and public placement of equity securities and our line of credit facility.

On July 7, 2017, our then wholly-owned subsidiary, ThermoGenesis, acquired the business and substantially all of the assets of SynGen, a privately held Sacramento, California-based technology company that develops, markets, and sells advanced cell separation tools and accessories. In the SynGen Transaction, ThermoGenesis acquired substantially all of SynGen’s operating assets, including its proprietary cell processing platform. In exchange, ThermoGenesis issued to SynGen 2,000,000 shares of ThermoGenesis common stock which had a fair market value of $2,499,000 based on an independent analysis and ThermoGenesis also made a one-time cash payment of $1,000,000 to SynGen. As part of the Asset Acquisition Agreement, the two companies agreed to cease the mutual litigation.

Table of Contents

The Company has a Revolving Credit Agreement with Boyalife Investment Fund II, Inc. As of September 30, 2017, the Company had drawn down $5,000,000 of the $10,000,000 available under the Credit Agreement and drew down an additional $1,700,000 in October 2017, $1,000,000 of which was used for the bond deposited with the Court. Boyalife Investment Fund II, Inc. is a wholly owned subsidiary of Boyalife Group Inc., which is owned and controlled by the Company’s Chief Executive Officer and Chairman of the Board.

The Company will need additional funding to support its operations and its clinical development programs, in particular the CLIRST trial. Accordingly, management has been exploring additional funding sources, with a primary focus on strategic partner relationships. The Company cannot assure that such funding will be available on a timely basis, in needed quantities, or on favorable terms, if at all.

Net cash used in operating activities for the three months ended September 30, 2017 was $1,450,000 compared to $2,009,000, for September 30, 2016. The improvement in net cash used in operating activities was primarily due to a limited number of above-average vendor payments during the quarter ended September 30, 2016.

Off-Balance Sheet Arrangements

As of September 30, 2017, the Company had no off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Cesca is a smaller reporting company as defined by Rule 12b-2 of the Securities and Exchange Act of 1934 and is not required to provide information under this item.

Item 4. Controls and Procedures

Cesca carried out an evaluation, under the supervision, and with the participation of management, including both the Company’s Chief Executive Officer (principal executive officer) and Principal Accounting Officer (principal financial officer), of the effectiveness of the design and operation of Cesca’s disclosure controls and procedures (as defined by Exchange Act Rule 13a-15(e) and 15d-15(e)) as of the end of our fiscal quarter pursuant to Exchange Act Rule 13a-15. Disclosure controls and procedures cover controls and other procedures that are designed to ensure that information required to be disclosed by the Company in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to management, including the Chief Executive Officer and the Principal Accounting Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon that evaluation, Cesca’s Chief Executive Officer and Principal Accounting Officer have both concluded that the Company’s disclosure controls and procedures were effective as of September 30, 2017.

There were no changes in Cesca’s internal controls over financial reporting that occurred during the three months ended September 30, 2017 that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting. Management believes that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within any company, have been detected.

Table of Contents

PART II - OTHER INFORMATION

Item 1.

Legal Proceedings.

In the normal course of operations, the Company may have disagreements or disputes with distributors, vendors or employees. Such potential disputes are seen by management as a normal part of business. There have been no material changes since the disclosures set forth in the Company’s 10-K, as amended, for fiscal year end June 30, 2017.

Item 1A.

Risk Factors.

Readers should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in Cesca’s Annual Report on Form 10-K for the fiscal year ended June 30, 2017, which could materially affect the Company’s business, financial condition or future results. There have been no material changes from those risk factors. Additional risks and uncertainties not currently known or knowable to the Company or that management currently deems to be immaterial, may also have a materially adverse effect on Cesca’s business, financial condition and/or operating results.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

Cesca had no unregistered sales of equity securities during the three months ended September 30, 2017.

Item 3.

Defaults upon Senior Securities.

None.

Item 4.

Mine Safety Disclosure.

Not applicable.

Item 5.

Other Information.

None.

Item 6.

Exhibits.

An index of exhibits is found on page 25 of this report.

Table of Contents

Item 6.

Exhibits.

Exhibit No.	Document Description	Incorporated by Reference
10.1	Asset Acquisition Agreement, dated July 7, 2017, between SynGen Inc. and ThermoGenesis Corp.*	Incorporated by reference to Exhibit 2.1 to Form 8-K filed with the SEC on July 10, 2017.
10.2	Voting Agreement, dated July 7, 2017, among ThermoGenesis Corp., Cesca Therapeutics Inc., Bay City Capital Fund V, L.P., and Bay City Capital Fund V Co-Investment Fund, L.P.	Incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on July 10, 2017.
10.3	Investors’ Rights Agreement, dated July 7, 2017, among ThermoGenesis Corp., Bay City Capital Fund V, L.P., and Bay City Capital Fund V Co-Investment Fund, L.P.	Incorporated by reference to Exhibit 10.2 to Form 8-K filed with the SEC on July 10, 2017.
10.4	Right of First Refusal and Co-Sale Agreement, dated July 7, 2017, among ThermoGenesis Corp., Cesca Therapeutics Inc., Bay City Capital Fund V, L.P., and Bay City Capital Fund V Co-Investment Fund, L.P.	Incorporated by reference to Exhibit 10.3 to Form 8-K filed with the SEC on July 10, 2017.
10.5	Amended and Restated Certificate of Incorporation of ThermoGenesis Corp.	Incorporated by reference to Exhibit 10.4 to Form 8-K filed with the SEC on July 10, 2017.
10.6	Amendment No. 1 to Revolving Credit Agreement, dated September 13, 2017, between Cesca Therapeutics Inc. and Boyalife Investment Fund II, Inc.	Incorporated by reference to Exhibit 10.1 to Form 8-K/A filed with the SEC on September 21, 2017.
10.7	Amended and Restated Convertible Promissory Note, dated September 13, 2017, issued by Cesca Therapeutics Inc. to Boyalife Investment Fund II, Inc.	Incorporated by reference to Exhibit 10.2 to Form 8-K/A filed with the SEC on September 21, 2017.
31.1	Certification by the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	Filed herewith
31.2	Certification by the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	Filed herewith
32	Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes Oxley Act of 2002.	Filed herewith
101.INS	XBRL Instance Document‡
101.SCH	XBRL Taxonomy Extension Schema Document‡
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document‡
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document‡
101.LAB	XBRL Taxonomy Extension Label Linkbase Document‡
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document‡

Footnotes to Exhibit Index

‡

XBRL information is furnished and not filed for purpose of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement or prospectus to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document.

Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished supplementally to the Securities and Exchange Commission upon request.

Table of Contents

Cesca Therapeutics Inc.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		Cesca Therapeutics Inc. (Registrant)


Dated: November 14, 2017		/s/ Xiaochun (Chris) Xu, Ph.D.
		Xiaochun (Chris) Xu, Ph.D. Chief Executive Officer (Principal Executive Officer)


Dated: November 14, 2017		/s/ Jeff Cauble
		Jeff Cauble Principal Financial and Accounting Officer (Principal Financial Officer and Principal Accounting Officer)

EX-31.1 2 ex_100156.htm EXHIBIT 31.1 ex_100156.htm

Exhibit 31.1

PRINCIPAL EXECUTIVE OFFICER’S CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Xiaochun (Chris) Xu, certify that:

1. I have reviewed this report on Form 10-Q of Cesca Therapeutics Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusion about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 14, 2017

/s/ Xiaochun (Chris) Xu, Ph.D.

Xiaochun (Chris) Xu, Ph.D.

Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 ex_100157.htm EXHIBIT 31.2 ex_100157.htm

Exhibit 31.2

PRINCIPAL FINANCIAL OFFICER’S CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jeff Cauble, certify that:

1. I have reviewed this report on Form 10-Q of Cesca Therapeutics Inc.;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 14, 2017

/s/ Jeff Cauble

Jeff Cauble

Principal Financial and Accounting Officer

(Principal Financial Officer and Principal Accounting Officer)

EX-32 4 ex_100158.htm EXHIBIT 32 ex_100158.htm

Exhibit 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Cesca Therapeutics Inc. (the "Company") on Form 10-Q for the period ended September 30, 2017, as filed with the Securities and Exchange Commission (the "Report"), we, Xiaochun (Chris) Xu, Chief Executive Officer and Jeff Cauble, Principal Financial and Accounting Officer, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of our knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 14, 2017		/s/ Xiaochun (Chris) Xu, Ph.D.
		Xiaochun (Chris) Xu, Ph.D. Chief Executive Officer (Principal Executive Officer)


Dated: November 14, 2017		/s/ Jeff Cauble
		Jeff Cauble Principal Financial and Accounting Officer (Principal Financial Officer and Principal Accounting Officer)

EX-101.INS 5 kool-20170930.xml XBRL INSTANCE DOCUMENT false --12-31 Q1 2017 2017-09-30 10-Q 0000811212 9965276 Yes Smaller Reporting Company CESCA THERAPEUTICS INC. No No kool -0.22 -3.80 4130192 0 9.60 0 9.37 0.9 0.1999 P10D P2Y P3Y 27000 -71000 500000 1000000 P21Y 0.2 0.2 P1Y P2Y 2000000 5312000

2038000

1601000

3404000

3701000

751000

308000

-34000

-38000

218801000

216222000

132000

298000

139000

102000

10011000

9851000

404412

698529

3725782

420185

270016

9163

161170

5258071

5259909

48942000

46932000

10307000

11178000

2499000

2000000

-2439000

-23141000

3069000

4078000

187000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.</div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">     </div></div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-weight: bold;">Acquisition</div></div><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-weight: bold;"> of SynGen</div></div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 7, 2017, </div>Cesca, through its then wholly-owned subsidiary ThermoGenesis, entered into an Asset Acquisition Agreement (the “Asset Acquisition Agreement”) with SynGen, and pursuant to the terms of the Asset Acquisition Agreement, ThermoGenesis acquired on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 7, 2017 </div>substantially all of SynGen<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">’s operating assets, including its proprietary cell processing platform technology (the “Transaction”).</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The business acquired in the Transaction excludes certain assets and liabilities of SynGen that ThermoGenesis did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> acquire under the Asset Acquisition Agreement including cash and cash equivalents, accounts receivable, certain prepaid expenses and other current assets, other assets, accounts payable and other accrued liabilities<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">. The acquisition was consummated for the purpose of enhancing the Company’s cord blood product portfolio and settling litigation between the Company and SynGen. </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The acquisition was accounted for under the acquisition method of accounting for business combinations which requires, among other things that the assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. Acquisition-related costs are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> included as a component of the acquisition accounting, but are recognized as expenses in the periods in which the costs are incurred. Acquisition related costs of $<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">187,000</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>were included in general and administrative expenses. Subsequent to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 7, 2017, </div>Cesca has recorded revenues of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$47,000</div> associated with the operations of SynGen. The amount of net loss specifically related to SynGen operations for the period beginning <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 7, 2017, </div>included in the condensed consolidated statements of operations and comprehensive loss is impracticable due to the fact that SynGen and its operations are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer accounted for on a stand-alone basis. </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The consideration for t<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">he Transaction consisted of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,000,000</div> in cash and ThermoGenesis’ issuance at closing to SynGen of an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,000,000</div> shares of its common stock, constituting a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20%</div> interest, which had a fair market value of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,499,000.</div> All outstanding SynGen stock options to purchase shares of SynGen common stock were cancelled.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Preliminary Allocation of Consideration Transferred to Net Assets Acquired </div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following is the summary of the preliminary fair value of the assets acquired and the liabilities assumed by Cesca in the Transaction, reconciled to the consideration transferred.</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">ThermoGenesis <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,000,000</div> shares of its common stock that had a total fair value of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,499,000</div> based on an independent valuation. The final determination of the fair value of certain assets and liabilities will be completed within the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div>-month measurement period from the date of acquisition as required. It is anticipated that the goodwill will be deductible for tax purposes. Any potential adjustments made could be material in relation to the preliminary values presented below:</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Purchase Price:</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Cash</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,000,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">2,000,000 common shares of ThermoGenesis</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,499,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Fair value of assets acquired:</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Inventories</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">649,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Developed technology</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">318,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Trade name</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">In process technology</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,296,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Customer relationships</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 36pt;">Total intangible assets</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,681,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Property and equipment</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">585,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 72pt;">Total assets</div> </td> <td style="border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,915,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Fair value of liabilities assumed:</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Other liabilities</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,900,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Preliminary goodwill</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">599,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Supplemental Pro Forma Data</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company used the acquisition method of accounting to account for the <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">SynGen acquisition and, accordingly, the results of SynGen are included in the Company’s consolidated financial statements for the period subsequent to the date of acquisition. The following unaudited supplemental pro forma data for the quarters ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> present consolidated information as if the acquisition had been completed on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 1, 2016. </div>The pro forma results were calculated by combining the results of Cesca Inc with the stand-alone results of SynGen Inc. for the pre-acquisition periods:</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three Months Ended<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">September 30,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">2016</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net revenues</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,069,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,078,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,439,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(23,141,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic and diluted net loss per common share</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.22</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3.80</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> </table> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The unaudited pro forma financial information reflects certain adjustments related to the acquisition, such as the incremental amortization expense in connection with recording acquired identifiable intangible assets at fair value, <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">the revised payroll expense associated with the new salaries of SynGen employees resulting from the merger, the elimination of SynGen expenses related to debt issuance costs, interest and other warrant related expenses, the elimination of the legal fees paid by both parties related to the litigation between Cesca and SynGen as ceasing the litigation was part of the Asset Acquisition Agreement and costs directly related to the acquisition.</div></div></div>

47000

2915000

15000

318000

26000

1296000

41000

1681000

649000

2900000

585000

2464000

3623000

5835000

5608000

-1159000

-227000

404412

4828723

0.001

350000000

9959943

9915868

9959943

9915868

10000

-2346000

-22443000

-237000

-2583000

-22443000

120000

2018000

2138000

142000

2243000

2385000

2138000

2385000

10000000

0.22

603000

597000

6968000

160000

261000

75000

85000

160000

139000

122000

261000

-13000

-326000

743000

730000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;">.     </div><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-weight: bold;">Stockholders</div></div><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-weight: bold;">’ </div></div><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-weight: bold;">Equity</div></div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Stock Based Compensation</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> recorded stock-based compensation of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$132,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$298,000</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The following is a summary of option activity for <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">the Company’s stock option plans: </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Number of</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted-</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Average</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Exercise</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Price</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted-</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Average</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Remaining</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Contractual</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Life</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Aggregate</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Intrinsic</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Value</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">2017</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">397,389</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.80</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.47</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(14,765</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.52</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expired<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> </div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,439</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27.04</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">September 30, 2017</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">420,185</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.54</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">182,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to v<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">est at September 30, 2017</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">397,590</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.66</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">175,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">September 30, 2017</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">278,487</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.64</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">128,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">’s common stock. There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> options exercised during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017.</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">The fair value of the Company<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">’s stock options granted for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>was estimated using the following weighted-average assumptions:</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected life (years)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">108</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </table> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Common Stock Restricted </div></div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Units</div></div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The following is a summary of <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">restricted stock activity during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017:</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Average</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Number of</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Grant Date</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Fair Value</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at June 30, <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">2017</div></div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59,694</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.62</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.26</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(60,531</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.54</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at September 30, 201<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">7</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,163</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.65</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Warrants</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">There was <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> </div>warrant activity for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017. </div>At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>there were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,828,723</div> warrants outstanding with a weighted-average exercise price per share of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$9.37</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,130,192</div> warrants exercisable with a weighted-average exercise price per share of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$9.60.</div> </div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>the total intrinsic value of warrants outstanding and exercisable was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0</div>.</div></div></div></div>

606000

5000000

3500000

-0.24

-3.71

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Net Loss per Share</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding. The calculation<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30:</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table border="0px" cellpadding="0pt" cellspacing="0pt" style="; font-size: 10pt; text-indent: 0px; margin: 0pt 2.5%; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">2016</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested Series A warrants</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">404,412</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">404,412</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested Series A warrants<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">(1)</div></div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">698,529</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">698,529</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">– other</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,725,782</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,725,782</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock options</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">420,185</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">270,016</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock units</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,163</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">161,170</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,258,071</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,259,909</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <table border="0" cellpadding="0" cellspacing="0" style=";font-family:Times New Roman, Times, serif;font-size:10pt; min-width: 700px;"> <tr> <td style="width:4pt;"> </td> <td style="width:18pt;vertical-align:top;"> <div style=" font-family:Times New Roman, Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>)</div></div> </td> <td style="vertical-align:top;"> <div style=" font-family:Times New Roman, Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">The unvested Series A warrants were subject to vesting based upon the amount of funds actually received<div style="display: inline; font-size:10pt;font-family:Times New Roman, Times, serif;"> by the Company in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> close of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2015 </div>financing which never occurred. The warrants will remain outstanding but unvested until they expire in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2021</div></div><div style="display: inline; font-size:10pt;font-family:Times New Roman, Times, serif;">.</div></div> </td> </tr> </table></div></div></div></div></div></div>

2000

429000

385000

P3Y146D

P3Y255D

1.02

1.1

0.017

0.0166

1701000

2179000

599000

13794000

13195000

6000

925000

931000

14000

1368000

1382000

931000

1382000

446000

-832000

-258000

-155000

6000

-224000

44000

-77000

-85000

-258000

-53000

-122000

30000

48000

-43000

21809000

20165000

197000

198000

10535000

319000

122000

4157000

3617000

1257000

1230000

18109000

16095000

48942000

46932000

4995000

4520000

5000000

10000000

5000000

10000000

1000000

-237000

0.8

1431000

1934000

-1140000

-154000

-1450000

-2009000

-2587000

-22445000

-237000

-2350000

-22445000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Recently </div></div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Adopted Accounting Standards</div></div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2016, </div>the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> “<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic;">Compensation - Stock Compensation (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div>): Improvements to Employee Share-Based Payment Accounting”. </div>ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> simplifies several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The Company adopted ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 1, 2017. </div>The Company has elected to continue its current policy of estimating forfeitures rather than recognizing forfeitures when they occur. Adoption of the new standard did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on the financial statements of the Company.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2015, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,</div> “<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic;">Inventory: Simplifying the Measurement of Inventory</div>”, that requires inventory <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> measured using either the last in, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> out (“LIFO”) or the retail inventory method to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal and transportation. The Company adopted ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 1, 2017. </div>Adoption of the new standard did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on the financial statements of the Company.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Recently Issued Accounting </div></div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Standards</div></div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2014, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> “<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic;">Revenue from Contracts with Customers (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div>)</div>” (“ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09”</div>). ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> supersedes the revenue recognition requirements in ASC Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605,</div> “Revenue Recognition” and some cost guidance included in ASC Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">35,</div> "<div style="display: inline; font-style: italic;">Revenue Recognition</div><div style="display: inline; font-style: italic;"> </div><div style="display: inline; font-style: italic;">- Construction-Type and Production-Type Contracts</div>.” The core principle of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> is that revenue is recognized when the transfer of goods or services to customers occurs in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> requires the disclosure of sufficient information to enable readers of the Company’s financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> provides <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> methods of retrospective application. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> method would require the Company to apply ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> to each prior reporting period presented. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> method would require the Company to retrospectively apply ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> with the cumulative effect recognized at the date of initial application. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> will be effective for the Company beginning in fiscal <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> as a result of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,</div> "<div style="display: inline; font-style: italic;">Revenue from Contracts with Customers (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div>): Deferral of the Effective Date</div>," which was issued by the FASB in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2015 </div>and extended the original effective date by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year. The Company is currently evaluating the impact of adopting the available methodologies of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14</div> upon its financial statements in future reporting periods. The Company is also in the process of evaluating the new standard against its existing accounting policies, including the timing of revenue recognition, and its contracts with customers to determine the effect the guidance will have on its financial statements and what changes to systems and controls <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be warranted.</div></div></div></div></div></div></div></div>

2499000

1169000

2112000

3281000

1964000

1366000

3330000

3281000

3330000

-1163000

-1187000

-2350000

-1950000

2000

-1948000

-2350000

-1948000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">     </div></div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-weight: bold;">Summary of Significant Accounting Policies</div></div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Revenue Recognition</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Revenues from the sale of <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">the Company’s products and services are recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured. The Company generally ships products F.O.B. shipping point. There is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> conditional evaluation on any product sold and recognized as revenue. Amounts billed in excess of revenue recognized are recorded as deferred revenue on the balance sheet.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">There is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> right of return provided for distributors<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> or customers. For sales of products made to distributors, the Company considers a number of factors in determining whether revenue is recognized upon transfer of title to the distributor, or when payment is received. These factors include, but are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> limited to, whether the payment terms offered to the distributor are considered to be non-standard, the distributor history of adhering to the terms of its contractual arrangements with the Company, the level of inventories maintained by the distributor, whether the Company has a pattern of granting concessions for the benefit of the distributor, and whether there are other conditions that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>indicate that the sale to the distributor is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> substantive. The Company currently recognizes revenue primarily on the sell-in method with its distributors. </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Revenue arrangements with multiple deliverables are divided into units of accounting if certain criteria are met, including whether the deliverable item(s) has (have) value to the customer on a stand-alone basis. Revenue for each unit of accounting is recognized as the unit of accounting is delivered. Arrangement consideration is allocated to each unit of accounting based upon the relative estimated selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables. Estimated selling prices are determined using vendor specific objective evidence of value (<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">“VSOE”), when available, or an estimate of selling price when VSOE is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> available for a given unit of accounting. Significant inputs for the estimates of the selling price of separate units of accounting include market and pricing trends and a customer’s geographic location. The Company accounts for training and installation, and service agreements and the collection, processing and testing of the umbilical cord blood and the storage as separate units of accounting. </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Service revenue generated from contracts for providing maintenance of equipment is amortized over the life of the agreement. <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">Revenue generated from storage contracts is deferred and recorded ratably over the life of the agreement, up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21</div> years. </div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">All other service revenue is recognized at the time the service is completed.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Fair Value </div></div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Measurements</div></div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In accordance with ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">820,</div> “<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic;">Fair Value Measurements and Disclosures</div>,” fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> levels of inputs that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be used to measure fair value:</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 45pt;"> <div style=" margin: 0pt; text-align: justify; font-size: 10pt; font-family: Times\ New\ Roman, Times, serif;"><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1:</div> </div></div> </td> <td> <div style=" margin: 0pt; text-align: justify; font-size: 10pt; font-family: Times\ New\ Roman, Times, serif;"><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">Quoted market prices in active markets for identical assets or liabilities.</div></div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 45pt;"> <div style=" margin: 0pt; text-align: justify; font-size: 10pt; font-family: Times\ New\ Roman, Times, serif;">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2:</div></div> </td> <td> <div style=" margin: 0pt; text-align: justify; font-size: 10pt; font-family: Times\ New\ Roman, Times, serif;">Observable market-based inputs or unobservable inputs that are corroborated by market data.</div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 45pt;"> <div style=" margin: 0pt; text-align: justify; font-size: 10pt; font-family: Times\ New\ Roman, Times, serif;">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3:</div></div> </td> <td> <div style=" margin: 0pt; text-align: justify; font-size: 10pt; font-family: Times\ New\ Roman, Times, serif;">Unobservable inputs reflecting the reporting entity<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">’s own assumptions.</div></div> </td> </tr> </table> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The carrying values of cash and cash equivalents, accounts receivabl<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">e and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> within the fair value hierarchy since the valuation model of the derivative obligation is based on unobservable inputs.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Segment Reporting</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (“CODM”), or decision making group, whose function is to allocate resources to and assess the performance of the operating <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">segments. The Company has identified its chief executive officer and chief operating officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> reportable business segments:</div> <table border="0" cellpadding="0" cellspacing="0" style=";font-family:Times New Roman, Times, serif;font-size:10pt; min-width: 700px;"> <tr> <td style="width:18pt;"> </td> <td style="width:18pt;vertical-align:top;"> <div style=" font-family:Times New Roman, Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">●</div> </td> <td style="vertical-align:top;"> <div style=" font-family:Times New Roman, Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">T<div style="display: inline; font-size:10pt;font-family:Times New Roman, Times, serif;">he Clinical Development Division, is devel</div><div style="display: inline; font-size:10pt;font-family:Times New Roman, Times, serif;">op</div><div style="display: inline; font-size:10pt;font-family:Times New Roman, Times, serif;">ing autologous (utilizing the patient’s own cells) stem cell-based </div><div style="display: inline; font-size:10pt;font-family:Times New Roman, Times, serif;">therapeutics</div><div style="display: inline; font-size:10pt;font-family:Times New Roman, Times, serif;"> that address significant unmet medical needs for applications within the </div><div style="display: inline; font-size:10pt;font-family:Times New Roman, Times, serif;">vascular, cardiology and orthopedic </div><div style="display: inline; font-size:10pt;font-family:Times New Roman, Times, serif;">markets. </div></div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style=";font-family:Times New Roman, Times, serif;font-size:10pt; min-width: 700px;"> <tr> <td style="width:18pt;"> </td> <td style="width:18pt;vertical-align:top;"> <div style=" font-family:Times New Roman, Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">●</div> </td> <td style="vertical-align:top;"> <div style=" font-family:Times New Roman, Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">T<div style="display: inline; font-size:10pt;font-family:Times New Roman, Times, serif;">he Device Division, engages in the development and commercialization of automated technologies for c</div><div style="display: inline; font-size:10pt;font-family:Times New Roman, Times, serif;">ell-based t</div><div style="display: inline; font-size:10pt;font-family:Times New Roman, Times, serif;">herapeutics</div><div style="display: inline; font-size:10pt;font-family:Times New Roman, Times, serif;"> and bio-processing. The device division is operated through the Company’s ThermoGenesis subsidiary. </div></div> </td> </tr> </table> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Net Loss per Share</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding. The calculation<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30:</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table border="0px" cellpadding="0pt" cellspacing="0pt" style="; font-size: 10pt; text-indent: 0px; margin: 0pt 2.5%; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">2016</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested Series A warrants</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">404,412</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">404,412</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested Series A warrants<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">(1)</div></div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">698,529</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">698,529</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">– other</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,725,782</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,725,782</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock options</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">420,185</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">270,016</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock units</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,163</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">161,170</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,258,071</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,259,909</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <table border="0" cellpadding="0" cellspacing="0" style=";font-family:Times New Roman, Times, serif;font-size:10pt; min-width: 700px;"> <tr> <td style="width:4pt;"> </td> <td style="width:18pt;vertical-align:top;"> <div style=" font-family:Times New Roman, Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>)</div></div> </td> <td style="vertical-align:top;"> <div style=" font-family:Times New Roman, Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">The unvested Series A warrants were subject to vesting based upon the amount of funds actually received<div style="display: inline; font-size:10pt;font-family:Times New Roman, Times, serif;"> by the Company in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> close of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2015 </div>financing which never occurred. The warrants will remain outstanding but unvested until they expire in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2021</div></div><div style="display: inline; font-size:10pt;font-family:Times New Roman, Times, serif;">.</div></div> </td> </tr> </table> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:22.5pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Recently </div></div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Adopted Accounting Standards</div></div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2016, </div>the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> “<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic;">Compensation - Stock Compensation (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div>): Improvements to Employee Share-Based Payment Accounting”. </div>ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> simplifies several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The Company adopted ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 1, 2017. </div>The Company has elected to continue its current policy of estimating forfeitures rather than recognizing forfeitures when they occur. Adoption of the new standard did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on the financial statements of the Company.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2015, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,</div> “<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic;">Inventory: Simplifying the Measurement of Inventory</div>”, that requires inventory <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> measured using either the last in, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> out (“LIFO”) or the retail inventory method to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal and transportation. The Company adopted ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div> effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 1, 2017. </div>Adoption of the new standard did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on the financial statements of the Company.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Recently Issued Accounting </div></div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Standards</div></div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2014, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> “<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic;">Revenue from Contracts with Customers (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div>)</div>” (“ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09”</div>). ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> supersedes the revenue recognition requirements in ASC Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605,</div> “Revenue Recognition” and some cost guidance included in ASC Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">35,</div> "<div style="display: inline; font-style: italic;">Revenue Recognition</div><div style="display: inline; font-style: italic;"> </div><div style="display: inline; font-style: italic;">- Construction-Type and Production-Type Contracts</div>.” The core principle of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> is that revenue is recognized when the transfer of goods or services to customers occurs in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> requires the disclosure of sufficient information to enable readers of the Company’s financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> provides <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> methods of retrospective application. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> method would require the Company to apply ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> to each prior reporting period presented. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> method would require the Company to retrospectively apply ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> with the cumulative effect recognized at the date of initial application. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> will be effective for the Company beginning in fiscal <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> as a result of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,</div> "<div style="display: inline; font-style: italic;">Revenue from Contracts with Customers (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div>): Deferral of the Effective Date</div>," which was issued by the FASB in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2015 </div>and extended the original effective date by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year. The Company is currently evaluating the impact of adopting the available methodologies of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14</div> upon its financial statements in future reporting periods. The Company is also in the process of evaluating the new standard against its existing accounting policies, including the timing of revenue recognition, and its contracts with customers to determine the effect the guidance will have on its financial statements and what changes to systems and controls <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be warranted.</div></div></div>

61000

64000

4000

2000

1319000

1331000

403000

377000

-26000

215000

10373000

52000

134000

1000000

140000

154000

0.001

2000000

282000

237000

2091000

5000000

1500000

588000

327000

297000

-4000

40000

-2587000

-22445000

2971000

2330000

37000

7000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three Months Ended September 30, 2017</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:right;">Clinical</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:right;">Development</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:right;">Device</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:right;">Total</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net revenues</div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">126,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,943,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,069,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of revenues</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">120,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,018,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,138,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Gross profit</div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">925,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">931,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,169,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,112,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,281,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating loss</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,163,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,187,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,350,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Depreciation and amortization</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">75,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">85,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">160,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">85,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">47,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">132,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three Months Ended September 30, 2016</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:right;">Clinical</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:right;">Development</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:right;">Device</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:right;">Total</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net revenues</div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">156,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,611,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,767,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of revenues</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">142,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,243,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,385,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Gross profit</div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,368,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,382,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,964,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,366,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,330,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating profit (loss)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,950,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,948,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Depreciation and amortization</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">139,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">122,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">261,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">190,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">108,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">298,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div>

17000

23000

1063000

670000

-187707000

-185357000

751000

126000

2943000

3069000

156000

3611000

3767000

3069000

3767000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0px" cellpadding="0pt" cellspacing="0pt" style="; font-size: 10pt; text-indent: 0px; margin: 0pt 2.5%; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">2016</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested Series A warrants</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">404,412</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">404,412</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested Series A warrants<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">(1)</div></div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">698,529</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">698,529</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">– other</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,725,782</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,725,782</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock options</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">420,185</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">270,016</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock units</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,163</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">161,170</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,258,071</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,259,909</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Purchase Price:</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Cash</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,000,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">2,000,000 common shares of ThermoGenesis</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,499,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Fair value of assets acquired:</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Inventories</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">649,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Developed technology</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">318,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Trade name</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">In process technology</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,296,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Customer relationships</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 36pt;">Total intangible assets</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,681,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Property and equipment</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">585,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 72pt;">Total assets</div> </td> <td style="border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,915,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Fair value of liabilities assumed:</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Other liabilities</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,900,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Preliminary goodwill</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">599,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Number of</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted-</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Average</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Exercise</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Price</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted-</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Average</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Remaining</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Contractual</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Life</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Aggregate</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Intrinsic</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Value</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">2017</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">397,389</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.80</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.47</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(14,765</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.52</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expired<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> </div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,439</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27.04</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">September 30, 2017</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">420,185</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.54</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">182,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to v<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">est at September 30, 2017</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">397,590</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.66</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">175,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">September 30, 2017</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">278,487</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.64</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">128,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Average</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Number of</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Grant Date</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Fair Value</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at June 30, <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">2017</div></div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59,694</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.62</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.26</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(60,531</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.54</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">--</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at September 30, 201<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">7</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,163</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.65</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;">.     </div><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-weight: bold;">Segment Reporting</div></div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> reportable segments, which are the same as its operating segments:</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;">The Clinical Development <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">segment is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;">The <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">device segment is a pioneer and market leader in the development and commercialization of </div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">automated technologies for c</div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">ell-based t</div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">herapeutics</div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> and bio-processing.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following table summarizes the operating results of the Company<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">’s reportable segments:</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three Months Ended September 30, 2017</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:right;">Clinical</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:right;">Development</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:right;">Device</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:right;">Total</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net revenues</div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">126,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,943,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,069,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of revenues</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">120,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,018,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,138,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Gross profit</div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">925,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">931,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,169,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,112,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,281,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating loss</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,163,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,187,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,350,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Depreciation and amortization</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">75,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">85,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">160,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">85,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">47,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">132,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three Months Ended September 30, 2016</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:right;">Clinical</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:right;">Development</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:right;">Device</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:right;">Total</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net revenues</div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">156,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,611,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,767,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of revenues</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">142,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,243,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,385,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Gross profit</div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,368,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,382,000</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,964,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,366,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,330,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating profit (loss)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,950,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,948,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Depreciation and amortization</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">139,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">122,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">261,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">190,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">108,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">298,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table> </div></div>

517000

481000

132000

298000

85000

47000

132000

190000

108000

298000

10000

3.26

59694

9163

4.62

3.65

60531

4.54

1.08

0.017

278487

6.64

2439

14765

40000

182000

397389

420185

5.80

5.54

175000

397590

5.66

27.04

3.52

3.47

3.56

3.17

P4Y

128000

P5Y182D

P6Y

23905000

31070000

30837000

30833000

30837000

9950776

6048982

The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021. xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0000811212 2016-07-01 2016-09-30 0000811212 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0000811212 us-gaap:RestrictedStockUnitsRSUMember 2016-07-01 2016-09-30 0000811212 kool:UnvestedSeriesAWarrantsMember 2016-07-01 2016-09-30 0000811212 kool:VestedSeriesAWarrantsMember 2016-07-01 2016-09-30 0000811212 kool:WarrantOtherMember 2016-07-01 2016-09-30 0000811212 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0000811212 kool:SynGenMember 2016-07-01 2016-09-30 0000811212 us-gaap:IntersegmentEliminationMember 2016-07-01 2016-09-30 0000811212 us-gaap:OperatingSegmentsMember kool:ClinicalProtocolsMember 2016-07-01 2016-09-30 0000811212 us-gaap:OperatingSegmentsMember kool:DeviceRegistrationMember 2016-07-01 2016-09-30 0000811212 kool:SeriesAWarrantMember 2016-07-01 2017-06-30 0000811212 us-gaap:RevolvingCreditFacilityMember kool:BoyalifeInvestmentFundIiIncMember 2017-03-06 2017-03-06 0000811212 kool:LitigationRelatedToStrategicAdvisoryServicesMember 2017-05-04 2017-05-04 0000811212 2017-07-01 2017-09-30 0000811212 us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0000811212 us-gaap:RestrictedStockUnitsRSUMember 2017-07-01 2017-09-30 0000811212 kool:UnvestedSeriesAWarrantsMember 2017-07-01 2017-09-30 0000811212 kool:VestedSeriesAWarrantsMember 2017-07-01 2017-09-30 0000811212 kool:WarrantOtherMember 2017-07-01 2017-09-30 0000811212 us-gaap:EmployeeStockOptionMember 2017-07-01 2017-09-30 0000811212 us-gaap:RestrictedStockUnitsRSUMember 2017-07-01 2017-09-30 0000811212 kool:SynGenMember 2017-07-01 2017-09-30 0000811212 kool:SynGenMember us-gaap:GeneralAndAdministrativeExpenseMember 2017-07-01 2017-09-30 0000811212 us-gaap:IntersegmentEliminationMember 2017-07-01 2017-09-30 0000811212 us-gaap:OperatingSegmentsMember kool:ClinicalDevelopmentMember 2017-07-01 2017-09-30 0000811212 us-gaap:OperatingSegmentsMember kool:DeviceMember 2017-07-01 2017-09-30 0000811212 us-gaap:RevolvingCreditFacilityMember kool:BoyalifeInvestmentFundIiIncMember 2017-07-01 2017-09-30 0000811212 kool:SeriesAWarrantMember 2017-07-01 2017-09-30 0000811212 us-gaap:MaximumMember 2017-07-01 2017-09-30 0000811212 us-gaap:MinimumMember 2017-07-01 2017-09-30 0000811212 kool:BoyalifeGroupLtdMember 2017-07-01 2017-09-30 0000811212 kool:SynGenMember 2017-07-07 2017-07-07 0000811212 kool:SynGenMember kool:ThermoGenesisMember 2017-07-07 2017-07-07 0000811212 kool:SynGenMember 2017-07-08 2017-09-30 0000811212 kool:BoyalifeWSNMember 2017-08-21 2017-08-21 0000811212 kool:LitigationRelatedToStrategicAdvisoryServicesMember us-gaap:SubsequentEventMember 2017-10-01 2017-10-31 0000811212 2016-06-30 0000811212 kool:SeriesAWarrantMember 2016-06-30 0000811212 2016-09-30 0000811212 us-gaap:RevolvingCreditFacilityMember kool:BoyalifeInvestmentFundIiIncMember 2017-03-06 0000811212 2017-06-30 0000811212 us-gaap:EmployeeStockOptionMember 2017-06-30 0000811212 us-gaap:RestrictedStockUnitsRSUMember 2017-06-30 0000811212 us-gaap:RevolvingCreditFacilityMember kool:BoyalifeInvestmentFundIiIncMember 2017-06-30 0000811212 kool:SeriesAWarrantMember 2017-06-30 0000811212 us-gaap:FairValueInputsLevel1Member 2017-06-30 0000811212 us-gaap:FairValueInputsLevel2Member 2017-06-30 0000811212 us-gaap:FairValueInputsLevel3Member 2017-06-30 0000811212 kool:BoyalifeGroupLtdMember 2017-06-30 0000811212 kool:SynGenMember 2017-07-07 0000811212 kool:SynGenMember us-gaap:CustomerRelationshipsMember 2017-07-07 0000811212 kool:SynGenMember us-gaap:DevelopedTechnologyRightsMember 2017-07-07 0000811212 kool:SynGenMember us-gaap:InProcessResearchAndDevelopmentMember 2017-07-07 0000811212 kool:SynGenMember us-gaap:TradeNamesMember 2017-07-07 0000811212 kool:SynGenMember kool:ThermoGenesisMember 2017-07-07 0000811212 us-gaap:RevolvingCreditFacilityMember kool:BoyalifeInvestmentFundIiIncMember 2017-09-13 0000811212 kool:ConvertiblePromissoryNoteMember kool:BoyalifeInvestmentFundIiIncMember 2017-09-13 0000811212 2017-09-30 0000811212 us-gaap:EmployeeStockOptionMember 2017-09-30 0000811212 us-gaap:RestrictedStockUnitsRSUMember 2017-09-30 0000811212 us-gaap:RevolvingCreditFacilityMember kool:BoyalifeInvestmentFundIiIncMember 2017-09-30 0000811212 kool:SeriesAWarrantMember 2017-09-30 0000811212 us-gaap:FairValueInputsLevel1Member 2017-09-30 0000811212 us-gaap:FairValueInputsLevel2Member 2017-09-30 0000811212 us-gaap:FairValueInputsLevel3Member 2017-09-30 0000811212 kool:ThermoGenesisMember 2017-09-30 0000811212 kool:BoyalifeGroupLtdMember 2017-09-30 0000811212 2017-11-10

EX-101.SCH 6 kool-20170930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Disclosure - Note 1 - Description of Business and Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 3 - Acquisition of SynGen link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 5 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 6 - Derivative Obligations link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 7 - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 8 - Segment Reporting link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 3 - Acquisition of SynGen (Tables) link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 5 - Commitments and Contingencies (Tables) link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 6 - Derivative Obligations (Tables) link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 7 - Stockholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 8 - Segment Reporting (Tables) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 1 - Description of Business and Basis of Presentation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 3 - Acquisition of SynGen (Details Textual) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 3 - Acquisition of SynGen - Preliminary Allocation of Consideration Transferred to Net Assets Acquired (Details) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 3 - Acquisition of SynGen - Preliminary Allocation of Consideration Transferred to Net Assets Acquired (Details) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 3 - Acquisition of SynGen - Supplemental Pro Forma Data (Details) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 5 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 5 - Commitments and Contingencies - Changes In Product Liability Included In Accrued Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 6 - Derivative Obligations (Details Textual) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 6 - Derivative Obligations - Fair Value Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 6 - Derivative Obligations - Fair Value Hierarchy (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 6 - Derivative Obligations - Change In Fair Value of Derivative Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 7 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 7 - Stockholders' Equity - Option Activity for Stock Option Plans (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 7 - Stockholders' Equity - Schedule of Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 7 - Stockholders' Equity - Restricted Stock Unit Activity Granted to Employees (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 8 - Segment Reporting (Details Textual) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 8 - Segment Reporting - Summary of Operating Results by Reportable Segments (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 kool-20170930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 kool-20170930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 kool-20170930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information kool_PeriodOfWarrantyOnProducts Period Of Warranty On Products This line item represents the minimum period of warranty that an entity offers on all of its products. kool_ShortTermInvestmentMinimum Short Term Investment Minimum Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios, and adherence to certain clauses which must be met in order to avoid default. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants. Note To Financial Statement Details Textual statementsignificantaccountingpoliciespolicies statementnote2summaryofsignificantaccountingpoliciestables statementnote3acquisitionofsyngentables statementnote5commitmentsandcontingenciestables statementnote6derivativeobligationstables statementnote7stockholdersequitytables statementnote8segmentreportingtables Expenses: statementnote2summaryofsignificantaccountingpoliciescalculationforbasicanddilutedearningspersharedetails statementnote3acquisitionofsyngenpreliminaryallocationofconsiderationtransferredtonetassetsacquireddetails statementnote3acquisitionofsyngenpreliminaryallocationofconsiderationtransferredtonetassetsacquireddetailsparentheticals statementnote3acquisitionofsyngensupplementalproformadatadetails statementnote5commitmentsandcontingencieschangesinproductliabilityincludedinaccruedliabilitiesdetails statementnote6derivativeobligationsfairvalueassumptionsdetails statementnote6derivativeobligationsfairvaluehierarchydetails statementnote6derivativeobligationschangeinfairvalueofderivativeliabilitiesdetails statementnote7stockholdersequityoptionactivityforstockoptionplansdetails statementnote7stockholdersequityscheduleofassumptionsdetails statementnote7stockholdersequityrestrictedstockunitactivitygrantedtoemployeesdetails 2,000,000 common shares of ThermoGenesis Business Acquisition, Equity Interest Issued or Issuable, Value Assigned statementnote8segmentreportingsummaryofoperatingresultsbyreportablesegmentsdetails Common shares issued (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Notes To Financial Statements Notes To Financial Statements [Abstract] kool_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights Class Of Warrant Or Right, Weighted Average Exercise Price Of Warrants Or Rights The weighted average exercise price of each class of warrants or rights outstanding. us-gaap_PaymentsForRepurchaseOfCommonStock Cash paid for taxes on vested restricted stock Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 3 [Member] us-gaap_LineOfCredit Long-term Line of Credit Fair Value Hierarchy [Domain] (Recovery of) reserve for excess and slow-moving inventories The amount of change in the reserve for inventory. Fair Value, Hierarchy [Axis] Net cash flows used in investing activities: Proceeds from issuance of common stock, net Equity Component [Domain] Equity Components [Axis] us-gaap_IncreaseDecreaseInDeferredRevenue Deferred revenue us-gaap_ComprehensiveIncomeNetOfTax Comprehensive loss attributable to common stockholders us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Accrued payroll and related expenses Preferred stock, shares outstanding (in shares) Common stock, shares outstanding (in shares) us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity New Accounting Pronouncements, Policy [Policy Text Block] Anti-dilutive securities (in shares) Weighted average common shares outstanding – basic and diluted (in shares) Fair value change of derivative instruments Derivative, Gain (Loss) on Derivative, Net Change in fair value of derivative Change in fair value of derivative obligation Basic and diluted net loss per common share (in dollars per share) us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet Net assets acquired Market price of common stock (in dollars per share) Subsequent Event [Member] Related Party [Axis] us-gaap_RevenueFromRelatedParties Revenue from Related Parties Supplemental non-cash financing and investing information: Subsequent Event Type [Domain] Per share data: Related Party [Domain] Subsequent Event Type [Axis] Net revenues Net revenues Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period us-gaap_IncreaseDecreaseInAccountsPayableTrade Accounts payable Other liabilities us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities Other noncurrent liabilities Boyalife Group Ltd. [Member] Related to the entity Boyalife Group Ltd. us-gaap_IncreaseDecreaseInOtherCurrentLiabilities Other current liabilities Total assets Property and equipment Scenario, Unspecified [Domain] General and Administrative Expense [Member] Scenario [Axis] Finite-lived intangible assets Expected volatility Inventories Proceeds from long-term debt-related party Discount rate Income Statement Location [Domain] Consolidation Items [Domain] Income Statement Location [Axis] Consolidation Items [Axis] Intersegment Eliminations [Member] us-gaap_ProceedsFromLongTermLinesOfCredit Proceeds from Long-term Lines of Credit Operating Segments [Member] Maximum [Member] Range [Domain] Loss attributable to noncontrolling interests Minimum [Member] Range [Axis] Accounting Policies [Abstract] Statement of Financial Position [Abstract] us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets us-gaap_MinorityInterestOwnershipPercentageByParent Noncontrolling Interest, Ownership Percentage by Parent Comprehensive loss attributable to noncontrolling interests Subsidiary common stock issued for acquisition of net assets Statement of Cash Flows [Abstract] us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Derivatives and Fair Value [Text Block] us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss Net loss Business Acquisition, Pro Forma Information [Table Text Block] us-gaap_AllocatedShareBasedCompensationExpense Allocated Share-based Compensation Expense us-gaap_BusinessAcquisitionsProFormaRevenue Net revenues ThermoGenesis [Member] Information pertaining to ThermoGensis. Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] SynGen [Member] Information pertaining to SynGen. us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Comprehensive loss Ownership [Domain] Ownership [Axis] us-gaap_ProfitLoss Net loss Net loss us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Forfeited (in shares) Granted, options (in shares) Other non-current liabilities us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations Payments on capital lease obligations Long-term debt-related party Trade Names [Member] Noncurrent deferred tax liability us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders’ equity Accumulated deficit Retained Earnings (Accumulated Deficit) Clinical Development [Member] Information pertaining to the reportable segment of Clinical Development. Derivative obligation Balance Balance Device [Member] Information pertaining to the Device business segment. Accumulated other comprehensive loss Segments [Axis] Segments [Domain] us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_IncreaseDecreaseInInventories Inventories Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Credit Facility [Domain] Statement [Table] Revolving Credit Facility [Member] kool_ClassOfWarrantOrRightExercisableIntrinsicValue Class of Warrant or Right, Exercisable, Intrinsic Value Amount of difference between fair value of the warrant and exercise price of vested portions of options outstanding and currently exercisable. Credit Facility [Axis] Cash flows from financing activities: Income Statement [Abstract] Developed Technology Rights [Member] us-gaap_NumberOfReportableSegments Number of Reportable Segments Class of Stock [Axis] Award Type [Axis] In Process Research and Development [Member] Equity Award [Domain] Customer Relationships [Member] Finite-Lived Intangible Assets, Major Class Name [Domain] Segment Reporting Disclosure [Text Block] Fair Value of Financial Instruments, Policy [Policy Text Block] Derivative Instruments, Gain (Loss) [Table Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Segment Reporting, Policy [Policy Text Block] us-gaap_LossContingencyDamagesSoughtValue Loss Contingency, Damages Sought, Value Prepaid expenses and other current assets Dividend rate us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Exercise price (in dollars per share) kool_WorkingCapital Working Capital A measure of both a company's efficiency and its short-term financial health. The working capital is calculated as: Working Capital= Current Asset - Current Liabilities. us-gaap_AccountsReceivableRelatedParties Accounts Receivable, Related Parties Contractual term (years) (Year) us-gaap_LiabilitiesCurrent Total current liabilities Other current liabilities Cash Payments to Acquire Businesses, Gross Cash paid for business acquisition Related party payable Earnings Per Share, Policy [Policy Text Block] Other income and (expenses) kool_DistributorAgreementTerm Distributor Agreement Term Represents the term of the distributor agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. kool_DistributorAgreementRenewalTerm Distributor Agreement, Renewal Term Represents the renewal term of the distributor agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block] Operating expenses us-gaap_OperatingExpenses Total operating expenses Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Net change in operating assets and liabilities: Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Share-based Compensation, Stock Options, Activity [Table Text Block] General and administrative Convertible Promissory Note [Member] Information pertaining to the Convertible Promissory Note. Boyalife W.S.N. [Member] Information pertaining to Boyalife W.S.N. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Dividend yield us-gaap_PaidInKindInterest Non-cash accrued interest us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Risk-free interest rate us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Expected volatility Operating profit (loss) us-gaap_OperatingIncomeLoss Operating loss Loss from operations Deferred revenue Cost of revenues Cost of revenues Business Combination Disclosure [Text Block] us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Expected life (years) (Year) Gross profit us-gaap_GrossProfit Gross profit Litigation Case [Domain] Derivative Contract [Domain] Derivative Instrument [Axis] Amendment Flag Litigation Case [Axis] EX-101.PRE 10 kool-20170930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Sep. 30, 2017	Nov. 10, 2017
Document Information [Line Items]
Entity Registrant Name	CESCA THERAPEUTICS INC.
Entity Central Index Key	0000811212
Trading Symbol	kool
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		9,965,276
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Amendment Flag	false

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2017	Jun. 30, 2017
Current assets:
Cash and cash equivalents	$ 2,464,000	$ 3,623,000
Accounts receivable, net of allowance for doubtful accounts of $139,000 ($102,000 at June 30, 2017)	3,404,000	3,701,000
Inventories, net of reserves of $1,257,000 ($1,230,000 at June 30, 2017)	4,157,000	3,617,000
Prepaid expenses and other current assets	282,000	237,000
Total current assets	10,307,000	11,178,000
Equipment, less accumulated depreciation	2,971,000	2,330,000
Preliminary goodwill	13,794,000	13,195,000
Intangible assets, net	21,809,000	20,165,000
Other assets	61,000	64,000
Total assets	48,942,000	46,932,000
Current liabilities:
Accounts payable	2,038,000	1,601,000
Accrued payroll and related expenses	429,000	385,000
Deferred revenue	603,000	597,000
Related party payable	606,000	606,000
Other current liabilities	1,319,000	1,331,000
Total current liabilities	4,995,000	4,520,000
Long-term debt-related party	5,000,000	3,500,000
Noncurrent deferred tax liability	6,968,000	6,968,000
Derivative obligation	743,000	730,000
Other non-current liabilities	403,000	377,000
Total liabilities	18,109,000	16,095,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding
Common stock, $0.001 par value; 350,000,000 shares authorized; 9,959,943 issued and outstanding (9,915,868 at June 30, 2017)	10,000	10,000
Paid in capital in excess of par	218,801,000	216,222,000
Accumulated deficit	(187,707,000)	(185,357,000)
Accumulated other comprehensive loss	(34,000)	(38,000)
Total Cesca Therapeutics Inc. stockholders’ equity	31,070,000	30,837,000
Noncontrolling interests	(237,000)
Total equity	30,833,000	30,837,000
Total liabilities and stockholders’ equity	$ 48,942,000	$ 46,932,000

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2017	Jun. 30, 2017
Accounts Receivable, Allowance for Doubtful Accounts	$ 139,000	$ 102,000
Inventories, Reserves	$ 1,257,000	$ 1,230,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	9,959,943	9,915,868
Common stock, shares outstanding (in shares)	9,959,943	9,915,868

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Net revenues	$ 3,069,000	$ 3,767,000
Cost of revenues	2,138,000	2,385,000
Gross profit	931,000	1,382,000
Expenses:
Sales and marketing	517,000	481,000
Research and development	1,063,000	670,000
General and administrative	1,701,000	2,179,000
Total operating expenses	3,281,000	3,330,000
Loss from operations	(2,350,000)	(1,948,000)
Fair value change of derivative instruments	(13,000)	(326,000)
Amortization of debt discount		(9,851,000)
Interest Expense	(198,000)	(10,535,000)
Other income and (expenses)	(26,000)	215,000
Net loss	(2,587,000)	(22,445,000)
Loss attributable to noncontrolling interests	(237,000)
Net loss attributable to common stockholders	(2,350,000)	(22,445,000)
Net loss	(2,587,000)	(22,445,000)
Foreign currency translation adjustments	4,000	2,000
Comprehensive loss	(2,583,000)	(22,443,000)
Comprehensive loss attributable to noncontrolling interests	(237,000)
Comprehensive loss attributable to common stockholders	$ (2,346,000)	$ (22,443,000)
Per share data:
Basic and diluted net loss per common share (in dollars per share)	$ (0.24)	$ (3.71)
Weighted average common shares outstanding – basic and diluted (in shares)	9,950,776	6,048,982

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net loss	$ (2,587,000)	$ (22,445,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	160,000	261,000
Stock based compensation expense	132,000	298,000
(Recovery of) reserve for excess and slow-moving inventories	27,000	(71,000)
Bad debt expense	37,000	7,000
Amortization of debt discount and issue costs		10,011,000
Change in fair value of derivative	13,000	326,000
Non-cash accrued interest		10,373,000
Net change in operating assets and liabilities:
Accounts receivable	258,000	155,000
Inventories	85,000	258,000
Prepaid expenses and other current assets	(48,000)	43,000
Accounts payable	446,000	(832,000)
Accrued payroll and related expenses	44,000	(77,000)
Deferred revenue	6,000	(224,000)
Other current liabilities	(53,000)	(122,000)
Other noncurrent liabilities	30,000	30,000
Net cash used in operating activities	(1,450,000)	(2,009,000)
Net cash flows used in investing activities:
Cash paid for business acquisition	(1,000,000)
Capital expenditures	(140,000)	(154,000)
Net cash used in investing activities:	(1,140,000)	(154,000)
Cash flows from financing activities:
Payments on capital lease obligations	(17,000)	(23,000)
Cash paid for taxes on vested restricted stock	(52,000)	(134,000)
Proceeds from long-term debt-related party	1,500,000
Proceeds from issuance of common stock, net		2,091,000
Net cash provided by financing activities	1,431,000	1,934,000
Effects of foreign currency rate changes on cash and cash equivalents		2,000
Net decrease in cash and cash equivalents	(1,159,000)	(227,000)
Cash and cash equivalents at beginning of period	3,623,000	5,835,000
Cash and cash equivalents at end of period	2,464,000	5,608,000
Supplemental non-cash financing and investing information:
Common stock issued for payment of convertible debentures and interest		23,905,000
Subsidiary common stock issued for acquisition of net assets	$ 2,499,000

XML 16 R6.htm IDEA: XBRL DOCUMENT

Note 1 - Description of Business and Basis of Presentation	3 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Description of Business and Basis of Presentation Organization and Basis of Presentation Cesca Therapeutics Inc. (“Cesca Therapeutics,” “Cesca,” the “Company,” “we,” “our,” “us”), a Delaware corporation, is a regenerative medicine company that was founded in 1986 and is headquartered in Rancho Cordova, CA. We develop, commercialize and market a range of automated technologies and products for cell-based therapeutics. ThermoGenesis Corp. (“ThermoGenesis”), our device subsidiary, provides the AutoXpress ® and BioArchive platforms for automated clinical biobanking, PXP™ platform for point-of-care cell-based therapies and CAR-TXpress™ platform under development for bio-manufacturing for immuno-oncology applications. Cesca is also leveraging its proprietary PXP™ technology platform to develop autologous cell-based therapies that address significant unmet needs in the vascular and orthopedic markets. Cesca is an affiliate of the Boya life Group, a China-based industry research alliance encompassing top research institutions for stem cell and regenerative medicine. Liquidit y T he Company has a Revolving Credit Agreement (“Credit Agreement”) with Boyalife Investment Fund II, Inc. (the “Lender”) (Refer to Note 4 ). As of September 30, 2017, the Company had drawn down $5,000,000 of the $10,000,000 available under the Credit Agreement. Boyalife Investment Fund II, Inc. is a wholly owned subsidiary of Boyalife Group Inc., which is owned and controlled by the Company’s Chief Executive Officer and Chairman of the Board. On July 7, 2017, the Company, through its wholly-owned subsidiary, ThermoGenesis, acquired the business and substantially all the assets of SynGen Inc. (“SynGen”). In exchange, ThermoGenesis issued to SynGen shares of ThermoGenesis common stock that, after giving effect to the issuance, constitute 20% of ThermoGenesis ’ outstanding common shares, and ThermoGenesis also made a one -time cash payment of $1,000,000 to SynGen. (Refer to Note 3 ). At September 30, 2017, the Company had cash and cash equivalents of $2,464,000 and working capital of $5,312,000. The Company has incurred recurring operating losses and as of September 30, 2017 had an accumulated deficit of $187,707,000. The Company anticipates requiring additional capital to grow the device business (see Note 8 ), initiate the Phase III Critical Limb Ischemia trial, to fund other operating expenses and to make interest payments on the line of credit with Boyalife. These conditions raised substantial doubt about the Company’s ability to meet its obligations. To alleviate the substantial doubt, management plans to use existing cash and cash equivalents balances, revenue generating activities and draw down on the available balance from the line of credit. Other sources of liquidity could include potential issuances of debt or equity securities in public or private financings and strategic partnerships. Based upon the additional funds available to draw down under the amended Credit Agreement, the Company ’s cash balance, historical trends, expected outflows and projections for revenues, management believes it will have sufficient cash to provide for its projected needs to maintain operations and working capital requirements for at least the next 12 months from the date of this filing. Principles of Consolidation The consolidated financial statements include the accounts of Cesca , its majority-owned subsidiary, ThermoGenesis, and its wholly-owned subsidiaries, TotipotentRX Cell Therapy, Pvt. Ltd. and TotipotentSC Scientific Product Pvt. Ltd. All significant intercompany accounts and transactions have been eliminated upon consolidation. Noncontrolling Interests The 20% ownership interest of ThermoGenesis that is not owned by Cesca, is accounted for as a non-controlling interest as the Company has an 80% ownership interest in the subsidiary. Earnings or losses attributable to other stockholders of a consolidated affiliated company are classified separately as "noncontrolling interest" in the Company's consolidated statements of operations. Net loss attributable to noncontrolling interest reflects only its share of the after-tax earnings or losses of an affiliated company. The Company's consolidated balance sheets reflect noncontrolling interests within the equity section of the consolidated balance sheets. Interim Reporting The a ccompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 -Q and Article 10 of Regulation S- X. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (“SEC”) rules and regulations and accounting principles applicable for interim periods. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed consolidated financial statements through the date of issuance. Operating results for the three month period ended September 30, 2017 are not necessarily indicative of the results that may be expected for the six months ending December 31, 2017. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Annual Report on Form 10 -K for the fiscal year ended June 30, 2017.

XML 17 R7.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies

3 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

Summary of Significant Accounting Policies

Revenue Recognition

Revenues from the sale of

the Company’s products and services are recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured. The Company generally ships products F.O.B. shipping point. There is

conditional evaluation on any product sold and recognized as revenue. Amounts billed in excess of revenue recognized are recorded as deferred revenue on the balance sheet.

There is

right of return provided for distributors

or customers. For sales of products made to distributors, the Company considers a number of factors in determining whether revenue is recognized upon transfer of title to the distributor, or when payment is received. These factors include, but are

not

limited to, whether the payment terms offered to the distributor are considered to be non-standard, the distributor history of adhering to the terms of its contractual arrangements with the Company, the level of inventories maintained by the distributor, whether the Company has a pattern of granting concessions for the benefit of the distributor, and whether there are other conditions that

may

indicate that the sale to the distributor is

not

substantive. The Company currently recognizes revenue primarily on the sell-in method with its distributors.

“VSOE”), when available, or an estimate of selling price when VSOE is

not

available for a given unit of accounting. Significant inputs for the estimates of the selling price of separate units of accounting include market and pricing trends and a customer’s geographic location. The Company accounts for training and installation, and service agreements and the collection, processing and testing of the umbilical cord blood and the storage as separate units of accounting.

Service revenue generated from contracts for providing maintenance of equipment is amortized over the life of the agreement.

Revenue generated from storage contracts is deferred and recorded ratably over the life of the agreement, up to

years.

All other service revenue is recognized at the time the service is completed.

Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.

Fair Value

Measurements

In accordance with ASC

820,

“

Fair Value Measurements and Disclosures

,” fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date.

that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes

three

levels of inputs that

may

be used to measure fair value:

Level

Quoted market prices in active markets for identical assets or liabilities.

Level

Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level

Unobservable inputs reflecting the reporting entity

’s own assumptions.

The carrying values of cash and cash equivalents, accounts receivabl

e and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level

within the fair value hierarchy since the valuation model of the derivative obligation is based on unobservable inputs.

Segment Reporting

segments. The Company has identified its chief executive officer and chief operating officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets.

The Company has

two

reportable business segments:

●

he Clinical Development Division, is devel

ing autologous (utilizing the patient’s own cells) stem cell-based

therapeutics

that address significant unmet medical needs for applications within the

vascular, cardiology and orthopedic

markets.

●

he Device Division, engages in the development and commercialization of automated technologies for c

ell-based t

herapeutics

and bio-processing. The device division is operated through the Company’s ThermoGenesis subsidiary.

Net Loss per Share

Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding. The calculation

of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at

September 30:

	2017		2016
Vested Series A warrants		404,412		404,412
Unvested Series A warrants (1)		698,529		698,529
Warrants – other		3,725,782		3,725,782
Stock options		420,185		270,016
Restricted stock units		9,163		161,170
Total		5,258,071		5,259,909

(

)

The unvested Series A warrants were subject to vesting based upon the amount of funds actually received

by the Company in the

second

close of the

August 2015

financing which never occurred. The warrants will remain outstanding but unvested until they expire in

February 2021

Recently

Adopted Accounting Standards

March 2016,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)

2016

09,

“

Compensation - Stock Compensation (Topic

718

): Improvements to Employee Share-Based Payment Accounting”.

ASU

2016

simplifies several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The Company adopted ASU

2016

effective

July 1, 2017.

The Company has elected to continue its current policy of estimating forfeitures rather than recognizing forfeitures when they occur. Adoption of the new standard did

not

have a material impact on the financial statements of the Company.

July 2015,

the FASB issued ASU

No.

2015

11,

“

Inventory: Simplifying the Measurement of Inventory

”, that requires inventory

not

measured using either the last in,

first

out (“LIFO”) or the retail inventory method to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal and transportation. The Company adopted ASU

2015

effective

July 1, 2017.

Adoption of the new standard did

not

have a material impact on the financial statements of the Company.

Recently Issued Accounting

Standards

May 2014,

the FASB issued ASU

2014

09,

“

Revenue from Contracts with Customers (Topic

606

)

” (“ASU

2014

09”

). ASU

2014

supersedes the revenue recognition requirements in ASC Topic

605,

“Revenue Recognition” and some cost guidance included in ASC Subtopic

605

35,

Revenue Recognition

- Construction-Type and Production-Type Contracts

.” The core principle of ASU

2014

is that revenue is recognized when the transfer of goods or services to customers occurs in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASU

2014

requires the disclosure of sufficient information to enable readers of the Company’s financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. ASU

2014

also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU

2014

provides

two

methods of retrospective application. The

first

method would require the Company to apply ASU

2014

to each prior reporting period presented. The

second

method would require the Company to retrospectively apply ASU

2014

with the cumulative effect recognized at the date of initial application. ASU

2014

will be effective for the Company beginning in fiscal

2018

as a result of ASU

2015

14,

Revenue from Contracts with Customers (Topic

606

): Deferral of the Effective Date

," which was issued by the FASB in

August 2015

and extended the original effective date by

one

year. The Company is currently evaluating the impact of adopting the available methodologies of ASU

2014

and

2015

upon its financial statements in future reporting periods. The Company is also in the process of evaluating the new standard against its existing accounting policies, including the timing of revenue recognition, and its contracts with customers to determine the effect the guidance will have on its financial statements and what changes to systems and controls

may

be warranted.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Note 3 - Acquisition of SynGen

3 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Business Combination Disclosure [Text Block]

Acquisition

of SynGen

July 7, 2017,

Cesca, through its then wholly-owned subsidiary ThermoGenesis, entered into an Asset Acquisition Agreement (the “Asset Acquisition Agreement”) with SynGen, and pursuant to the terms of the Asset Acquisition Agreement, ThermoGenesis acquired on

July 7, 2017

substantially all of SynGen

’s operating assets, including its proprietary cell processing platform technology (the “Transaction”).

The business acquired in the Transaction excludes certain assets and liabilities of SynGen that ThermoGenesis did

not

acquire under the Asset Acquisition Agreement including cash and cash equivalents, accounts receivable, certain prepaid expenses and other current assets, other assets, accounts payable and other accrued liabilities

. The acquisition was consummated for the purpose of enhancing the Company’s cord blood product portfolio and settling litigation between the Company and SynGen.

not

included as a component of the acquisition accounting, but are recognized as expenses in the periods in which the costs are incurred. Acquisition related costs of $

187,000

for the

three

months ended

September 30, 2017

were included in general and administrative expenses. Subsequent to

July 7, 2017,

Cesca has recorded revenues of approximately

$47,000

associated with the operations of SynGen. The amount of net loss specifically related to SynGen operations for the period beginning

July 7, 2017,

included in the condensed consolidated statements of operations and comprehensive loss is impracticable due to the fact that SynGen and its operations are

longer accounted for on a stand-alone basis.

The consideration for t

he Transaction consisted of

$1,000,000

in cash and ThermoGenesis’ issuance at closing to SynGen of an aggregate of

2,000,000

shares of its common stock, constituting a

20%

interest, which had a fair market value of

$2,499,000.

All outstanding SynGen stock options to purchase shares of SynGen common stock were cancelled.

Preliminary Allocation of Consideration Transferred to Net Assets Acquired

The following is the summary of the preliminary fair value of the assets acquired and the liabilities assumed by Cesca in the Transaction, reconciled to the consideration transferred.

ThermoGenesis

issued

2,000,000

shares of its common stock that had a total fair value of

$2,499,000

based on an independent valuation. The final determination of the fair value of certain assets and liabilities will be completed within the

-month measurement period from the date of acquisition as required. It is anticipated that the goodwill will be deductible for tax purposes. Any potential adjustments made could be material in relation to the preliminary values presented below:

Purchase Price:
Cash			$	1,000,000
2,000,000 common shares of ThermoGenesis				2,499,000
Fair value of assets acquired:
Inventories		649,000
Developed technology	318,000
Trade name	26,000
In process technology	1,296,000
Customer relationships	41,000
Total intangible assets		1,681,000
Property and equipment		585,000
Total assets		2,915,000
Fair value of liabilities assumed:
Other liabilities		15,000
Net assets acquired				(2,900,000	)
Preliminary goodwill			$	599,000

Supplemental Pro Forma Data

The Company used the acquisition method of accounting to account for the

SynGen acquisition and, accordingly, the results of SynGen are included in the Company’s consolidated financial statements for the period subsequent to the date of acquisition. The following unaudited supplemental pro forma data for the quarters ended

September 30, 2017

and

2016

present consolidated information as if the acquisition had been completed on

July 1, 2016.

The pro forma results were calculated by combining the results of Cesca Inc with the stand-alone results of SynGen Inc. for the pre-acquisition periods:

	Three Months Ended September 30,
	2017			2016
Net revenues	$	3,069,000		$	4,078,000
Net loss	$	(2,439,000	)	$	(23,141,000	)
Basic and diluted net loss per common share	$	(0.22	)	$	(3.80	)

the revised payroll expense associated with the new salaries of SynGen employees resulting from the merger, the elimination of SynGen expenses related to debt issuance costs, interest and other warrant related expenses, the elimination of the legal fees paid by both parties related to the litigation between Cesca and SynGen as ceasing the litigation was part of the Asset Acquisition Agreement and costs directly related to the acquisition.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Note 4 - Related Party Transactions	3 Months Ended
Note 4 - Related Party Transactions	Sep. 30, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	4 . Related Party Transactions Revolving Credit Agreement On March 6, 2017, Cesca entered into the Credit Agreement with Boyalife Investment Fund II, Inc. (the “Lender”). The Lender is a wholly owned subsidiary of Boyalife Group Inc., which is owned and controlled by the Company ’s Chief Executive Officer and Chairman of the Board of Directors. The Credit Agreement grants to the Company the right to borrow up to $5,000,000 in amounts of $500,000 per advance on an unsecured basis (the “Loan”) at any time prior to March 6, 2022 ( the “Maturity Date”). The Company has drawn down a total of $5,000,000 as of September 30, 2017. The Credit Agreement and the Convertible Promissory Note issued thereunder (the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% per annum, simple interest, except that certain borrowed amounts used to pay legal expenses under the bill payment arrangement will not bear interest. The Note can be prepaid in whole or in part by the Company at any time without penalty. If the Note is not repaid in full on or before the Maturity Date, the Lender has the right after the Maturity Date to convert any unpaid principal and accrued interest into shares of the Company ’s common stock at a conversion price equal to 90% of the average daily volume-weighted average trading price of the Company’s common stock during the 10 trading days immediately prior to the Maturity Date, provided that the number of shares issuable upon such conversion may not exceed 19.99% of the number of outstanding shares of common stock of the Company on the date of the Credit Agreement (unless the Company obtains stockholder approval for such issuance in the manner required by the Marketplace Rules of the Nasdaq Stock Market, Inc.). On September 13, 2017, the Company entered into Amendment No. 1 to the Credit Agreement (the “Amended Credit Agreement”). The Amended Credit Agreement amends the Credit Agreement originally entered into by the Company and Lender on March 6, 2017, by increasing the Company ’s maximum borrowing availability thereunder from $5,000,000 to $10,000,000. In connection with such amendment, the Company and Lender entered into an amended and restated convertible promissory note to reflect the new aggregate maximum principal amount of $10,000,000. The Maturity Date of the Note is subject to acceleration at the option of the Lender upon customary events of default, which include a breach of the Loan documents, termination of operations, or bankruptcy. The Lender ’s obligation to make advances under the Loan is subject to the Company’s representations and warranties in the Credit Agreement continuing to be true at all times and there being no continuing event of default under the Note. The Credit Agreement provides that if the Lender at any time in the future purchases the Company’s blood and bone marrow processing device business, the Lender would refund to the Company legal fees expended by the Company in connection with certain litigation expenses funded by the Company with proceeds of the Loan. No default has occurred through the date of filing. The Company recorded interest expense of $ 197,000 for the three months ended September 30, 2017 and had an interest payable balance of $319,000 and $122,000 at September 30, 2017 and June 30, 2017, respectively. Distributo r Agreement On August 21, 2017, ThermoGenesis entered into an International Distributor Agreement with Boyalife W.S.N. Under the terms of the agreement, Boyalife W.S.N. was granted the exclusive right, subject to existing distributors and customers (if any), to develop, sell to, and service a customer base for ThermoGenesis ’ AXP ® (“AutoXpress ® ” ) System and BioArchive ® System in the People’s Republic of China (excluding Hong Kong and Taiwan), Singapore, Indonesia, and the Philippines (the “Territories”). Boyalife W.S.N. is an affiliate of our Chief Executive Officer and Chairman of our Board of Directors, and Boyalife (Hong Kong) Limited, our largest stockholder. Boyalife W.S.N,’s rights under the agreement include the exclusive right to distribute AXP ® Disposable Blood Processing Sets and use rights to the AXP ® (“AutoXpress ® ” ) System, BioArchive System and other accessories used for the processing of stem cells from cord blood in the Territories. Boyalife W.S.N. is also appointed as the exclusive service provider to provide repairs and preventative maintenance to ThermoGenesis products in the Territories. The term of the agreement is for three years with ThermoGenesis having the right to renew the agreement for successive two -year periods at its option. However, ThermoGenesis has the right to terminate the agreement early if Boyalife W.S.N. fails to meet specified minimum purchase requirements. Revenues During the three months ended September 30, 2017, the Company recorded $751,000 of revenues from Boyalife and had an accounts receivable balance of $751,000 and $308,000 at September 30, 2017 and June 30, 2017, respectively. Bill Payment Arrangement The Company entered into a bill payment arrangement whereby Boyalife Group Ltd. (“Payor”), the Company ’s largest shareholder, agreed to pay the Company’s legal expenses payable to the Company’s attorney related to certain litigation involving SynGen Inc. (the “Bill Payment Arrangement”), although the Company remains jointly and severally liable for the payment of such legal fees. The terms of the Bill Payment Arrangement provided that the Company will reimburse Payor for any and all amounts paid by Payor in connection with the Bill Payment Arrangement under certain specified events. There is no interest payable on outstanding balance of related party payable. This litigation was terminated as part of the SynGen acquisition agreement. As of September 30, 2017, invoices totaling $606,000 had been paid by Payor and are included in related party payable as the Company anticipates repaying this within a year.

XML 20 R10.htm IDEA: XBRL DOCUMENT

Note 5 - Commitments and Contingencies

3 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

Commitments

and Contingencies

Financial Covenants

Effective

May 15, 2017,

the Company entered into a Sixth Amended and Restated Technology License and Escrow Agreement with CBR Systems, Inc. which modified the financial covenant that the Company must meet in order to avoid an event of default. The Company must maintain a cash balance and short-term investments net of debt or borrowed funds that are payable within

one

year of

not

less than

$2,000,000.

The Company was in compliance with this financial covenant as of

September 30, 2017.

Warranty

The Company

offers a warranty on all of its non-disposable products of

one

two

years. The Company warrants disposable products through their expiration date. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary.

The warranty liability is included in other current liabilitie

s in the unaudited balance sheets. The change in the warranty liability for the

three

months ended

September 30, 2017

is summarized in the following table:

Balance at July 1, 2017	$	588,000
Warranties issued during the period		40,000
Settlements made during the period		(297,000	)
Changes in liability for pre-existing warranties during the period		(4,000	)
Balance at September 30, 2017	$	327,000

Contingency

In fiscal

2016,

the Company signed an engagement letter with a strategic consulting firm. Included in the engagement letter was a success fee due upon the successful conclusion of certain strategic

transactions. On

May 4, 2017,

a lawsuit was filed against the Company and its CEO by the consulting firm as the consulting firm argues that it is owed a transaction fee of

$1,000,000

under the terms of the engagement letter due to the conversion of the Boyalife debentures in

August 2016.

October 2017,

to streamline the case and without acknowledging any liability, the Company deposited

$1,000,000

with the Court and the consulting firm is in the process of dismissing the Company’s CEO from the case, without liability. The Company intends to defend the lawsuit vigorously and

accrual has been recorded for this contingent liability as of

September 30, 2017.

XML 21 R11.htm IDEA: XBRL DOCUMENT

Note 6 - Derivative Obligations

3 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Derivatives and Fair Value [Text Block]

Derivative Obligation

Series A Warrants

Series A warrants to purchase

404,412

common shares were issued and vested during the year ended

June 30, 2016.

At the time of issuance, the Company determined that as such warrants can be settled for cash at the holders

’ option in a future fundamental transaction they constituted a derivative liability. The Company has estimated the fair value of the derivative liability, using a Binomial Lattice Valuation Model and the following assumptions:

	Series A
	September 30, 2017			June 30, 2017
Market price of common stock	$	3.56		$	3.17
Expected volatility		102	%		110	%
Contractual term (years)		3.4			3.7
Discount rate		1.7	%		1.66	%
Dividend rate		0	%		0	%
Exercise price	$	8.00		$	8.00

Expected volatilities are based on the historical volatility of the Company

’s common stock. Contractual term is based on remaining term of the respective warrants. The discount rate represents the yield on U.S. Treasury bonds with a maturity equal to the contractual term.

The Company recorded a

loss of

$13,000

and

$326,000

during the

three

months ended

September 30, 2017

and

2016,

respectively, representing the net change in the fair value of the derivative liability, which is presented as fair value change of derivative instruments, in the accompanying consolidated statements of operations and comprehensive loss.

he following table represents the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of

September 30, 2017

and

June 30, 2017:

		Balance at September 30, 2017				Level 1				Level 2				Level 3
Derivative obligation		$	743,000			$	-			$	-			$	743,000

		Balance at June 30, 2017				Level 1				Level 2				Level 3
Derivative obligation		$	730,000			$	-			$	-			$	730,000

The following table reflects the change in fair value of the Company

’s derivative liabilities for the

three

months ended

September 30, 2017:

	Amount
Balance – July 1, 2017	$	730,000
Change in fair value of derivative obligation		13,000
Balance – September 30, 2017	$	743,000

XML 22 R12.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity

3 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Stockholders

’

Equity

Stock Based Compensation

The Company

recorded stock-based compensation of

$132,000

and

$298,000

for the

three

months ended

September 30, 2017

and

2016,

respectively.

The following is a summary of option activity for

the Company’s stock option plans:

	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life		Aggregate Intrinsic Value

Outstanding at June 30, 2017		397,389		$	5.80

Granted		40,000		$	3.47
Forfeited		(14,765	)	$	3.52
Expired		(2,439	)	$	27.04

Outstanding at September 30, 2017		420,185		$	5.54		6	$	182,000

Vested and expected to v est at September 30, 2017		397,590		$	5.66		6	$	175,000

Exercisable at September 30, 2017		278,487		$	6.64		5.5	$	128,000

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company

’s common stock. There were

options exercised during the

three

months ended

September 30, 2017.

The fair value of the Company

’s stock options granted for the

three

months ended

September 30, 2017

was estimated using the following weighted-average assumptions:

Expected life (years)	4
Risk-free interest rate	1.7	%
Expected volatility	108	%
Dividend yield	0	%

Common Stock Restricted

Units

The following is a summary of

restricted stock activity during the

three

months ended

September 30, 2017:

				Weighted Average
	Number of Shares			Grant Date Fair Value
Balance at June 30, 2017		59,694		$	4.62
Granted		10,000		$	3.26
Vested		(60,531	)	$	4.54
Forfeited		--			--
Outstanding at September 30, 201 7		9,163		$	3.65

Warrants

There was

warrant activity for the

three

months ended

September 30, 2017.

September 30, 2017,

there were

4,828,723

warrants outstanding with a weighted-average exercise price per share of

$9.37

and

4,130,192

warrants exercisable with a weighted-average exercise price per share of

$9.60.

September 30, 2017,

the total intrinsic value of warrants outstanding and exercisable was

XML 23 R13.htm IDEA: XBRL DOCUMENT

Note 8 - Segment Reporting

3 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

Segment Reporting

The

Company has

two

reportable segments, which are the same as its operating segments:

The Clinical Development

segment is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets.

The

device segment is a pioneer and market leader in the development and commercialization of

automated technologies for c

ell-based t

herapeutics

and bio-processing.

The following table summarizes the operating results of the Company

’s reportable segments:

	Three Months Ended September 30, 2017
	Clinical Development			Device			Total
Net revenues	$	126,000		$	2,943,000		$	3,069,000
Cost of revenues		120,000			2,018,000			2,138,000
Gross profit		6,000			925,000			931,000

Operating expenses		1,169,000			2,112,000			3,281,000
Operating loss	$	(1,163,000	)	$	(1,187,000	)	$	(2,350,000	)

Depreciation and amortization	$	75,000		$	85,000		$	160,000
Stock-based compensation expense	$	85,000		$	47,000		$	132,000

	Three Months Ended September 30, 2016
	Clinical Development			Device		Total
Net revenues	$	156,000		$	3,611,000	$	3,767,000
Cost of revenues		142,000			2,243,000		2,385,000
Gross profit		14,000			1,368,000		1,382,000

Operating expenses		1,964,000			1,366,000		3,330,000
Operating profit (loss)	$	(1,950,000	)	$	2,000	$	(1,948,000	)

Depreciation and amortization	$	139,000		$	122,000	$	261,000
Stock-based compensation expense	$	190,000		$	108,000	$	298,000

XML 24 R14.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

3 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Revenues from the sale of

conditional evaluation on any product sold and recognized as revenue. Amounts billed in excess of revenue recognized are recorded as deferred revenue on the balance sheet.

There is

right of return provided for distributors

not

may

indicate that the sale to the distributor is

not

substantive. The Company currently recognizes revenue primarily on the sell-in method with its distributors.

“VSOE”), when available, or an estimate of selling price when VSOE is

not

Service revenue generated from contracts for providing maintenance of equipment is amortized over the life of the agreement.

Revenue generated from storage contracts is deferred and recorded ratably over the life of the agreement, up to

years.

All other service revenue is recognized at the time the service is completed.

Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value

Measurements

In accordance with ASC

820,

“

Fair Value Measurements and Disclosures

three

levels of inputs that

may

be used to measure fair value:

Level

Quoted market prices in active markets for identical assets or liabilities.

Level

Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level

Unobservable inputs reflecting the reporting entity

’s own assumptions.

The carrying values of cash and cash equivalents, accounts receivabl

e and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level

within the fair value hierarchy since the valuation model of the derivative obligation is based on unobservable inputs.

Segment Reporting, Policy [Policy Text Block]

Segment Reporting

The Company has

two

reportable business segments:

●

he Clinical Development Division, is devel

ing autologous (utilizing the patient’s own cells) stem cell-based

therapeutics

that address significant unmet medical needs for applications within the

vascular, cardiology and orthopedic

markets.

●

he Device Division, engages in the development and commercialization of automated technologies for c

ell-based t

herapeutics

and bio-processing. The device division is operated through the Company’s ThermoGenesis subsidiary.

Earnings Per Share, Policy [Policy Text Block]

Net Loss per Share

Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding. The calculation

September 30:

	2017		2016
Vested Series A warrants		404,412		404,412
Unvested Series A warrants (1)		698,529		698,529
Warrants – other		3,725,782		3,725,782
Stock options		420,185		270,016
Restricted stock units		9,163		161,170
Total		5,258,071		5,259,909

(

)

The unvested Series A warrants were subject to vesting based upon the amount of funds actually received

by the Company in the

second

close of the

August 2015

financing which never occurred. The warrants will remain outstanding but unvested until they expire in

February 2021

New Accounting Pronouncements, Policy [Policy Text Block]

Recently

Adopted Accounting Standards

March 2016,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)

2016

09,

“

Compensation - Stock Compensation (Topic

718

): Improvements to Employee Share-Based Payment Accounting”.

ASU

2016

effective

July 1, 2017.

The Company has elected to continue its current policy of estimating forfeitures rather than recognizing forfeitures when they occur. Adoption of the new standard did

not

have a material impact on the financial statements of the Company.

July 2015,

the FASB issued ASU

No.

2015

11,

“

Inventory: Simplifying the Measurement of Inventory

”, that requires inventory

not

measured using either the last in,

first

2015

effective

July 1, 2017.

Adoption of the new standard did

not

have a material impact on the financial statements of the Company.

Recently Issued Accounting

Standards

May 2014,

the FASB issued ASU

2014

09,

“

Revenue from Contracts with Customers (Topic

606

)

” (“ASU

2014

09”

). ASU

2014

supersedes the revenue recognition requirements in ASC Topic

605,

“Revenue Recognition” and some cost guidance included in ASC Subtopic

605

35,

Revenue Recognition

- Construction-Type and Production-Type Contracts

.” The core principle of ASU

2014

also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU

2014

provides

two

methods of retrospective application. The

first

method would require the Company to apply ASU

2014

to each prior reporting period presented. The

second

method would require the Company to retrospectively apply ASU

2014

with the cumulative effect recognized at the date of initial application. ASU

2014

will be effective for the Company beginning in fiscal

2018

as a result of ASU

2015

14,

Revenue from Contracts with Customers (Topic

606

): Deferral of the Effective Date

," which was issued by the FASB in

August 2015

and extended the original effective date by

one

year. The Company is currently evaluating the impact of adopting the available methodologies of ASU

2014

and

2015

may

be warranted.

XML 25 R15.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Tables)

3 Months Ended

Sep. 30, 2017

Notes Tables

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	2017		2016
Vested Series A warrants		404,412		404,412
Unvested Series A warrants (1)		698,529		698,529
Warrants – other		3,725,782		3,725,782
Stock options		420,185		270,016
Restricted stock units		9,163		161,170
Total		5,258,071		5,259,909

XML 26 R16.htm IDEA: XBRL DOCUMENT

Note 3 - Acquisition of SynGen (Tables)

3 Months Ended

Sep. 30, 2017

Notes Tables

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

Purchase Price:
Cash			$	1,000,000
2,000,000 common shares of ThermoGenesis				2,499,000
Fair value of assets acquired:
Inventories		649,000
Developed technology	318,000
Trade name	26,000
In process technology	1,296,000
Customer relationships	41,000
Total intangible assets		1,681,000
Property and equipment		585,000
Total assets		2,915,000
Fair value of liabilities assumed:
Other liabilities		15,000
Net assets acquired				(2,900,000	)
Preliminary goodwill			$	599,000

Business Acquisition, Pro Forma Information [Table Text Block]

	Three Months Ended September 30,
	2017			2016
Net revenues	$	3,069,000		$	4,078,000
Net loss	$	(2,439,000	)	$	(23,141,000	)
Basic and diluted net loss per common share	$	(0.22	)	$	(3.80	)

XML 27 R17.htm IDEA: XBRL DOCUMENT

Note 5 - Commitments and Contingencies (Tables)

3 Months Ended

Sep. 30, 2017

Notes Tables

Schedule of Product Warranty Liability [Table Text Block]

Balance at July 1, 2017	$	588,000
Warranties issued during the period		40,000
Settlements made during the period		(297,000	)
Changes in liability for pre-existing warranties during the period		(4,000	)
Balance at September 30, 2017	$	327,000

XML 28 R18.htm IDEA: XBRL DOCUMENT

Note 6 - Derivative Obligations (Tables)

3 Months Ended

Sep. 30, 2017

Notes Tables

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]

	Series A
	September 30, 2017			June 30, 2017
Market price of common stock	$	3.56		$	3.17
Expected volatility		102	%		110	%
Contractual term (years)		3.4			3.7
Discount rate		1.7	%		1.66	%
Dividend rate		0	%		0	%
Exercise price	$	8.00		$	8.00

Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]

		Balance at September 30, 2017				Level 1				Level 2				Level 3
Derivative obligation		$	743,000			$	-			$	-			$	743,000

		Balance at June 30, 2017				Level 1				Level 2				Level 3
Derivative obligation		$	730,000			$	-			$	-			$	730,000

Derivative Instruments, Gain (Loss) [Table Text Block]

	Amount
Balance – July 1, 2017	$	730,000
Change in fair value of derivative obligation		13,000
Balance – September 30, 2017	$	743,000

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

XML 29 R19.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity (Tables)

3 Months Ended

Sep. 30, 2017

Notes Tables

Share-based Compensation, Stock Options, Activity [Table Text Block]

	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life		Aggregate Intrinsic Value

Outstanding at June 30, 2017		397,389		$	5.80

Granted		40,000		$	3.47
Forfeited		(14,765	)	$	3.52
Expired		(2,439	)	$	27.04

Outstanding at September 30, 2017		420,185		$	5.54		6	$	182,000

Vested and expected to v est at September 30, 2017		397,590		$	5.66		6	$	175,000

Exercisable at September 30, 2017		278,487		$	6.64		5.5	$	128,000

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Expected life (years)	4
Risk-free interest rate	1.7	%
Expected volatility	108	%
Dividend yield	0	%

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]

				Weighted Average
	Number of Shares			Grant Date Fair Value
Balance at June 30, 2017		59,694		$	4.62
Granted		10,000		$	3.26
Vested		(60,531	)	$	4.54
Forfeited		--			--
Outstanding at September 30, 201 7		9,163		$	3.65

XML 30 R20.htm IDEA: XBRL DOCUMENT

Note 8 - Segment Reporting (Tables)

3 Months Ended

Sep. 30, 2017

Notes Tables

Reconciliation of Revenue from Segments to Consolidated [Table Text Block]

	Three Months Ended September 30, 2017
	Clinical Development			Device			Total
Net revenues	$	126,000		$	2,943,000		$	3,069,000
Cost of revenues		120,000			2,018,000			2,138,000
Gross profit		6,000			925,000			931,000

Operating expenses		1,169,000			2,112,000			3,281,000
Operating loss	$	(1,163,000	)	$	(1,187,000	)	$	(2,350,000	)

Depreciation and amortization	$	75,000		$	85,000		$	160,000
Stock-based compensation expense	$	85,000		$	47,000		$	132,000

	Three Months Ended September 30, 2016
	Clinical Development			Device		Total
Net revenues	$	156,000		$	3,611,000	$	3,767,000
Cost of revenues		142,000			2,243,000		2,385,000
Gross profit		14,000			1,368,000		1,382,000

Operating expenses		1,964,000			1,366,000		3,330,000
Operating profit (loss)	$	(1,950,000	)	$	2,000	$	(1,948,000	)

Depreciation and amortization	$	139,000		$	122,000	$	261,000
Stock-based compensation expense	$	190,000		$	108,000	$	298,000

XML 31 R21.htm IDEA: XBRL DOCUMENT

Note 1 - Description of Business and Basis of Presentation (Details Textual) - USD ($)		3 Months Ended
	Jul. 07, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 13, 2017	Jun. 30, 2017	Mar. 06, 2017	Jun. 30, 2016
Payments to Acquire Businesses, Gross		$ 1,000,000
Cash and Cash Equivalents, at Carrying Value		2,464,000	$ 5,608,000		$ 3,623,000		$ 5,835,000
Working Capital		5,312,000
Retained Earnings (Accumulated Deficit)		$ (187,707,000)			$ (185,357,000)
ThermoGenesis [Member]
Noncontrolling Interest, Ownership Percentage by Parent		80.00%
SynGen [Member]
Percentage Of Common Stock Issued To Acquiree Shareholders	20.00%
Payments to Acquire Businesses, Gross	$ 1,000,000
ThermoGenesis [Member] \| SynGen [Member]
Percentage Of Common Stock Issued To Acquiree Shareholders	20.00%
Payments to Acquire Businesses, Gross	$ 1,000,000
Boyalife Investment Fund II, Inc. [Member] \| Revolving Credit Facility [Member]
Long-term Line of Credit		$ 5,000,000
Line of Credit Facility, Maximum Borrowing Capacity		$ 10,000,000		$ 10,000,000		$ 5,000,000

XML 32 R22.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Details Textual)	3 Months Ended
	Sep. 30, 2017
Maximum Period Of Agreement	21 years
Number of Reportable Segments	2

XML 33 R23.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Calculation for Basic and Diluted Earnings Per Share (Details) - shares

3 Months Ended

Sep. 30, 2017

Sep. 30, 2016

Anti-dilutive securities (in shares)

5,258,071

5,259,909

Vested Series A Warrants [Member]

Anti-dilutive securities (in shares)

404,412

Unvested Series A Warrants [Member]

Anti-dilutive securities (in shares)

^[1]

698,529

Warrant, Other [Member]

Anti-dilutive securities (in shares)

3,725,782

Employee Stock Option [Member]

Anti-dilutive securities (in shares)

420,185

270,016

Restricted Stock Units (RSUs) [Member]

Anti-dilutive securities (in shares)

9,163

161,170

[1]	The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021.

XML 34 R24.htm IDEA: XBRL DOCUMENT

Note 3 - Acquisition of SynGen (Details Textual) - USD ($)		3 Months Ended
	Jul. 07, 2017	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016
Payments to Acquire Businesses, Gross		$ 1,000,000
SynGen [Member]
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual			$ 47,000
Payments to Acquire Businesses, Gross	$ 1,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	2,000,000
Percentage Of Common Stock Issued To Acquiree Shareholders	20.00%
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	$ 2,499,000
SynGen [Member] \| General and Administrative Expense [Member]
Business Combination, Acquisition Related Costs		$ 187,000

XML 35 R25.htm IDEA: XBRL DOCUMENT

Note 3 - Acquisition of SynGen - Preliminary Allocation of Consideration Transferred to Net Assets Acquired (Details) - USD ($)		3 Months Ended
	Jul. 07, 2017	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2017
Cash		$ 1,000,000
Preliminary goodwill		$ 13,794,000		$ 13,195,000
SynGen [Member]
Cash	$ 1,000,000
2,000,000 common shares of ThermoGenesis	2,499,000
Inventories	649,000
Finite-lived intangible assets	1,681,000
Property and equipment	585,000
Total assets	2,915,000
Other liabilities	15,000
Net assets acquired	(2,900,000)
Preliminary goodwill	599,000
SynGen [Member] \| Developed Technology Rights [Member]
Finite-lived intangible assets	318,000
SynGen [Member] \| Trade Names [Member]
Finite-lived intangible assets	26,000
SynGen [Member] \| In Process Research and Development [Member]
Finite-lived intangible assets	1,296,000
SynGen [Member] \| Customer Relationships [Member]
Finite-lived intangible assets	$ 41,000

XML 36 R26.htm IDEA: XBRL DOCUMENT

Note 3 - Acquisition of SynGen - Preliminary Allocation of Consideration Transferred to Net Assets Acquired (Details) (Parentheticals)	Jul. 07, 2017 shares
SynGen [Member]
Common shares issued (in shares)	2,000,000

XML 37 R27.htm IDEA: XBRL DOCUMENT

Note 3 - Acquisition of SynGen - Supplemental Pro Forma Data (Details) - SynGen [Member] - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Net revenues	$ 3,069,000	$ 4,078,000
Net loss	$ (2,439,000)	$ (23,141,000)
Basic and diluted net loss per common share (in dollars per share)	$ (0.22)	$ (3.80)

XML 38 R28.htm IDEA: XBRL DOCUMENT

Note 4 - Related Party Transactions (Details Textual) - USD ($)			3 Months Ended
	Aug. 21, 2017	Mar. 06, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 13, 2017	Jun. 30, 2017
Interest Expense			$ 198,000	$ 10,535,000
Boyalife Investment Fund II, Inc. [Member] \| Convertible Promissory Note [Member]
Debt Instrument, Face Amount					$ 10,000,000
Boyalife Investment Fund II, Inc. [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 5,000,000	10,000,000		$ 10,000,000
Line of Credit Facility, Amount of Unsecured Debt Per Advance		$ 500,000
Proceeds from Long-term Lines of Credit			5,000,000
Debt Instrument, Interest Rate, Stated Percentage		22.00%
Debt Instrument, Convertible, Percentage of Conversion Price		90.00%
Debt Instrument, Number of Trading Days Prior to the Maturity Date		10 days
Debt Instrument, Maximum Number of Shares Issued Upon Conversion, Percent		19.99%
Interest Expense			197,000
Interest Payable			319,000			$ 122,000
Boyalife W.S.N. [Member]
Distributor Agreement Term	3 years
Distributor Agreement, Renewal Term	2 years
Boyalife Group Ltd. [Member]
Revenue from Related Parties			751,000
Accounts Receivable, Related Parties			751,000			$ 308,000
Due to Related Parties			$ 606,000

XML 39 R29.htm IDEA: XBRL DOCUMENT

Note 5 - Commitments and Contingencies (Details Textual) - USD ($)		1 Months Ended	3 Months Ended
	May 04, 2017	Oct. 31, 2017	Sep. 30, 2017
Short Term Investment Minimum			$ 2,000,000
Litigation Related to Strategic Advisory Services [Member]
Loss Contingency, Damages Sought, Value	$ 1,000,000
Litigation Related to Strategic Advisory Services [Member] \| Subsequent Event [Member]
Loss Contingency, Negotiation Condition Bond		$ 1,000,000
Minimum [Member]
Period Of Warranty On Products			1 year
Maximum [Member]
Period Of Warranty On Products			2 years

XML 40 R30.htm IDEA: XBRL DOCUMENT

Note 5 - Commitments and Contingencies - Changes In Product Liability Included In Accrued Liabilities (Details)	3 Months Ended
	Sep. 30, 2017 USD ($)
Beginning balance	$ 588,000
Warranties issued during the period	40,000
Settlements made during the period	(297,000)
Changes in liability for pre-existing warranties during the period	(4,000)
Ending balance	$ 327,000

XML 41 R31.htm IDEA: XBRL DOCUMENT

Note 6 - Derivative Obligations (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2016
Class of Warrant or Right, Outstanding	4,828,723
Derivative, Gain (Loss) on Derivative, Net	$ (13,000)	$ (326,000)
Series A Warrant [Member]
Class of Warrant or Right, Outstanding			404,412

XML 42 R32.htm IDEA: XBRL DOCUMENT

Note 6 - Derivative Obligations - Fair Value Assumptions (Details) - Series A Warrant [Member] - $ / shares	3 Months Ended	12 Months Ended
	Sep. 30, 2017	Jun. 30, 2017
Market price of common stock (in dollars per share)	$ 3.56	$ 3.17
Expected volatility	102.00%	110.00%
Contractual term (years) (Year)	3 years 146 days	3 years 255 days
Discount rate	1.70%	1.66%
Dividend rate	0.00%	0.00%
Exercise price (in dollars per share)	$ 8	$ 8

XML 43 R33.htm IDEA: XBRL DOCUMENT

Note 6 - Derivative Obligations - Fair Value Hierarchy (Details) - USD ($)	Sep. 30, 2017	Jun. 30, 2017
Derivative obligation	$ 743,000	$ 730,000
Fair Value, Inputs, Level 1 [Member]
Derivative obligation
Fair Value, Inputs, Level 2 [Member]
Derivative obligation
Fair Value, Inputs, Level 3 [Member]
Derivative obligation	$ 743,000	$ 730,000

XML 44 R34.htm IDEA: XBRL DOCUMENT

Note 6 - Derivative Obligations - Change In Fair Value of Derivative Liabilities (Details) - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Balance	$ 730,000
Change in fair value of derivative obligation	13,000	$ 326,000
Balance	$ 743,000

XML 45 R35.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Class of Warrant or Right, Outstanding	4,828,723
Class Of Warrant Or Right, Weighted Average Exercise Price Of Warrants Or Rights	$ 9.37
Class of Warrant or Right, Exercisable	4,130,192
Class of Warrant Or Right, Exercisable, Weighted-Average Exercise Price	$ 9.60
Class of Warrant or Right, Outstanding, Intrinsic Value	$ 0
Class of Warrant or Right, Exercisable, Intrinsic Value	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	0
Employee Stock Option [Member]
Allocated Share-based Compensation Expense	$ 132,000	$ 298,000

XML 46 R36.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity - Option Activity for Stock Option Plans (Details) - Employee Stock Option [Member]	3 Months Ended
	Sep. 30, 2017 USD ($) $ / shares shares
Outstanding, options (in shares) \| shares	397,389
Outstanding, weighted average exercise price, options (in dollars per share) \| $ / shares	$ 5.80
Granted, options (in shares) \| shares	40,000
Granted, weighted average exercise price, options (in dollars per share) \| $ / shares	$ 3.47
Forfeited (in shares) \| shares	(14,765)
Forfeited (in dollars per share) \| $ / shares	$ 3.52
Expired, options (in shares) \| shares	(2,439)
Expired, weighted average exercise price, options (in dollars per share) \| $ / shares	$ 27.04
Outstanding, options (in shares) \| shares	420,185
Outstanding, weighted average exercise price, options (in dollars per share) \| $ / shares	$ 5.54
Outstanding, weighted average remaining contractual life, options (Year)	6 years
Outstanding, aggregate intrinsic value, options \| $	$ 182,000
Vested and Expected to Vest, options (in shares) \| shares	397,590
Vested and Expected to Vest, weighted average exercise price, options (in dollars per share) \| $ / shares	$ 5.66
Vested and Expected to Vest, weighted average remaining contractual life, options (Year)	6 years
Vested and Expected to Vest, aggregate intrinsic value, options \| $	$ 175,000
Exercisable, options (in shares) \| shares	278,487
Exercisable, weighted average exercise price, options (in dollars per share) \| $ / shares	$ 6.64
Exercisable, weighted average remaining contractual life, options (Year)	5 years 182 days
Exercisable, aggregate intrinsic value, options \| $	$ 128,000

XML 47 R37.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity - Schedule of Assumptions (Details)	3 Months Ended
	Sep. 30, 2017
Expected life (years) (Year)	4 years
Risk-free interest rate	1.70%
Expected volatility	108.00%
Dividend yield	0.00%

XML 48 R38.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity - Restricted Stock Unit Activity Granted to Employees (Details) - Restricted Stock Units (RSUs) [Member]	3 Months Ended
	Sep. 30, 2017 $ / shares shares
Balance, Number of Shares (in shares) \| shares	59,694
Balance, Weighted Average Grant Date Fair Value, (in dollars per share) \| $ / shares	$ 4.62
Granted, Number of Shares (in shares) \| shares	10,000
Granted, Weighted Average Grant Date Fair Value (in dollars per share) \| $ / shares	$ 3.26
Vested, Number of Shares (in shares) \| shares	(60,531)
Vested, Weighted Average Grant Date Fair Value (in dollars per share) \| $ / shares	$ 4.54
Forfeited, Number of Shares (in shares) \| shares
Forfeited, Weighted Average Grant Date Fair Value (in dollars per share) \| $ / shares
Outstanding, Number of Shares (in shares) \| shares	9,163
Outstanding, Weighted Average Grant Date Fair Value, (in dollars per share) \| $ / shares	$ 3.65

XML 49 R39.htm IDEA: XBRL DOCUMENT

Note 8 - Segment Reporting (Details Textual)	3 Months Ended
Note 8 - Segment Reporting (Details Textual)	Sep. 30, 2017
Number of Reportable Segments	2

XML 50 R40.htm IDEA: XBRL DOCUMENT

Note 8 - Segment Reporting - Summary of Operating Results by Reportable Segments (Details) - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Net revenues	$ 3,069,000	$ 3,767,000
Cost of revenues	2,138,000	2,385,000
Gross profit	931,000	1,382,000
Operating expenses	3,281,000	3,330,000
Operating loss	(2,350,000)	(1,948,000)
Depreciation and amortization	160,000	261,000
Stock-based compensation expense	132,000	298,000
Operating profit (loss)	(2,350,000)	(1,948,000)
Intersegment Eliminations [Member]
Net revenues	3,069,000	3,767,000
Cost of revenues	2,138,000	2,385,000
Gross profit	931,000	1,382,000
Operating expenses	3,281,000	3,330,000
Operating loss	(2,350,000)	(1,948,000)
Depreciation and amortization	160,000	261,000
Stock-based compensation expense	132,000	298,000
Operating profit (loss)	(2,350,000)	(1,948,000)
Clinical Development [Member] \| Operating Segments [Member]
Net revenues	126,000
Cost of revenues	120,000
Gross profit	6,000
Operating expenses	1,169,000
Operating loss	(1,163,000)
Depreciation and amortization	75,000
Stock-based compensation expense	85,000
Operating profit (loss)	(1,163,000)
Clinical Protocols [Member] \| Operating Segments [Member]
Net revenues		156,000
Cost of revenues		142,000
Gross profit		14,000
Operating expenses		1,964,000
Operating loss		(1,950,000)
Depreciation and amortization		139,000
Stock-based compensation expense		190,000
Operating profit (loss)		(1,950,000)
Device [Member] \| Operating Segments [Member]
Net revenues	2,943,000
Cost of revenues	2,018,000
Gross profit	925,000
Operating expenses	2,112,000
Operating loss	(1,187,000)
Depreciation and amortization	85,000
Stock-based compensation expense	47,000
Operating profit (loss)	$ (1,187,000)
Device Registration [Member] \| Operating Segments [Member]
Net revenues		3,611,000
Cost of revenues		2,243,000
Gross profit		1,368,000
Operating expenses		1,366,000
Operating loss		2,000
Depreciation and amortization		122,000
Stock-based compensation expense		108,000
Operating profit (loss)		$ 2,000

EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 69 213 1 true 35 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://cescatherapeutics.com/20170930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://cescatherapeutics.com/20170930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://cescatherapeutics.com/20170930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://cescatherapeutics.com/20170930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://cescatherapeutics.com/20170930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 005 - Disclosure - Note 1 - Description of Business and Basis of Presentation Sheet http://cescatherapeutics.com/20170930/role/statement-note-1-description-of-business-and-basis-of-presentation Note 1 - Description of Business and Basis of Presentation Notes 6 false false R7.htm 006 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://cescatherapeutics.com/20170930/role/statement-note-2-summary-of-significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 7 false false R8.htm 007 - Disclosure - Note 3 - Acquisition of SynGen Sheet http://cescatherapeutics.com/20170930/role/statement-note-3-acquisition-of-syngen Note 3 - Acquisition of SynGen Notes 8 false false R9.htm 008 - Disclosure - Note 4 - Related Party Transactions Sheet http://cescatherapeutics.com/20170930/role/statement-note-4-related-party-transactions Note 4 - Related Party Transactions Notes 9 false false R10.htm 009 - Disclosure - Note 5 - Commitments and Contingencies Sheet http://cescatherapeutics.com/20170930/role/statement-note-5-commitments-and-contingencies Note 5 - Commitments and Contingencies Notes 10 false false R11.htm 010 - Disclosure - Note 6 - Derivative Obligations Sheet http://cescatherapeutics.com/20170930/role/statement-note-6-derivative-obligations Note 6 - Derivative Obligations Notes 11 false false R12.htm 011 - Disclosure - Note 7 - Stockholders' Equity Sheet http://cescatherapeutics.com/20170930/role/statement-note-7-stockholders-equity Note 7 - Stockholders' Equity Notes 12 false false R13.htm 012 - Disclosure - Note 8 - Segment Reporting Sheet http://cescatherapeutics.com/20170930/role/statement-note-8-segment-reporting Note 8 - Segment Reporting Notes 13 false false R14.htm 013 - Disclosure - Significant Accounting Policies (Policies) Sheet http://cescatherapeutics.com/20170930/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://cescatherapeutics.com/20170930/role/statement-note-2-summary-of-significant-accounting-policies 14 false false R15.htm 014 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://cescatherapeutics.com/20170930/role/statement-note-2-summary-of-significant-accounting-policies-tables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://cescatherapeutics.com/20170930/role/statement-note-2-summary-of-significant-accounting-policies 15 false false R16.htm 015 - Disclosure - Note 3 - Acquisition of SynGen (Tables) Sheet http://cescatherapeutics.com/20170930/role/statement-note-3-acquisition-of-syngen-tables Note 3 - Acquisition of SynGen (Tables) Tables http://cescatherapeutics.com/20170930/role/statement-note-3-acquisition-of-syngen 16 false false R17.htm 016 - Disclosure - Note 5 - Commitments and Contingencies (Tables) Sheet http://cescatherapeutics.com/20170930/role/statement-note-5-commitments-and-contingencies-tables Note 5 - Commitments and Contingencies (Tables) Tables http://cescatherapeutics.com/20170930/role/statement-note-5-commitments-and-contingencies 17 false false R18.htm 017 - Disclosure - Note 6 - Derivative Obligations (Tables) Sheet http://cescatherapeutics.com/20170930/role/statement-note-6-derivative-obligations-tables Note 6 - Derivative Obligations (Tables) Tables http://cescatherapeutics.com/20170930/role/statement-note-6-derivative-obligations 18 false false R19.htm 018 - Disclosure - Note 7 - Stockholders' Equity (Tables) Sheet http://cescatherapeutics.com/20170930/role/statement-note-7-stockholders-equity-tables Note 7 - Stockholders' Equity (Tables) Tables http://cescatherapeutics.com/20170930/role/statement-note-7-stockholders-equity 19 false false R20.htm 019 - Disclosure - Note 8 - Segment Reporting (Tables) Sheet http://cescatherapeutics.com/20170930/role/statement-note-8-segment-reporting-tables Note 8 - Segment Reporting (Tables) Tables http://cescatherapeutics.com/20170930/role/statement-note-8-segment-reporting 20 false false R21.htm 020 - Disclosure - Note 1 - Description of Business and Basis of Presentation (Details Textual) Sheet http://cescatherapeutics.com/20170930/role/statement-note-1-description-of-business-and-basis-of-presentation-details-textual Note 1 - Description of Business and Basis of Presentation (Details Textual) Details http://cescatherapeutics.com/20170930/role/statement-note-1-description-of-business-and-basis-of-presentation 21 false false R22.htm 021 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) Sheet http://cescatherapeutics.com/20170930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual Note 2 - Summary of Significant Accounting Policies (Details Textual) Details http://cescatherapeutics.com/20170930/role/statement-note-2-summary-of-significant-accounting-policies-tables 22 false false R23.htm 022 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Calculation for Basic and Diluted Earnings Per Share (Details) Sheet http://cescatherapeutics.com/20170930/role/statement-note-2-summary-of-significant-accounting-policies-calculation-for-basic-and-diluted-earnings-per-share-details Note 2 - Summary of Significant Accounting Policies - Calculation for Basic and Diluted Earnings Per Share (Details) Details 23 false false R24.htm 023 - Disclosure - Note 3 - Acquisition of SynGen (Details Textual) Sheet http://cescatherapeutics.com/20170930/role/statement-note-3-acquisition-of-syngen-details-textual Note 3 - Acquisition of SynGen (Details Textual) Details http://cescatherapeutics.com/20170930/role/statement-note-3-acquisition-of-syngen-tables 24 false false R25.htm 024 - Disclosure - Note 3 - Acquisition of SynGen - Preliminary Allocation of Consideration Transferred to Net Assets Acquired (Details) Sheet http://cescatherapeutics.com/20170930/role/statement-note-3-acquisition-of-syngen-preliminary-allocation-of-consideration-transferred-to-net-assets-acquired-details Note 3 - Acquisition of SynGen - Preliminary Allocation of Consideration Transferred to Net Assets Acquired (Details) Details 25 false false R26.htm 025 - Disclosure - Note 3 - Acquisition of SynGen - Preliminary Allocation of Consideration Transferred to Net Assets Acquired (Details) (Parentheticals) Sheet http://cescatherapeutics.com/20170930/role/statement-note-3-acquisition-of-syngen-preliminary-allocation-of-consideration-transferred-to-net-assets-acquired-details-parentheticals Note 3 - Acquisition of SynGen - Preliminary Allocation of Consideration Transferred to Net Assets Acquired (Details) (Parentheticals) Details 26 false false R27.htm 026 - Disclosure - Note 3 - Acquisition of SynGen - Supplemental Pro Forma Data (Details) Sheet http://cescatherapeutics.com/20170930/role/statement-note-3-acquisition-of-syngen-supplemental-pro-forma-data-details Note 3 - Acquisition of SynGen - Supplemental Pro Forma Data (Details) Details 27 false false R28.htm 027 - Disclosure - Note 4 - Related Party Transactions (Details Textual) Sheet http://cescatherapeutics.com/20170930/role/statement-note-4-related-party-transactions-details-textual Note 4 - Related Party Transactions (Details Textual) Details http://cescatherapeutics.com/20170930/role/statement-note-4-related-party-transactions 28 false false R29.htm 028 - Disclosure - Note 5 - Commitments and Contingencies (Details Textual) Sheet http://cescatherapeutics.com/20170930/role/statement-note-5-commitments-and-contingencies-details-textual Note 5 - Commitments and Contingencies (Details Textual) Details http://cescatherapeutics.com/20170930/role/statement-note-5-commitments-and-contingencies-tables 29 false false R30.htm 029 - Disclosure - Note 5 - Commitments and Contingencies - Changes In Product Liability Included In Accrued Liabilities (Details) Sheet http://cescatherapeutics.com/20170930/role/statement-note-5-commitments-and-contingencies-changes-in-product-liability-included-in-accrued-liabilities-details Note 5 - Commitments and Contingencies - Changes In Product Liability Included In Accrued Liabilities (Details) Details 30 false false R31.htm 030 - Disclosure - Note 6 - Derivative Obligations (Details Textual) Sheet http://cescatherapeutics.com/20170930/role/statement-note-6-derivative-obligations-details-textual Note 6 - Derivative Obligations (Details Textual) Details http://cescatherapeutics.com/20170930/role/statement-note-6-derivative-obligations-tables 31 false false R32.htm 031 - Disclosure - Note 6 - Derivative Obligations - Fair Value Assumptions (Details) Sheet http://cescatherapeutics.com/20170930/role/statement-note-6-derivative-obligations-fair-value-assumptions-details Note 6 - Derivative Obligations - Fair Value Assumptions (Details) Details 32 false false R33.htm 032 - Disclosure - Note 6 - Derivative Obligations - Fair Value Hierarchy (Details) Sheet http://cescatherapeutics.com/20170930/role/statement-note-6-derivative-obligations-fair-value-hierarchy-details Note 6 - Derivative Obligations - Fair Value Hierarchy (Details) Details 33 false false R34.htm 033 - Disclosure - Note 6 - Derivative Obligations - Change In Fair Value of Derivative Liabilities (Details) Sheet http://cescatherapeutics.com/20170930/role/statement-note-6-derivative-obligations-change-in-fair-value-of-derivative-liabilities-details Note 6 - Derivative Obligations - Change In Fair Value of Derivative Liabilities (Details) Details 34 false false R35.htm 034 - Disclosure - Note 7 - Stockholders' Equity (Details Textual) Sheet http://cescatherapeutics.com/20170930/role/statement-note-7-stockholders-equity-details-textual Note 7 - Stockholders' Equity (Details Textual) Details http://cescatherapeutics.com/20170930/role/statement-note-7-stockholders-equity-tables 35 false false R36.htm 035 - Disclosure - Note 7 - Stockholders' Equity - Option Activity for Stock Option Plans (Details) Sheet http://cescatherapeutics.com/20170930/role/statement-note-7-stockholders-equity-option-activity-for-stock-option-plans-details Note 7 - Stockholders' Equity - Option Activity for Stock Option Plans (Details) Details 36 false false R37.htm 036 - Disclosure - Note 7 - Stockholders' Equity - Schedule of Assumptions (Details) Sheet http://cescatherapeutics.com/20170930/role/statement-note-7-stockholders-equity-schedule-of-assumptions-details Note 7 - Stockholders' Equity - Schedule of Assumptions (Details) Details 37 false false R38.htm 037 - Disclosure - Note 7 - Stockholders' Equity - Restricted Stock Unit Activity Granted to Employees (Details) Sheet http://cescatherapeutics.com/20170930/role/statement-note-7-stockholders-equity-restricted-stock-unit-activity-granted-to-employees-details Note 7 - Stockholders' Equity - Restricted Stock Unit Activity Granted to Employees (Details) Details 38 false false R39.htm 038 - Disclosure - Note 8 - Segment Reporting (Details Textual) Sheet http://cescatherapeutics.com/20170930/role/statement-note-8-segment-reporting-details-textual Note 8 - Segment Reporting (Details Textual) Details http://cescatherapeutics.com/20170930/role/statement-note-8-segment-reporting-tables 39 false false R40.htm 039 - Disclosure - Note 8 - Segment Reporting - Summary of Operating Results by Reportable Segments (Details) Sheet http://cescatherapeutics.com/20170930/role/statement-note-8-segment-reporting-summary-of-operating-results-by-reportable-segments-details Note 8 - Segment Reporting - Summary of Operating Results by Reportable Segments (Details) Details 40 false false All Reports Book All Reports kool-20170930.xml kool-20170930.xsd kool-20170930_cal.xml kool-20170930_def.xml kool-20170930_lab.xml kool-20170930_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 57 0001437749-17-019375-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-17-019375-xbrl.zip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
&=.!GC:9MZ< M-X O,)U!'CM%-9MPKT?8#=;;<>^;N[T"##7=C;'@TD,*%Q9 M"/V2PX>S+Y!_N3JIR9=M)E%FNO9CO<['_;I_%E.Y-R3%2<28:5G;YH_NYI?G M %S(RG0G2'8(4&L;;/!LLR_GH;% C "UD$+2SCYNQ!/?9PEQZ(EI4=S0@@JB MRWF6]#V[0WV+/F<8T'!_ZB 5"E+#D.Z_X6_TG!U#ALP$'\7>B65'+'1YY_9+ M+$NNQ71"NH_N>%J'I%SE1T1 [ZGIW;G!5ID((XD)IKX51PSB0>L@=$%*(9D9B( M.C8!JK":&#M5W!+_@SS>42X$ECWLBZ[V!=4.^'+<0Y\N"IZ>_Y =AF89X. E M?H=,P>EC(7.^>M:X$0X%G9L&>D!/-69VS*SR;I:'M.U/SI$R 2@( T8,U(!(0K)S"14W]&* M,Y768;4EO6Z,S?B@"^Q23;Z*;A>;Q4$0A4& ME1FZRC%5Y6./))Y E5_-IX"/X&L@YXQ M%FIIR: -8;TN@PBDK/D1AP5^OPS MAI^/=='TD'%^W*QHD5P0"^MS,65XF]ME$!<]AP6?^BY[8LP-OL"& ^M[]F5Z M=$! Y5VU.2),A"8OJ%LX2'VW?&=5 M;S?Z=QX0L/(%N1?V/(ED MSM@HV_Z^('0!-1S@K";-?5868E7RO%0%X1:[?6))H[1)8CD[!@%-'LSNA"!''[^9G#H[=T+WS*$B>2=-Z(W2\W Z>;:DPW;XFS_Y+ M_#DENZV%Y88'[U,^>O;^[S? ;A>DOB'6OW_2H3>'_@GED>7TT/C1!?2F4C6] M0RK::^--P.=Y7+N]6^Y[6B.%7].KZQ5P=>!-#RT\?:SE _GE^3:GJC-^Q^?Q MWSX_3T[V/="VHU.C6<2/LW1H$N"@K&&2/8T8D MDL"C&Y/36N;2D7=L"Y[OJP9%@*E@_27)7%VMF2X)CN6HYTN,TW+PW7M,_P?8 M*PQMQ^[S;JI3XEI0W8K_;N' %<;%W\]C\88 MT=K._=C23&4% ]_ULSIP)8QGPI#5QT:U(?]&WB5=L*+,V?U&S._$:9^2=>GEYLF'?'A!2BMC0)A'#>(DQUU$G@_O\[^*WN?7=QE_R;^N/T]484Y9]*6II^CU1J\X[^_?O%? MW[U_\?+B]U!BNDE%59P6)M$BBF6^8)Y1 @Y-T0,\8%GQK%R*0P:HDG+)1%.: MD23:AKB8ZEV"?-!,.E >-S2CGZ)TB YI^<26*FET'4RC-#!869"CQF1+O\!U MDX1A3]&,&I<5?9-70W*O=YZZSFE;LEVJ1SNWX:[S:%G,LZ3ANGROHB&2J^R& M@B<6RIO%#U*SF:^U%/XN#YZ%P?L*JCE>YN0-L.>T ^ M[F_XFGBD^3T?NI7OZ.[>8#^>_*(Z$59V[,IU") M']J3ILDDJE:_ M696IMT+=W'0;P*>RZSJ2AM:D$/:GV'OUB:,2MSOM407)]A>D&-@!OD:%(2'7 M2^8#+4F\A'20<)C<[PSJ*:4T41MQ(&$JJ2"FI;/PL1FO@VXM]\,8%H]< M,*_X-DK9@OYR^T&_1+2-,(OBI#/7RZ F2'YY?OO\PW.\Z%M ;EO8C\;F7[;U MHL'-N#:Q6B^Z,AHC$RAYH^NJ"LQ8?+[N=)P/!'-'-$'NH@)WJJQ86T;39)KE M=JPMHR&U=^S.GN_7;2RYS/Z#99!#FK'K"-L -*WY]FU-:#\R7#=!%=PHV M0!N^)VD#M TDN U@A[L([0.$SQ:"\D[MA,N1Z6\]N3(&^J?Q"6O&VM+YF4-A MN)256]_GHW;*4]".[0B?I'YL'TIP#6F+PP@=69,FCSO:3U\_]JPIU\>EKFD, M%..K'E&^TV< Z6@Y-LYWWZ/W2-]USA>L),]2*+HT*F!VS"!PBJ^%=+ 1(!3+ M?A+2H,B'ARO+^A.@G>K -+&TPX8JMZS)MF!E'9\$QJA"YKG-+FACS3;T)XD M(YV-L0E&6CMU7_9-426Y(ALFKT@W/_DP)OD5G->\**\6%1Z-O+2V08K)05^> MMB:@"2%ZE8R@].)(W$.OY8< =B35[;/.C5CB5X;KA$_"FKQGF=P[S*L=#_L8 M*?5F1)Q?<]=IOAHP)E7V>.!<\'$,#N Y.8EG/3WTW \Y],#SYA==#A.G!,?X M29P \^H><3("M%=D(OP$<.T,\S)[G,%W(O'@M'0$:]=32 M AM^N^_)DT$I*59^#LR*'848I[(:)+TC1K@#S#GL*HJY13RY 3]\YVPOV8-4 M&*^%>K@3M"_X*F*99LWU-4?G;V_OUK5L[^D2($P^*K)A;-=>WO*A#//M0:K+ MQ-?%%GK%R>03M#=)W[5[GU)-F]3$PXJ6$9\YAGFA1.PR*\ISKKM6 M#O2?C!:QTZX]BMB>./D(I$.+6 >?6T6LCWD8$2MH_/R!/WZ34 ;2]0?X"PC5 M'QI")7[TM[D@FP#IMVGT<"1!VM\/%)>3?ES+QHX8 6I>I4'/,][+B)"&3X<" MT3>T8NSX4!8G9DXX-='!3:UY8T)/'/SMS=#W'(?=N;\R M 'JD ((S\D_GS\_/7T#*??((U/]"7GYW/CL_E_]7Q4X+$FW*)<_9/VCR%_+] M[/OOQ/__\)*PHH"885EQ?5,6I?@+W"<_$[]]\=WLSW_\,XE*\N^;C)*7YS," M/ _CI='.%S>=!,]A]#E/-G'Y2P2>G7([A]CL*+W.*17KH[I(/DA>HI%3=#_8 M(/RA])Q+NDQA4T .FSI=S59F0%WG]*P&13XIO$PT3#8R!2.\^EP+LX6'>9B" MGS=N;3*F(/&_[";F4FJ:06*N^]BJ;!\3<2W0>WJU\IVRQ&JGH%=,N_GJWRA@ MI4S3.L\2."8+AM,L%N#,KXYQG8PP*,R)^3 W*C325#C ,ZD[9>0D<3N) O6TS]:XQA1QNZ5EF:I#SI(UT"8XL]*FC\D?)D1;SG0NN MWRNI^V*\@_*X9[^^RA-OI%Q-ZJ?!78M:IK=[&;LY^:68+C_30JRPR^Q:VIC3 MLUZ0^"9GP P%IFC//90E@R"M/_F#$VM(,72V:4$ 4V9CK]^3VM M;1DQ?CSVK09,Y;N?G/&B=],;<>]+,5H^0,I46%S3LU>&0YNEZCY%$J[I989*4='*2#V*/ M7WFQ4>'56_7CR94ZGGQ=XZF4SG$X^Y;+%4^GM(Z'K>S#IJ6 1##ZTSU%*9Q? MT%%)#6BB5CJ6V^,//8KRKGQ@8>X]>J+,&G=NP;/KZ9Y*CE26WZ-'VV0'\S)? M1_E5+E8;)/N$3?>:YG)\_1[GOB_'>Y]U%/QZHG?O?:9T88V@D.- W/>J@J;8:?&Z29KO:--; MYC;V6.G&*Z8;1(/$-[DSU.); ]?FO:?LG+WJ[M_0ZXCSQX43+=J$4Q.O9X@ M??H:]F1(TU*R8SA^^!CY;M3+N=^0PM4O1Y^OWW0S[C(!7U7 Y"TKXBB%C-UO MLN3BM(:?25-$6CY=E\Z=[HHN480)4":"M#P(>L_7U\M7/H197\H>??B.(O + MM,GNSH:>W+:%Z/WI3K1V"_H1U9L_X"/.$*J5[G*YZ7[!]R9%>+ MMRR+LIAE#U"W"6+5('D1W^@3 PW]'*G>3,GX4D^F>##JQ<%8QR00:L(!O9#0 M^Y(D%8@@*F&PS/&QS#5=DK]RGLJ%=O[]RW.YS. G?[L5JYP6\RIUT7O:$M_8 MVV[@PM'VYWJ%*)ID3BJJY*.BVQ/BZPQ]PF.I@ENB*;H*U-.U^"UH;E+4 ZJR MA3[W*O/]:6IT+*]MZ^ZF:GZ2 M;A[L(O2J>6T]D3"]L9Z^1K 1+SO5]'WMHSC&PJ%$*5G4%5'W$2IDT+JS@". M,3,G,9#)%VJW/F*OA=TG,%_.'1%YC54HXQU864.^8?D^P2+R[I2&C:+SCB7+ MG^$,DF%F-I^T'&TT[WKT;3++2*4I&,RG/&TUES6,^M)<6/.'AUQ>WUZ*M<&R M@L5.GOS9PC-9)Y<&M^M5UKEO134FPFI0ZHG^;I?Z0GTR?4+DU4EC)!E/Z]A3 MN?@A>]3AH%P=8_H)!CJ6Z(&Y7OD-RM->Z6ZGW:)A:3J73W:M!O9%C$ 2?G5_ M:=X%Q-!"N!&\S #"7W"@?7]K_H$Q"]F-OI[NB?^Z3CVG>9K4V6[$:?^@/V]G M_>I>+-B#I&YN+R-)Q)O\OT E[YQTP.1?P]I7),6=(, MA=>LN"&?(A>/"0E/E1R:4&0,4]3 @-F=W8P-9ZZ88)G.&!%&Q8C9 M/H:E3RL&9'AL]+>.8D!&( D4 X) _%1B0!!#"Q$#XF4&$/KOP)C[K<6 C%G( M%F- 1LM&R)M^.;)BOKO:-KKTUWUDY?[_N'/OH0 GU_W!O12&W-?>^7>SU+,= M$2]ILDGIU>(ZY\DF+JNL7MNZ=/#6J+PUMAOL#CZ0G/-4=!4>>*1=(:JSTFW) M#M-4JE&C)XO;F@'/^05BE6E1;!: Z?5A??HCT>INC,TDT-JI\_0!%56R5F3# M9 CHYBH%I85;(X\# &M/# M/K9R/ A5:?KDF##)8M,#)T1[8IABR>DWJW7*MY16P1NUW<=HT6U@&7^'E,_> M_CV87?E&"*:PNL37J?2#YU7\3E7X.,PUGCGG.9J=GBW[HJ!EC[RUML':\P2GEV0,F>\1$028U M9JGZ&ZA)!7MZCB"[TM#J)W(PQ2[/<6\$Q'+[EJ4T?RTVO@>>;UN.W MEMZ?=DX\,#/.]^&M6.OK"R1A.N7^2,TVN9^$.8!'DYS-/1 M'?%E\Y'WD^3HFVQ@#4A__)S^6PG?C^:_A ).1>_CK37+Y4=%71/7Q;[F"(:K M#R!(,0ZJ!88C"*4 S)&Z M7OL2R6_67$!(C$WU@!4#SY$\R7]OBE*.YX[#57$6LY1^H.5E%O,5?<<+\?/7 M4;&\SODC2VCR:ON3&.]E=B7$(X+[G'E8V:9+0DJ4 ,/X6_QP(WV0BX1"QJ7@,FT0[Q#V%"@UR* ?,(ZF MV*CMP,GN[-/UM'<2'^+RMSP*A%^^(EX7W;A:D"D,)*G>V;6D*NL8RPT\@)*' MB'))R:H:F;I6A@CLJ 9$/BUI3DE2/PC+Z2/--E2>2/($?A"5T7VZ?>YU,9LM M$SZ(V7Z/Y*_3J"BN%M7#_JO\!CP'K9O[@"^0!^2.GEVK!TD:!*XB3GA.)/DP M5L$07G,$ R?F$#8/67":<5E+)WS(V=/*N'P"/'#0$Y9[=@+&!N==GC@_QH5[ M?2E9J/7*PDVPUI@LU)JSP"N^C2 QW67V2)7S\NTF2R[991:_IRUZ=MA'F--! M;^>N-6 -@.P1$(! +B]GXF?Q<_)1 >FQ!_R,#6MSK\5OE4M_"4FH]\D\Q (O MJ^R%PB3O989_6]M<^CB.[1.POAN+?H@)WO*933N\T;TO,Z0/!V87M3\VQ E> M>]J8$>/A^3QQM(E6W[%#RU._*^P]RWC.RNUE)N9)* #-BM(U0ZZ@X^Y(?SP[]_W)S+?1H( M[SN?AMNC)?K7D>.C@U*P8E,GB)Z*\Z,%>IB"4V,X^+WB8";KU"1W(QX/?"GG M_:XU8K7N5,^T^=5AIYG >N+N^C] :A1]Q\ZWQRH=1KI'$":8S8"W?#C#_ K4 M04C<_#%BJ4S]P\5J6?%,YD%<\C01"D>L$!9KI S9"U+T!E+SM5$-A(79A)R/ M')%V[D,=>1J59<[N-Z7,LE5R$DM0*E5HA2K(,L4*)[?$=P^1HGL8JLR!WF4U M["-\#&E'Y[X"2I7XW:I,M0I%TYT3S (:. 4G@)_C65Y0+@KK&8" M^NB>;TIYD[6IAUO4P_U4H0MP4V4F47PX5T,,C?CQR A&%(&G*[.6)HKI_U NO\6MW"L"SD,O..T=P&^G=$M(4 M<"*W4W+?RB(F73-[/D!C$M6O%J*"L(7>-_]9D&64D'M* M,_@I5*"&O EJ][ZG#RR3L5CP$*+J/D3,U7@UPBW/O]^-'T+',J$ MQ^H[MJC MK0G2"&AVY5HCUK2$H363HBTD#6(#RNO[=AY58T& MY7_^W9^_??&GOQ J$82Y2C-@,1_.-[]R=:.>P%4E-Z0NY2F+MWWE88R_0TI9 M;_^NA:T"0!H(9D1A(!^K/T-793&?!([FK,N+H+L\@CN V^WJGA^[W;6_1USO M'/3C6G J8D11\WY)T\XSWLN(0-80%"F41NQ-93'TV4;:#\9:2B<=>[6;:J)A MC2 ]<]M,HAZ.C71C"!L^AI/7 [U:-&X09:&$Y(Y7I:"HM/.K;;7-?S&B&XSC M D'.B\<"@6OPP=S+V!$^BCTNR'/0O&)7%4,210I@_G459 "_;(;$P.?WXI-/4&[E?DNJ]O3WA?J@&E, !\.8=!.J]Y!IG<:!:+(^<#+YF<9?%3=>']2ORE3%%GAE@& MKU]G8T2H+<9PFX.M8MR:'P'2 -?7-"ONY.S1%A[E>=C/?P M2<KW[797U)-J4; ?4IDU-O\'HUKZ^O;@-^D , MUKOV1V4W$\RTQH;;8532,AA?'7H, Y2;2E&7A0$\ 52]\8+A*)XZ5@$#BB)9 MZ\^%Z@A9L&@T0.O+,GC)QQ-U=-6FCF:D!GI6(:U_2\E38 S>SUF7MCIK+VW5 M" D5:@[^L44=EI+.!'OP9Y38LX M(F(]YM&:;DH6%RHU9Z$-,IQ(C&';,:*/DY[O!* \52'4XEN>7_#-?;G8I'-Q MO!?'<=WQTN03K-^_HVOGGL,H(0F]+Y7/N_!;"6@0;SF&89Y3[/'5BJGR:/,L MV=^+,6W0F,$7V#1[^IZ=9Q+:DY9.Z+A)/$R6/0,V:A\ M;=D-DIB]>A1B]":=FH)VGRRK39*U3/%L@5*9L54LIO=1_BN%Y?1&[3SX-=^9,X?A8WMS^U MWL(-^@;]%J2C;_?O0&KB5"0#%UX87=LZ>?YCPG*,8Z?LY0"EXSL0I M7[V'_T#%R3].-_!8X4?.DT\LU:5E&O(I^HE /PGWCP5J#%4> _G4,M!K@0$< MYV/8&,"1HV)]7W2Y<(Z:C''>5%WY.#+L(KB9"GF'D,G&S;F8]T>:EU+ Q(E5 M_!3"L^2&6B>"#^?_..;XL>>CE8W>[]#MU)S'=X2_C9]8O7B 0Q8I_U00$(8) M58(?,3G<'L<]9RP2YW.9N((]TBK81R"#KIWK6,-NF3/8"9 M+/@=MMZC,>=9K:5B@X%PPQ8O]PV-*7N$2$X9U+?@P!WA+ G*>N G#LK*\1P\-(8$J1&K4S@!F[XJ$8.Y=O5@V7R\4ZF ML _]]L"A='!_4SX%"]MX#*^V[1UT5!_S0-&J76\%6: C0/UU'>+(:3)5 UL=-('/@U-55H2 4GR%(?*F9$$<];Y$G)CICJZ]';WRQM&KRKH9 M'9S DOH$%M6?R&2<+[^O4W&>?SNA1)Q&T\4Q<^#[%DDL([A5><BG^JK/! M] W1-TK'';I/R%E1)!^!)I%$ YT[]-SDYBSR'F=!!:TE)"BFCS3E,FM =^B. MT3?X. M]WQ[B+"1QE2A[3SY49(4!ESF*=;YE;+>M;^_R*"O@"HUGQ04KXI07 MFWY_#Z('M/P94W(OC7N+;DN:8,@>3?A,#YBYX188[OG\M8,CT[+M"N)6\%_S MHBQ.ZN$6?7)MJ5?L>6T<==?RWQ!R+E,F[@#N#CL28E6C\.P>4)(:9OB%86MR MN:,9\QY>)R-X!*C&;86)\V+ E_C@NCX*OIP6!E P#@LG(T0X*VH-EV'($ZN3,V M,:XXKHM=-Z<)*]]&,;RYVKQ4^"F% !5!R\[LMKFL^31W"!':W!L=V@ M$N8.)^>YP7,/SR_H8.R:I+OBIP*25R$@-;484./C5#AX!?/**?=)@7CZZ7+=4Y3MF(9I(!^J&@&V?.ZWK*,>Z^B MV>5 HBYW60Y?[U]D'.:EAQ\7LNB=)D_3F'XP^QR&GI>-#@-LL([W,WK,Y31H M\\M&ULP&MAEI%,60'IX:'S+YDA\NX),NQ?L!JBQ+55;1HW=/92/-J&@HD]S2 M*O7\8*PND8BMD[1$AKL M$YG6WR?1MB!LM1*[DMA:!<&#??=]O>]>A-EW1RD=;DV*1A\T2O;0=.O=\5O! M_Y(^L%CL]*S@^?:6YH^";D>]>WPON&/&4&JNE>\>TS;E>S85.S9%-9N*:@!!S&FT*'-+ M4^0YTDB^3:X=C-UO-3O;8F.+VOIT_N)2D:N>EH=Y6]G-3#Z(0][SG;47@-"7 M>C;Y!)_O3-NU\Y=J-:T92:%@0A0+S;E1JBVAPIZ*5?F:4'G0^GG.,8RT>NY3 MZ8ZO%E6MS@MA]5V#H7?'A1U;6WE@Y/4?_09W-?[T9TPRP '0&-O(TX]#'M@X M!N[S:=>E:@$AN=:>)J;+CK$)Q1%'JUE]2/NT9/'2S3&0%613*&LPH5 $ YS6 MI>84VW&"#7X,'*Z VD^"2!$:K9?!)KT1=JJTR77OSHW:XC1K>Y_.@W\D7=(D MC#^@V1L$WOD#C2!I=M*HWU0MP(4XE9507.8HO5*0I=,C0GP02ZT:)>^CSVRU M6=7K4,8Y%2KMSD]K68ZP=LDH1TV_;8+M<;R),I1R $ME*,21.[1[CMBP6RJ4 M#?M% :V+. /4AB-[Y^*>/'-PBJUF1[9C1U552Q;B6D5;*-1<)?N2=;(:QH-H M?&0J%)6/6YQY>-Y4D#L+A6_*0BA):<,TK97@1@9:D[3;&N/F>W3)%K$?Q5$J MSIZ"MSSM<#+W-,456FGMTKGWJ2)+=G3QYH:U(?BT-H*4[NB6'CZ$GYZ? QPL MUXXL!_J&V*#]DP[=F^('FV#(7 (=W.3F+/(K*K+ (@3KYW1)LX(]4E5M[RW/ MQ?$\4S[DN/GV99XE\E^I7/?SY+\W15GY_,3Q,_I\K7;'>5GF['Y30C#R';^. M.D+H@V! "KA7K*[73@6:Q!5J\,#40$FT0QKFN7X8J>"3F.J0VT5OWLJ^YE:V M#G]Y*D^]O\'S4_9R6+N=3",?I3"%DDU<5H7*MO,XSC>1+OBRNS'^BJ^E4U\O M0-JI8QY4V!K'FN:,)[=EE)?#? ROZ /+9%C&?90.C?!V,XHWV<#W(6_4D=QH M .YN5KN$G _CU202=[]EF6#G03)FS0H?WH'=1-TMA'QI G-$F'7ER^J0EES]WNPF*JG,ZY+L@T2- M;#N3#JQ8>UV$O"5D,T:$RLGF<+PVK@YV;RAOY V^ D5,Q^S%#C:21JUE;,[R M2>RNE]FC #MB=^WHP.[NVD(H\.[:@LCB[FIEO&-V5QGXPC+QOPK(5(M^=(E@ M_];:R^=)K-.6DB3#UFE'!\[+U01>IRV(+*Y3*^.UL4[;BO-,:9EV22"J)D_( M90H0H6:N^ .BD1^C%!S8U])Q<)G%.8T*>D'5GYJ%BND"N52'D/*U6(=@PBQ7 MMV-&+MBD(@CK52Y>63<:_D+W&,.4CL9(([?!;K\+5Q9GZ,M(U]X(N?@.._.U MO ZI8A;06-R(X^('7M*"2,)A5H%FXKD95T:''$5%<;6H7+)7^0W$K5_M@[W$ MT3)G6<'BGZ-TT_KH!-<#+D!I""4O@9O#("'BF=R.&+%<)"2(:*I 0:R3A#4C M#6#2Z:*@D6D.?53>G/MMXP%(E8&.+"*6DT= 4P=\?:I81#_'E":%BJC\3/.8 M%73_A*-NU0BQ#!(2AEK&W,)T>2XHN%C0N+Q:O/D<+\744G":767MIH1FJ\9T M@2T[.("4\_>=$HM<_(OCZ!IXT4T41-%@:H8F:L*XC5D(>4?R-HJI4EA&-R*G MS:W9J( MN8 E6V[%,5'5H&^-7X/\LESL7#Q-U1XFKUDTJ\ENY^@R(#9 ^%JI=M!BUG4H M/B%\.'?PB=Q"RVV@ZBI6!9N[G06_&N75IF 9+8IY+. 73$*&O^:T.]#4^#ND M'NCMW_42KP&0!H(9J3&$C4$U9SY'-S/-0;T3?Q,_K'\D_@.E.,1/_C]02P,$% @ ;(5N2^RO"8;X-0 ME=P$ !4 !K;V]L+3(P,3/$B M 6!F$DOFEPO^\3_?YNFK)?GZ M%<\135#**/[M-66O_^>___,__O%_HN@CICA#.4Y>35>O[A\+FN#LC,WQJ_\] MN;UZ%;WZ_NVO[S],/KWZ;YO+;)-]U.&S\ MPYOUE[NF+X;^^KYL^_:77WYY4WZ[:\I)54,QZ-LW__OIZBY^Q',4$2HE$DM: M./F5EQ]>L1CEI1BU++RJ;2'_B[;-(OE1]/9=]/[M=]]X\EI(_=6KM>@REN); M_/!*_OYR>[E[9HRYH.)1O)4%+G(2\^]B-G\C9?_]+^^_?R.;OQ&DYWB.:1XE M+"[*/\3;C<1ODJ\$:P\LFY><".[*ASUF^.&WUW\RED;;D20]_V4\4+Y:B G$ MR7R1XM=O#MA99)B+;F7C*_'!IKTDURYK:XKPMQR+N;N1\):HE,5/!' XT3B. MOYNQY9L$$TG"!_F'%,Z'Z/NWF]?U7^*C?TT$#8FDXR)%L^U#4S3%Z6^O:[]? M$Y7*^<2RC9RZ).JTR#+Y2"($FOX_C+)SFIP)P570IVMJF]2SS6M<$W"#,\*2 M"_$9KZ!5V[9?8J6T8*2^:-D7H9?[!2%6';X4:T=%K:JY Y+OT32MFK.ZIGV1 MNIZ!]6M+V:XO(N_%A-]10#.O5$_GI7O\4+EN7BZ7?BV*S(MGA(M%0O//:%ZURE7-^B'Q M=Y860N_+UF*JGX(U[?HA\@^GT^,EMPQZP\LF1]] MDHS2# &+Y">?1 (R=L"B^=DGT< !'[!\?O%#/O7P(EQM\T23!:# <)EXHLN" MW"-PJ7BBS@+]6W"Y>*+;*GRH>UG\X\T+48@!_^SW64GG$XCDHW7&J=\!;>6R/[GJ+ M])L[]Q\0GY83MN#1#*%%2?4;G.9\^TGY&@[0SI?[Y:W8.K,E?NZ6@7?HGXF;K9+09+6;=7;-''#-PSH-@QG]T@'V MZI^=NQA3)([Z+Y0O<$P>"$XJXP# [1VPL%5Q7JBOSVFO;>B0Z.N'"T*%+D*$ MO<$X*0V(J?2XQ'7:BTE7AXQM9TJ%@QS4UB'I56%OZD;^N- ;S3(&D\_87:BP M>S=EE(*"VB]CCT4PDTH3 M(VCL(0IM)*2VJ,8>IM!>,NT=B0,-6# 3C3&2./:HA<;BZ6A!#31RH:58JM#. ML4#R]9IY=TB)?32W[RKQ.V0BEYP%(KYGGIHRYH.R]6))S M)BL;@PWZ7NS))X*&/S6"GV;IJ MXL+P16+Z.:5#/'V1!&RW,8 O(L7.\[*5PIE'^9.\RXJKG:K /FRQCXG#+1< MC;/7NZ# VHFAY&!ZF=^^FTYTFTOMNOBLEN M4=QLUH0NH,H5&<&C'3S:"KJ#1WLPZE;P: >/=G#JCMJD'3C,$4S:AB:M6^7- MD4'\7IA^.W2TM I7=(9-\]PTH_1MYH+(\<:B=93B%+*+_,XN.F7SJ9BHDJ"* MC53##:SSR $/3]APB=NL+WM.Q9DY2>:$EA?OY&2)S[\M9.5>9:R_45\753K% M.87WNM;F)F?%5@#H,1@VE)LSJ$_ K )F%3"K,=A3 ;,*F%7 K#J6"^2P9XV. M5%\D%)(40KS?4./]!BX)_<0 VQJ^B,1POVU@7/H?36[#FS+ZD.K@35$&")H@ M@8Y\(!^B;)U[)*]\RE=1?I"79.@(@0S5MS<$3E,KE\@V/>MCQHK%59[H:]%5 MMSR&"GG;9_UQ]UE/T(M&'1!PR@2764[$GG8C5CGAG&4K:>+7DP/LXEG]P%"\ M;(3%R_ TOZ3BG9>W/2JD7=_0-=&?T5SM_]0U'[E/RA,V7+K60F&SX18VJZ81 M[F9O,$*HWQ8\A\%S&#R'P7,8/(?#GC3![D=J-LC(G;*>L.'2M[Q?RZ>(8X53IKZA:Z+OQ?.5/CQ=\_X9 M^(2^D7DQ5SI0*]LX()50/:E5;1RXJ9'8\E01!<^_=T2BVF_^LD7PD@9JI)HFX]"/+5.XNN?0BQ""$6+T#W M$&(10BSJ=#X&T+5\X5YAM#%3^\@7F>B.1&9\^'@C&7T01;4%Y8L34[E9*(Q< M;YR52O[K\0A?WK]^ >A0,%\DH3XX.O$"^+)H +Y(B!'FR\QI?KP&[WWPW@?O MOT<^-M3Q/GUPX::Z^R6S!Y5N>7:]@-A09W7K^_A(E-^NX;D?G:!2/8[ M2@MMK .TV\C# CQAPV5T0_!C.B8Z^#%'J9\&5U1P10575,=RT>N1K(&^YHMT M -EV,#W<%R --%V YI4O,ND71AL_\!Q@M,HSV,IX MSN\>Q4(^05RFGZU*$6N!GFY&'3F X@D;+G&@<[')L17&=W('NE[(.:2,^=6V M#U!6$Q9V2_5P,4^DUCI;[[DGJQ?+N=S@]KL<36Y21+5%56T^*F" 0,,&&# M ,&&#! 4[E4J^NLSX/+%U'JX0^%;>0+(*:=3T!-UA=Y!( P (0= (1=X@Z. M\,.?(XYGY;\97K!,1@H:HH>*$?K&#K6D!.0PX$\#QI]\ &_6"_!VN_[@I8D, M>@9H)4 K 5H)T$J 5@*T,FS3SQ\[.)A^3\1BJJST;]YQ,J-B-<=(_(WBF!5E M&EBT8"F1F6"[/^#FGNF(/9I_S4AK90X>/+PQ&8>&8A?C.0@^V5%ULZ%%8WKI M.SCP^Z.,"H+X# MH\B7LSG*%M%[$%K#>3R%#>MV=;B"7W'E[4FM7.'0UNR= Z( M;M@.Z)8A"X\X*5)Q.$^$4C&9?[9.Y,"1EF'4:IG ME2^ 0H F S09H$FP)&K.1=:?'NG(]GTO#I._"L)+%+$\9U:RCGHS,QNIN,7;!LCB[I@_PE/])I? U'"19X M*PM\XT?X&R>7B9AH)743SG&^?@]BQY[0Y(J@*4G+K4Y\5\QQ M+A+3TEV-[! M]@ZV=["]K=G>P',VF-G!S YF=C"S@YG=N9EM05_T94+IQ=C*D'($1?P0Q?M+ MW2)$$_'_P;5NS2 )LT'[AB::4&<'HC"C! 15-&$NV/ -;7BQNI,BSC<7'ZRV M^^+*T$@W&R98X<$*#U9XL,*M6>&&1TBPQH,U'JSQ8(T':[QS:[R)8NC(CJR[ MD+J9 0DP38PQKL =6& MX1\(Z M=P2\(^ ='>$=#HP'7Z99/\+M1)(#K]YA LM9L6PG8H] MA*4D$=PD^EN"V@X8P,2 8 0$(R 8 <%H=90$_"+@%P&_"/A%P"\ZLA^[TFP= M68=OHT1TRLAB6^)JNBD:4B;:3F6XC?STD!C1(TL'5VCTBA8FA-48\2=LA5+R@"_I$O,RD_RBH,DEN:3Q)SR?XJS*9 =W MZH# SV)^W;-=?-9N?SU;3Y_[I[/GD$JSGAV0>H.S6$[O&;Y^.&7S^0:CO>2\ M$+L;VQ1FPB6/,F1@9B]VB M_NF*9AT0\0?+_A3&P2E:D+QZ5CUMX?)BZHHJ5MNYH81CP/V&P5(]QJ%IW3_Y MIX@_3F@B?YT+DI8HE5K.)#]%6;82DZ:,[ZUA!M37Y70[%8HHR2]07&:V*UY+ M?4/71"N7A:II_X1+\T%L_R5--00?-G$Y,0[IV(KO$_I&YL7\A&49^[K>+L4W M^0K BFX(EZQ^(I1E@H9+FF.AR^;77ZDX?1_)8G]FGZQN2N.IAE.#$5PRNB-+ ML1-S29?0@B:K:LF;C=?)*:?4SK$V1=)P'8; T/7EVR&^BFB]9Z/?6YHE'V8 MSQ0LA/?#% )\JP#Y#,<^)PRT7(U''RR)#\.6A'YB*+P9ODR'6M.OXTWBAV&+ MH=^(UA^]$48-:'N$$?%7"L^[O-&W\%EJ%V( M%G),=(@6&J5_,D0+A8"94<"% X>0 UQH:G)"];8CQ WA*I8C*^J]L =VGK/2 M5%C)R[5;&DR&H_9M&S4BKY49-$2K(Z1XMTGQ#@G.?B8X5Q!T7E8#WR)CZQE\ MG8O4)2TODUI36Y8_$AK@=G,G-,8'[)P) M9B9QQ4EG[3DNA2;C3#*43F@R2>:$$IYGY45=Y]]D@6&LS.0SZML_:Y=4Z%AX MKP++1ZOW>4"/P;"A/'E!?4+.=0"" Q <@. ! ]+- $(5LL%A+Q(* M694A06&H"0H#EX1^8H"-!%]$8KC?-K *_4]_L^&B''T.6'!1UIXZYDC;$?HM MK0-Q1Y0483W"WY\D"#L.@2-*E>@] 6?\61-V?'2.PCD^1-GZ((L6LL9&E!^4 MWV@9T]%DZ+X#.YK3V"JZ8UNU1&SCQ>(J3_37"E2W/(;+#K;/^N/NLYZ@%XTZ M(."4"2ZSG(@5+%2:.>&<92L)E]:3 ^S2 7%G>)I?4F'7%?(M'#[WR9XN/^:E M3D;BYS!WXW$Z#;]Y2L F0K#JL/ZR8/2 D#5Y>I9,1[3(W):&^PPEA,[.T(H+ M>;+LGMT_XD\H+V1>E=2$]5R!A^J6'0DDD&DA!MC%;MYBBK^B]!YG\TJRU5VL MDV="5^<$754D@T_F,JGJ^N$+Y3@N,IE;.,W%W)LD2T2KUVB#84(F%,@-.%FG MN/%;'&.RE+K:0>$Q\N*.7FBW<#5%*Z)'=#7%TUU9(>WZAJZ)%J+$Z]T$1/J^ MN%U*]9@N<^T%Q)1J@.&P^1G-U<&^NN8.&"C$_O]T+M_0=N9L/"LUC#QK-02";]!*'EP&;P/0,UR]TT\,7\9B MC!,N[P^]8G0F%5=).]?G[&ZK!:G'M>W=3J]P34J(=PWQ MKB'>-<2[AGA74[DHS'=F:G_Y(I-P*T:X%<-&2%JX%2/8"B^9G;T2CB=(!2^07[R1B$/(#US_'KZ\;19+#!>.)9FX8^@^7CS]J M.#A2!BXW8G"\/@&8DGR9)(E/\.9TMAG?'Z',?FHW21 M4<5DJ8FMN%:?\8SEI"1&?)J4N=@GXH]*NF%=O<^%(O&M5B/[S[QV1J Y5?]DB!*:'P'0%W5X'IELBMIAR_%J=1=<^9#6$K(8*81Q75L-+S88!- I?N%?8 M6\S4M/%%)KJ-GQEOL=Y(1I^W4&TG^!(WK-PL%*:<-_'!2O[KK6Y?WK]^ >@ M+%\DH3XX.@')?5DT@/!?B*GAR\QI?KR&@/D0,!\"YBOC3.!NGV.+C8=[Z8XP M!-[8TW-$(?!M'.:.8DM^C(3LR;*\YB9BTW2C?K4-*C$=MN]HDF;T'*C$*WYW&AV\%Y M&)R'#>6BUSI8@]/=%^D 2A+!M#9?H$_0= $JX[[(I%_@<_RN@@!\@C81A:5Q M1 AH<\/%$8+U4\3E[8O;BQ9Q>:=@2_C*:,R^L:L&Q+4"KBH7R_DWG,6$5]@ MH#Z=IKOH'G9)\XQ03N*J#(8&(_1*_!]8?H"3R5+,D1G>?(-K;Z9K,YY]Q@[V MV(9OI78$^\2K1+=KRS>-*_._.AC6^T2[;F"*25H^#2=E<9,3Q.7=XW-9H*+< MCM7WSL ZNX0C)U]1EFBBT2O;!#"X Y;.Q5'/5AB7USY?+^2<4"8U:-L'Y+<) M"Y6+ H:RJ5:?V-]GDJ^B%(/ MDBJ495]@<^U\ JJIOL@CN!&"&Z%EJ;5&.,$1.A.L^5O&'U=M"Q<\MK!K4X^# MO<27<9JX:1 +NX"(U[3^()?WBZ[?5)2SB.(\$L88EA7SY;CRXZW. MNI;I(Q:$H70G+:">[IS.OK7_@3#\\<72800MY$@9HXDH03+;)@%CF UW>61\:,,F>81D>I-6>HS2@F:DE1F M5A,:IT4BU!7Q+8IC\4Z2W;<'-T\:(FA]DM0W6-8_;ZUPL5H5N$\^0%A4_X+M MTRC;5-G=EMV=2!I?Q#BH&T> \@64+Z!\8U#Z!Z11!$ O 'HACF<\ MJ,1B'8>>HRP?8C0/S 3P;J(TD(E:B[, \/VREA#%,YD>.9[)4VNYV$NG&\\L M ML\]G+KUCO2.1W1E'INTSN"0*NK1O+X$2=%BJ7[%HFM8;YX<@V*(:;9ZAG# M**-I1*P=U+$582 8L0/6@^5OQH*N5$M=I98+1+(R3W*R?R.RKD LCM4SLB2) MF("WXN76B<+V6BF&D>=NW6)\^V1O!WA+^YX70'+9>P[[$6O5< MYT*=ZIF;FLP9>7_C6Y4TK3S0J1@#AAHPU&%AJ.W4J0"*!E T@*+C 44'F]S8 MWWEO;YH-6[A]JJ;VHBZ/0\8PJ\H>K'M<4E9! HX SW>1H'(NLU1D[@J94:%" MQ$A\B^*8%:6/.UJPE*S=W"B-BW2=N/+ LDCLD20NW>$)20O!8(111D47'BUP M%G$IH(8@:>]T]0VL.F*P%1C[A2[%/HR3IY?H\?I<:5"'#I*G?SKNY?CC?L'"#L_*XFH 0NWXL#)B%0!2Z*^4)+SV[LO2C9 ?8*;,8#C 1P? X(Y-,TG .H!4.]) M!6)-M0Q?A RX6*A!LU( AN&F(AB ?AUY([\4=BI&5DBR4G$IBF9 MH74\V ,B6;0LK\)Y)&+$+'Y<-70MMGI&WV["#HBUDW_1BC"0-Z@#UOM$NBJK0"?%F 20.('%CD-@(:1H:_+LNL"@K*![HPNSAL'G[8N.6GCX8 MR+@+-GH&D]N1W YF[D)<;@#HCT)!OV*<7]/]9Y^Q'H*NZ1?17X; 58>PNLL" MZ'88,4S:?B@4GZ;[%,9M1\C=.+A.Q5(5Q).F=E MK,P63B= F]N=U6?Q* M?%@VT0BH^P>-6VBG:T7GX(LR>ZL'*6J>/&ZQBF6'Z(R(QGU,R(JGC5U\2]&> M9:M>A/?L6>,67;WKI>.G.+U)M$M>;C(F;-1\=9,BFHL6\N!)UU0_^2!;5Y>T,>KCP?"UQ*H2;W./XD;*4S5:W9/984ZG/L)># M>']"28ZOR/)PMU]/L)/5)_1OEIVFPOA0I%VS8_'E.T U@YL_ MN/D!4"MK#"_[(J$F.CCK2*_U18;Z^ D0Y.]+. E@T6E\?KY( I!/U]0$]D5$ M+?Y-6U$U(#J LN8'7$FPI.3#VZLMR[#>6=.#+;LBQ MI$-,2S0#[WPY]6&RZ3*$Q+O-!B0YB]YH[S:L'@5:$QOABP+1OTB!3FNP@ => MC[A_ 5<%F(&E^6.09H- ,[!X?VJ8*S+$[ ?;$4%@H?[LPYRM]M;WGS(2,RI> MG1!(Z=AA*4GD_-N[B7CI\T'\,7I(V5<>%105B;!!=\SKDS]:/Z+'-(Z.:&V5 MD+'3ZD[+?-I+*G&.;/GUXO2J4AGDS@GR_5N,>5YAN+:6R4M/LJ!X.8LR\G? MFTKH9WB:GQ%>7K%UD^$Y*>9U4H#VJX>(WKMC]0R+8R0F MY?H1?Z>X5#=H#9QF*YQ4)CJST8M/V&]<*VETV5#B5\:.B!^:L?8EBL;C5M$]X.^CC= M,5]2MM. 3]&"Y"C5:-KF PR"26GVO01TX#Q6]Q_6O"R)W!>A:,QGY1##8E78 M,PM$DNV.>/YM(4UU<6*7#"@S>IL-YG31"C6KRG:](!0)._?0=JWA&3Z 2_4; M3J5FCVH^T&"8OBQO'&WQ;BL&&."[K:"RV;L%##08IBLP)S-F*P88X+LU1_&: M#^2$Z3VV6,_/RS8.2!7GN1#K=7:#LGSSST&TAJ!2?#AG%.&H9<-7>J# MVW"L"Y;=XD61Q8]"C[M^.&5S,<'*VWAKV=!U=*KG64HM'19/IF43X .XY5,& M(N.$RXMLRT@W&L.F)+2?6Y8VF(SH2=+F2INSUO@)S#5OP 9PN)A]2TLL[Y85, M$WFM-:93 0 "C=PM,.:WLQW_: MFWAY_[=!6!77D\1_\Z@X>Q/78T'##$A?TBMM2]4@GMZ7!,N^)BH<5_,ES[(O MR1H&_UO(LG29N-;?B68:#VTO =/C\TSO;_3E+(/IMTVC+BUHK*46=BT[8+J%A>(;GLD0E,IAK]Q&SF1DR8C$V#S@VA<@J)4;!QR% M;]TNZ7?2M1"'097!YGK@.,P22U*$QXO:PQ0<;(3=2+-Y=I$O^&VK#1&<[B(/=Y$WG!A= MUE88N,]VR+45' 2(-KZ.5:>\VUL\HY22TH*S&"(V-%EU#'@Y@FA_%%KJ-CTS M8@<10P^(9-&R= AB2DOUA\W@V=;/J5O:+83$_ZE -"!= M^F?D0LR4[7WJVWER_@UG,>'X)B-Q'=8![C<4EH3=+,Z4,R*C 6@BHW:,.*OO M/BP&[W%6=[DCM-NP&/J=I6+1I"1?-7QGU0,X9/*2+HJ<;VMK0+BJ[Q' \Z:5 M=56;V\L& >$/"/_1(_QMU#](\'[AQBZ7:?G>KN!+]J*A;'2&NKV\Q$&+ MQ0A).Z[L&4,6"LGS"/]5B!TQ8B6Y$5IG4JUD8->ZW?:; M18H:.\2Z?&3?WK'N:6_E*JLUZ+ND$^2PZEXP?4)$DZ\H2Z3MJ4"U*MOT3^JV M!%^95G9=2K'210IN'X#FSJYPFTBC=%:NBI/5OLFFMD8Y@:Z?' 32F/E<*-Y> MY\]Q&IW?'3-_8#)[%,K&9"EV[QF&^#5[>OJX!;P@V1KYO:3K7'UKPGSQI!>5 ME<YO8^S)3\?)8ZW8T5UE['%)XU/;-?"<1361V M-P2^>\[Q"1Q :1&@_>"$T!XH+\.F>S,H!"WC$ M,_AWS"57--D!PTQ^=,#Y9#;+RO*'O1Q'K>GQ\158W9"ACQ^S_:/GT<'NTHZH M0;\.7L?Z'FNCB:S-_!G-U;'D-A\U)L'5F]JM2JI6'SAJ(3Z;);=8GC3R I)- &2!4AES MT8-TH90XWY5;L%NO)-6Q^\Z2X!M0,F;!&RNM?2^$[@AT^II"*DE()1E6*DFG M@2 AKR3DE=2&WCP/=[9J_OLB2GT@O2+.R9?H<>U\ @9-^2*/D&HRDE039_=7 M&&2=V/24VUMPQR-9$Q^P=VO:JI"U 4;'E3OC#%^UD(OC\H*_?B8O)*[PN!)X MW/IBP+*&WRGV=!+?#ZVH8)^QQ6#ICN%Z^)ZFUL?%WQ+*VHH"\ M-;\[>M!O8)!N,]%D:J .B6]0)ZDQDH6A0):FW._F6$2U?A'3Y[=T79>$@ M4)]0/*C/-,7S#L-G#3/Y_^H7XV7JV;M-G"F!SU]O*>FP%,FA[<& M#.D;M"(4*L:$1."0"#P0IXHKI#=D!8>LX) 5'+*"^YY/!AX17V02,H-#9K#3 M<*&V"&/(&!X0W&5O(QAV\)8#'Y.]5..C%[4Q@F(]']F_5,ZVR**]3.4CG/XM M <20R>PBS"9D. \DH";D/??K[@[YT(/QH3J*;_\YXGA6_IOA!V6V6C563[J6A"8I2> MX25.V4(^IC*0&=;8Q'>D(>@F8SF+6SU-Q*K"4).6[*T\DA>=6W7@(Q"OC M!'3-73# \^N'6[&AT=IHDB=M(H=7)YQA<3[%I)2>^#O%I59"D\E<+H"_R\]K M>(!T=!/;.0/)*_AX*"%2T(O:6FRE;O'>4KFA-9OT$9]^F?E>KM'RC1X MRG'=IO.BG4OY[XBYI$+MPE?U5]Q6M!POX0[CR';DW&W.3.5[/&OEVC,P0=!F"+O76/#,UG'V1"^R 8B!=PCN9Z./E],>Z=Q&5 MNHEB E][)YS:&0-!$WV1!GRO!5FPWH7A&JT@IQQHPFL=O.<'D-3NR08%H3:4:W@.&:%L#MOT$KJT*=K FL<6.K&#@H=;^BYQ3$F MR_(>!)S#6%!U<<)(,2]2.67*('>Y&6;X44PHLL3[]2](O7ZX1]_J>6LRB@-V M$S'KQ=)#Z0TBR24]10N2H[2.+75K!^1S+A9S';7EE]%[U^1IEL%AF\$0.YGR M\K8'"-'/VSH(=T7\4>AT\I=,55D*JUH">/DIRK*5.+=51=6,^KJ(Y)W/2;X& M) 65C$H]!-.8U,8U GJX88/1LB:*\F74-',1E+S6739!XPE7TE:I\D]_]I)Q@&B,R+4_K4R M(73A\V]Q6LA[ZC3$FW1UP9@X!,3#5O5AV55-^B?T8+K6T'G0PJ5F>D"&T&CN M#DI&KA.3]=17=AL(2^HMYF7#89&M,13T'?IGXA.A+"OSV7,L:XW6D%[7S$&J MBH00-EN=[H15MG5$.GBR:UJ[)Q\F_H%IFS=;'%YK?BE:.B%[@4BR\?&)'?Q@ M:JNGD4%/%VS)^/I\)6O&YO*R7G$6E4&;]>H"I(N+"^-R1"A.SE$F[P?E!YBG M,"1)7)OR"N\8LM2.+N'H^N&"4$1C@M(;QDNT6:-BF'0-F53N,ZEL$0NT"H9E M![RD1CO;=1V&P,0EW9CC-S+*0JS#/,_(M"CSQ^Z95(KD;=(L34NGNE(-[V9P MV#L>>0X-9 ,,.7HA1Z_WX.6!)]$,.7C9D21>\GEXT8/>^^N+0-2L'D8MF[N1 M?5D^8!G!(WY\R1$!BZ;>(^!+A@A8%,;HC<5H;Y:CM-^(5/AB4L4-V0OU'NRD M@4)D]H*[!RJ::H^HO4#N@8K!W&D,%I%Q5>Z!B@C@.P++Q+AR]O#WVL:;[,#U M-YC2#_7D^J+Y _BM4&U5\?B^S!%\L!5,9&837VS,< MABPB:#@87#4TUIK'M$Q;H""=,%\&/]LS5P0O4-"=P+RK'=9UV#?C!%0VB082H;'FP_T:IK$_5 M7:6GUD]V7_NI(Q9ZK09U4)]N%]=+9[(XIIRY9X2O'4Y;"I\7: %VC^C/3WGL MN2C(<[5!4U=)T<-E%+^"K!:1[QV-.BAQ=)@8T/%3W,X?P^LZW9&Z!WT_"D-) M:OG7=/]9?0XCN)^#ZA\;6^\&9]LBF"0N-\FT.#@#GM?^@/4:'#N:_"+#W@X* MFV JCN]4EG!-YH1NZO O\29>M(8M8*^AWQ#K<(]:[[ [I%8SC32M'5UP*[9Y M]31YULJI=B3VQ#V4TN*<;#R.:Y:7B*1K.@] W(VU5FY+((:UH[A<5,WO*AX2 MT9J]0-O>(0N-;BUV*?L:N/6"99C,Z-JY&*_N,T2YD/"ZUGGY7[H&=Y)_%SS? M!,:7NG*EBGR#=#5.^J;!D:C%#LF>S@#U 0+KY*3JB- ?%/-\W\#EI=PF9#I< MA;>88Y3%,N'OX-8]]
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end